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  1. Introduction and scope of this work 
 
More than 50% of all sexually active adults, both men and women, have come in contact with human 
papillomaviruses (HPV). In most cases, the viral infection is normally not noticed by the respective 
person, as it is blocked by the immune system. In some cases, though, malignancies like cervix 
carcinoma, which represents the most prevalent HPV-based tumor disease, or more unique tumor 
diseases are evoked. Within the last years, a vaccination against HPV was established, based on 
seminal efforts in HPV research, which culminated in October 2008, when Harald zur Hausen was 
awarded with the Nobel Prize for medicine or physiology for elucidating the connection between 
HPV infection and HPV induced cancer. In this context, the following chapters first describe the onset 
of HPV research, followed by a detailed characterization of HPVs and infection with HPVs, especially 
highlighting the high-risk type HPV 16. Then, the focus will be on the HPV16 L2 protein (L=late), one 
of the two viral capsid proteins of HPV16, and its various eminent interactions with the host cell 
during viral infection. In this study, small ubiquitin-like modifiers (SUMOs) were identified as 
important L2 interaction partners. SUMO proteins are ubiquitously and constitutively expressed and 
establish the very complex host cell SUMO apparatus also involved in viral defense. The SUMO 
apparatus itself is represented by a smaller pool of free SUMO proteins and a large pool of SUMO 
monomers or SUMO chains that are covalently or noncovalently linked with multiple SUMO targets, 
thereby administrating fundamental cellular regulation mechanisms, as will be depicted in detail. 
Finally, an introduction will be given into the broad range of experiments and experimental 
techniques, which are used in this thesis for the characterization of the interaction of HPV16 L2 with 
SUMO. 
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1.1 Human papillomaviruses (HPV) 
1.1.1 Historical review of HPV 
The general phenotype of an infection with papillomaviruses (PVs) has been described already 2000 
years ago. Nevertheless, the finding that the observed, mostly benign, warts on the skin (papillomas) 
or mucosa (condylomas) were connected to an infection with viruses was made not until the early 
1930s. At that time, it was found that filtered extracts prepared from warts of rabbits, were able to 
induce lesions on the dermis of other rabbits and that the cottontail rabbit papillomavirus (CRPV) 
was even carcinogenic for some rabbits (Shope and Hurst 1933). For humans, a connection of viruses 
with skin and genital warts was first proven in 1949 (skin warts) and 1968 (genital warts), when virus 
particles were detected by electron microscopy within extracts from the respective tissues. The first 
molecular biological detection of viral DNAs succeeded in 1977, when DNA stemming from bovine 
papillomaviruses (BPV) was found in cancer tissue of horses (Lancaster, Olson et al. 1977). Four years 
later, the first PV-DNA was isolated (de Villiers, Gissmann et al. 1981). The first completely sequenced 
genome was that of the bovine papilloma virus type 1 (BPV1)(Chen 1982). Within the next years, also 
the DNAs of HPV types 1, 6, 16, and 18 were sequenced (Danos, Katinka et al. 1982; Dürst, Gissmann 
et al. 1983; Schwarz, Dürst et al. 1983; Boshart, Gissmann et al. 1984). In radio-labeling experiments 
based on viral DNA, it was found that most genital carcinomas contained PV-DNA manifesting the 
close connection of cervix carcinomas and infection with PVs, which contribute to about 99.8% of all 
cervix carcinomas (Walboomers and Snijders 1999). The HPV types 16 and 18 share a very high 
prevalence in about 70% of all cervix carcinomas and were therefore classified as high-risk HPV types. 
They are part of a HPV family, which, nowadays, comprises more than 180 different high- and low-
risk HPV types (de Villiers 2004; Calleja-Macias, Kalantari et al. 2005; Bernard 2010). They are found 
in most mammalians and birds and share an extraordinary specificity concerning the target tissue 
within their hosts. 90% of the known HPVs are classified as α- or β-papillomaviruses. The rest is 
characterized as γ-, µ-, or ν-papillomaviruses, which mostly cause cutaneous papillomas or benign 
condylomas most frequently associated with HPV6 and HPV70 (de Villiers 2004; Nielsen, Iftner et al. 
2012). 
 
1.1.2 HPV epidemiology 
The infection with HPV is normally not accessible for clinical observation, since, in most cases, the 
concerning individuals are not aware of the HPV infection. Only sometimes, cutaneous papillomas, or 
benign condylomas are observed, which heal after several months or years. Thus, HPVs are most 
often associated with warts on skin and mucosa, but also cervix, penis, or pharynx carcinomas. As 
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indicated before, the prevalence of a HPV infection of a sexually active adult is remarkably high (60%) 
(Eckert, Watts et al. 1999; Ho 2002; Cutts, Franceschi et al. 2007). It is even more remarkable that 
17.8 % of the 1.9 million cancer incidents worldwide, in 2002, were based on an infectious disease 
containing a fraction of even 5.2%, which were directly associated to HPV (Parkin 2006). In general, 
the HPV prevalence is very high in developing countries in Africa and Southeast Asia (83%) (Akogbe, 
Ajidahun et al. 2012). Based on fundamental efforts in development of vaccines against HPV, since 
2006, two commercial vaccines are available. CervarixTM (GlaxoSmithKline) is a bivalent vaccine 
targeting the two most relevant HPV high-risk types 16 and 18, which also contains an adjuvant. The 
tetravalent vaccine Gardasil® (Merck) targets HPV 16 and 18 as well, but additionally, also the low 
risk types 6 and 11, which are responsible for the majority of cutaneous papillomas. Both vaccines 
recognize surface loops of the HPV L1 capsid protein in a very HPV type-specific manner and thereby 
effectively block the HPV infection pathway. The two vaccines provide a long-term and almost 100% 
protection against infection with HPV16 and 18 (Einstein 2009; Etter, Zimet et al. 2012). 
 
1.1.3  The HPV genome 
The HPV genome is represented by a circular, double-stranded DNA with a size of between7,400 and 
8,200 base pairs depending on the respective HPV type. In the viruses, the genome is organized 
together with cellular histones and forms a chromatin-like structure (Howley 2007). The DNA codes 
for eight viral gene products (Fig. 1.1).  
 
Fig. 1.1: The HPV16 genome. The double stranded, circular HPV16 genome comprises 7904 base pairs and is sub-divided 
into three major parts, i) the long control region (LCR) containing several control elements, ii) the early region, and iii) the 
late region. The early region contains the early genes controlled by the early promoter p97 (E6 and E7) or the p670 
promoter (E1, E2, E4, E5). The late genes L1 and L2 within the late region are regulated by the p670 promoter. Two 
different polyadenylation signals are used during transcription: the polyadenylation signal for the early genes, PAE, and the 
polyadenylation signal for the late genes, PAL. Figure according to Doorbar 2006. 
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The respective genes are found on all three reading frames. Depending on the function of the 
respective part of the DNA, the genome is divided into three segments, i) the non-coding control 
region (LCR) with the origin of replication (1 kB), ii) the early region (4 kb), iii) the late region, which 
codes for the structure proteins L1 and L2, which build up the viral capsid (L = late, 3kb). The early 
region comprises the early genes, which encode proteins triggering the amplification of the viral 
genome and viral expression of genes (E1 and E2), as well as transformation (E6, E7). These proteins 
are classified as E proteins (E= early) and comprise the proteins E1, E2, E4, E5, E6, and E7. Expression 
of E6 and E7 is under control of an early promoter (p97 for HPV16), which is constitutively active in 
non-differentiated suprabasal cells (Hummel, Hudson et al. 1992). The promoter element is part of 
the LCR region, which is located between the poly-adenylation signal of the late gene L1 and the 
early gene E6 and regulated by several cellular transcription factors (Sichero, Sobrinho et al. 2012). 
The expression of the late genes L1 and L2 is regulated by a late promoter element (p670 for HPV16), 
which is not located within the LCR and activated by differentiation of the keratinocytes. The same 
promoter element also regulates the transcription of E1, E2, E4, and E5 (Grassmann, Rapp et al. 
1996). More recent studies report the existence of two additional promoters for regulation of late 
genes, one is located 157 nucleotides upstream of P97 and the other one in the E5 open reading 
frame (Milligan, Veerapraditsin et al. 2007). For the late transcription, a total number of 13 mRNAs 
divided into two pools of late mRNA transcripts was identified. One population of transcripts 
contains L1 alone, while the other one contains L1 and L2. Alternative splicing leads to the possible 
expression of four additional late proteins (E6*^*E7, E1^E2C, E6*^E4, and E1^*E4)(Milligan, 
Veerapraditsin et al. 2007).  
 
1.1.4 HPV structure 
Papillomaviruses represent non-enveloped DNA viruses with a diameter of about 52-55 nm. The viral 
capsid comprises about 360 copies of the major capsid protein L1 and 12-72 copies of the minor 
capsid protein L2 (Fig. 1.2) (Buck, Cheng et al. 2008).  
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Fig.1.2: 3D-reconstruction of HPV16 capsids. The picture shows single particle 3D-reconstructions of HPV16 capsids 
assembled from viral L1 (blue) and L2 proteins (red). L1 is arranged in pentamers forming the viral capsomers. The L2 
molecules are located beneath the capsomers as shown in the detailed view of the capsid shell on the right (Figure 
according to Buck et al., 2008; with friendly permission of Benes Trus). 
Thereby, five L1 monomers are arranged within homopentamers to build up a L1 capsomer. Up to 72 
capsomeres are assembled based on an icosahedral symmetry (triangulation number = 7) to establish 
the full capsid of the virus (Baker, Newcomb et al. 1991; Belnap and Christensen 1996). Finally, the 
capsid comprises 12 pentavalent and 60 hexavalent capsomers, meaning that the respective 
capsomers are located within five or six neighboring capsomers. The L1 protein and, most 
interestingly, also L1 deletion mutants lacking the first 29 amino acids, feature a very strong 
tendency for spontaneous formation of capsids (Paintsil 1996; Schäfer 2002). Stabilization of the 
capsomers is achieved by the formation of intercapsomeric disulfide bridges between neighboring 
capsomers (Sapp, Fligge et al. 1998; Day 2009; Sapp and Bienkowska-Haba 2009). The L2 molecules 
are located directly beneath the geometrical center of the L1 pentamers. The interaction of L2 with 
the L1 capsomers (no interaction of L2 with L1 monomers) is reported to be of noncovalent nature 
and based on a well-characterized hydrophobic C-terminal L1 binding domain of L2 and an additional 
L1 binding domain at the N-terminus of the L2 sequence (Volpers 1995; Okun, Day et al. 2001; 
Finnen, Erickson et al. 2003). L2 incorporation enhances the formation of infectious viruses. In 
addition, it is discussed whether an L2 network is established within the viral capsid. Direct hints for a 
L2 network came from fluorescence studies, in which an intermolecular interaction of neighboring L2 
N- and C-termini was proposed (Buck, Cheng et al. 2008). 
 
1.1.5 The HPV life cycle 
In order to reproduce themselves, viruses established a manifold of interaction and regulation 
mechanism to take benefit from the host cell. For correct reproduction, the viruses are obliged to 
infect the virus host, which allows for replication of the viral genome by the cellular replication 
machinery and for the survival of the virus. A simplified overview of the HPV life cycle is given in 
Figure 1.3. 
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Fig. 1.3: The general infection pathway of HPVs. The HPV replication cycle after infection of epithelial basal cells is 
schematically illustrated for the respective cell layers. For each step, the characteristic main aspects are highlighted 
including an overview of viral gene expression. After infection of the epithelial basal cells via microlesions, the viral genome 
is manifested within the nuclei of the host cells and amplified as episomes. Expression of the early genes E6 and E7 induces 
the differentiation of the keratinocytes. Then, increased activation of the late promoter results in expression of E1, E2, E4, 
and E5, which results in enhanced amplification of the viral genome in cells of the late suprabasal layer (stratum spinosum) 
and granular layer (stratum granulosum). In the top-most layers, the late proteins L1 and L2 are expressed, and, together 
with viral DNA, assembled into new viral capsids. The mature viruses are finally released by desquamation of the host cells 
in the stratum corneum. 
After infection of basal epithelia cells from skin or mucosa of the host, the replication cycle of the 
papillomaviruses is closely correlated to the differentiation of the epithelia cells, which are steadily 
regenerated from basal cells located on top of the basal membrane (Stanley 2012). The 
differentiation is triggered by several cellular transcription factors, which target the regulation of the 
early promoter, like e.g. AP-1 proteins, POU-domain proteins, NF-κB proteins, and CCAAT/enhancer 
binding proteins (Eckert 1997; Ryan 1997; Seitz, Lin et al. 1998; Maytin 1999; Thierry 2009). The viral 
genome is consecutively replicated to a number of about 20-100 copies per infected basal cell by 
expression of E1 and E2 (Lambert 1991; Stubenrauch 1999). Meanwhile, the cells are pushed further 
and form the suprabasal layer (stratum spinosum) and differentiate. This step is mainly driven by 
expression of E6 and E7 and leads to an enhanced formation of new tissue and therefore also to 
enhanced productive infection (Stubenrauch 1999). Then, activation of the late promoter induces the 
expression of the capsid proteins L1 and L2 together with E4. L1 and L2 reach maximum expression 
levels within the granular layer. Here, the cells partially lose their nuclei and develop a flattened 
shape. L1 and L2 are assembled into new viral capsids, which are loaded with viral DNA. The new 
viruses are released during desquamation of the host cells in the stratum corneum (Meyers 1992; 
Flores 1999). 
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1.1.6 Virus binding & uptake, and nuclear transport of the viral DNA 
The papillomaviruses enter the host organism via micro lesions. At the level of the basal membrane 
or basal cells, the PVs first bind to a primary receptor molecule, which is represented by heparan 
sulfate proteoglycans (HSPGs, Fig. 1.4)(Volpers 1995; Joyce 1999; Giroglou, Florin et al. 2001; Culp 
2004; Selinka 2007; Johnson 2009; Kines 2009; Broutian 2010; Schiller 2010). HSPGs represent matrix 
glycans, which are localized in the extracellular matrix (ECM) and on the cell surface of mammalian 
cells. The high abundance of HSPGs expressed by different host cell tissues can in some cases also 
result in a primary binding of PVs to non-keratinocytes (Roden, Kirnbauer et al. 1994; Müller, 
Gissmann et al. 1995; Tiwari, Maus et al. 2012). HSPGs generally function as a kind of cell glue and 
facilitate internalization of cell-bound ligands (Lindahl 1998). PVs interact with the negatively charged 
HSPGs via ionic interactions based on positively charged lysine residues of the L1 capsid protein 
(Knappe 2007; Dasgupta 2011), which can be blocked by incubation with polyanionic or polycationic 
molecules (Giroglou, Florin et al. 2001; Buck 2006; Selinka 2007; Spoden 2011). As for HPV16, the 
presence of an additional, non-HSPG binding moiety on the ECM, most likely laminin 332, was 
reported, since HPV16 binding was not completely inhibited by heparin or enzymatic removal of 
haparan sulfates (Selinka 2007; Bienkowska-Haba, Williams et al. 2012). The primary binding of the 
capsid to the HSPGs leads to a conformation change of L1 within the capsids (Selinka 2003; Day 
2008b). Then, a conformation change of L2 is induced by the host cell chaperone cyclophilin B (CyPB) 
and allows for a transfer of the PV to a secondary receptor (Selinka 2003; Schelhaas 2008; Day 2008a; 
Day 2008b; Bienkowska-Haba, Williams et al. 2012). Recent results show that, during the transfer, 
the viral particles reside in high molecular weight complexes with HSPGs, including syndecan-1, and 
bioactive compounds like growth factors (Surviladze, Dziduszko et al. 2012). The nature of the 
secondary receptor is still under debate. One candidate, α6-integrin, was presented already in 1997 
for HPV6 (Evander, Frazer et al. 1997; Culp, Budgeon et al. 2006), but is not necessary for infection of 
HPV11 and HPV33 (Giroglou, Florin et al. 2001; Shafti-Keramat, Handisurya et al. 2003). Remarkably, 
a colocalization of HPV16 was observed with tetraspanins (Spoden, Freitag et al. 2008), which drift on 
cell membranes as compact raft structures forming tetraspanin-enriched micro domains (TEMs) 
(Sterk 2000; Odintsova 2003; André 2006; Lazo 2007; Spoden, Freitag et al. 2008; Yang 2008). The 
TEMs allow for binding of HPVs even after very short infection times (<10 min), as was seen in 
colocalization with the tetraspanins CD63 and CD151 (Spoden, Freitag et al. 2008). Then, the HPVs 
are internalized via endocytosis (Selinka 2002), which functionally depends on the tetraspanin CD151 
for HPV16 (Spoden, Freitag et al. 2008). Since preparation of virus-like particles (VLPs, composed of 
L1 and L2, no DNA), and pseudoviruses (PsVs, containing reporter DNA) was established, new insights 
into the binding of the viruses to host cells were achieved. Thus, L2 does not seem to be crucial for 
viral binding and uptake, although the L2 protein is able to bind to the cell surface and is taken up by 
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the host cell (Kawana, Kawana et al. 2001; Yang, Day et al. 2003a). It is also known that during cell 
binding of the viruses, L2 undergoes a cleavage step by furin (or PACE, for Paired basic Amino acid 
Cleaving Enzyme) recognizing a basic amino acid target sequence of L2 (Arg-X-(Arg/Lys) -Arg'), which 
gets accessible after binding to HSPGs (Richards, Lowy et al. 2006; Day 2009). Endocytosis of HPV16 
viruses does not depend on clathrin, caveolin, or dynamin and may occur via a so far uncharacterized 
endocytotic pathway supported by tetraspanins and actin (Spoden, Freitag et al. 2008; Schelhaas, 
Shah et al. 2012). After the disruption of the capsids in the acidified late endosomes (Selinka 2002; 
Smith 2008b; Schelhaas, Shah et al. 2012), L1 is dissociated from a complex of L2 and the viral DNA 
by cyclophilins (Bienkowska-Haba, Williams et al. 2012). L2 partly penetrates into the endosomal 
membrane via its C-terminal transmembrane domain probably enabling interaction with cytoplasmic 
proteins. L2 interaction with sorting nexin 17, syntaxin 18, and the intramembranous cleaving γ-
secretase are putative factors involved in the release of a complex of L2 and the viral DNA into the 
cytoplasm (Day 2004; Bossis 2005; Kämper, Day et al. 2006; Karanam 2010; Marusic, Ozbun et al. 
2012). This step is additionally regulated by protein disulfide isomerases (PDIs). PDIs catalyze the 
reduction/oxidation and isomerization of disulfide bonds highlighting the role of the two conserved 
N-terminal cysteines within L2, which are able to form an intramolecular disulfide bond (Campos and 
Ozbun 2009; Conway 2009; Gambhira 2009). Inhibition of PDIs by bacitracin had no effect on cellular 
binding and uptake of viruses or lysosomal trafficking, but inhibited the accumulation of the viral 
DNA at the PML-NBs (Campos, Chapman et al. 2012). In the cytoplasm, the complex of L2 and viral 
DNA is further transported to the periphery of the nucleus via the motor protein dynein (Florin, 
Becker et al. 2006; Schneider 2011). Then, the L2-DNA complex is released from the dynein transport 
complex and transported to the PML NBs, where induction of viral protein expression leads to a very 
complex reorganization of nuclear structures (Day 1998; Florin 2002b; Day 2004; Jiang and Imperiale 
2012).  
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Fig. 1.4: The HPV life cycle. 1 The viruses bind to the primary receptor heparan sulfate proteoglycans (HSPGs) of the target 
cell and laminin 322. 2 After a structural rearrangement of L1 by binding to HSPGs, L2 interacts with cyclophilin B, which 
induces a conformation change of L2 and enables the N-terminus of L2 to be processed by furin. 3 The viruses attach to 
tetraspanin-enriched microdomains (TEMs) representing the secondary receptor. 4 Clathrin- and caveolin-independent 
endocytosis. 5 Disassembly of the viral capsids in the acidified late endosomes. A complex of L2 and viral DNA escapes the 
endosome by interaction with sorting nexin 17, PDIs, γ-secretase, and syntaxin 18. 6 The L2-DNA complex interacts with the 
dynein subunits DYNLT1 and DYNLT3 and is transported to the micrutubuli organizing center (MTOC) near the periphery of 
the nucleus. 7 The L2-DNA complex is released from the dynein transport complex, transported into the nucleus, and 
accumulates at the PML-NBs. 8 During papillomavirus morphogenesis, the late proteins L1 and L2 are expressed upon 
increased transcription of viral late mRNAs. 9 L2 and L1 pentamers are independently transported into the nucleus and 
assembled into new capsids containing viral DNA. The mature viruses are released from the nucleus by cellular breakdown 
during desquamination of the host cell. 
 
1.1.7  Manifestation of the viral genome 
After the viral DNA is imported into the nucleus, the expression of E1 and E2 triggers the replication 
and transcription of the viral genome (Chiang, Ustav et al. 1992). E2 plays a key role as viral 
transcription regulator, which, depending on the HPV type, interacts with various target proteins in 
the host cell (Muller, Jacob et al. 2012). E2 recognizes four palindromic motifs in the non-coding 
region of the PV genome (Dell 2003). For low expression levels of E2, only two of the motifs are used, 
while for high expression levels, all four binding motifs are occupied (Demeret 1998; Hines 1998). E2 
dimers bind to the DNA and recruit the E1 protein to the origin of replication. E1 functions as 
replication initiator protein and binds to the DNA as a dimer recognizing an incomplete palindromic 
DNA motif via its N-terminal region (Demeret 1998). The origin of replication is located within 60-80 
base pairs in the non-coding control region. Then, E2 detaches from the DNA and triggers unwinding 
of the superhelical DNA, while the recruited E1 proteins form a dihexameric ring structure (Chow 
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1994). The complex of E1 proteins is stabilized by the heat shock proteins HSP40 and HSP70 (Lee 
1999). Finally, E1 associates with the cellular DNA-polymerase primase and the single-strand-DNA-
binding protein A (RPA) to recruit the cellular replication machinery to the viral initiation complex 
(Park 1994; Loo and Melendy 2004). For high E2 expression levels, in a negative feedback regulation, 
the E2 binding to all four palindromic DNA motifs leads to the detachment of the basal transcription 
factors Sp1, TFIID, and TBP (TATA-box binding protein) and to a stop of replication (Steger and 
Corbach 1997). For low E2 expression levels, E2 also controls the expression of E6 and E7 by 
regulation of the early promoter p97 (Demeret 1998). In general, the replication of the viral genome 
is synchronized with the cellular replication cycle. Separation of the replicated viral DNAs into the 
daughter cells after mitosis is performed by anchoring of the viral episomes at the human 
chromosomes mediated by E2 (You 2004; McBride 2006). E2 also transactivates the SF2/ASF 
promoter, which is a key factor in the alternative splicing regulation and, thus, directly regulates 
cellular gene expression and/or expression of an RNA processing factor (Mole, Milligan et al. 2009). 
 
1.1.8  Stimulation of the cell proliferation 
The cell proliferation phase is characterized by a strong neoplastic growth of infected cells within the 
suprabasal layer induced by the expression of the viral proteins E6 and E7. In general, during 
infection, the viral genome is frequently integrated into the host genome at certain integration sites, 
which partially disrupt host genes (Schwarz 1985; Baker, Phelps et al. 1987; Schmitz, Driesch et al. 
2012). Thereby, only the E6 and E7 genes remain fully functional, which causes increased expression 
levels of E6 and E7 (Kraus 2006). E6 and E7 inhibit the exit of the cell cycle, which leads to the 
thickening of the intermediary layer and to the formation of characteristic papillomas (zur Hausen 
2000; Munger 2002). 
In particular, E6, together with E6AP, binds to the tumor suppressor p53 and induces an ubiquitin 
dependent degradation of p53. This effects a deregulation of cell division and DNA repair, which are 
controlled by p53 (Scheffner 1990). As a consequence, the cell division is drastically upregulated and 
mutations within the DNA are passed on to daughter cells, which finally results in malignancy 
(Mantovani 1999; Mantovani 2001; Munger K 2006). E6 from high-risk PV types also delays the 
senescence of the cells based on activation of the catalytic subunit of telomerases (Klingelhutz 1996; 
Zhang, Tian et al. 2012). The oncogene E7 interacts with several target factors thereby inactivating 
proteins involved in cell growth (Yu and Munger 2012). This includes the tumor suppressor protein 
pRb and its relatives p107 and p130 (Zerfass, Schulze et al. 1995), but also cyclin E and A by E7 
binding at the p21 and p27 promoter (Arroyo, Bagchi et al. 1993; McIntyre 1996), histone 
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deacetylases (Brehm 1999; Longworth 2005), components of the AP1 transcription complex 
(Antinore, Birrer et al. 1996), and the cycline-dependent kinase inhibitors p21 and p27 (Zerfass-
Thome 1996; Funk 1997). Both, E6 and E7, comprise DNA binding domains (zinc finger domains) 
allowing direct regulation as transcription factors. 
 
1.1.9 The vegetative amplification of the genome 
For the final assembly of new virus particles, an adequate number of initial viral DNA is necessary for 
large-scale expression of the viral protein. This threshold level of viral DNA has not been reached at 
this state of the infection, since the viral genome was only replicated once per cell cycle. During 
vegetative amplification, the late promoter (p670 for HPV16) is activated allowing that the early 
proteins E1, E2, E4, and E5 are expressed without a negative feedback regulation based on the E2 
expression level. Now, the replication of viral DNA is significantly increased. Thereby, again E1 and E2 
trigger replication, while the transmembrane protein E5 localizes in the Golgi apparatus and the 
endoplasmatic reticulum and interacts with receptors of growth factors like EGF (Conrad, Bubb et al. 
1993; Straight, Herman et al. 1995). E5 has several functions, like e.g. transformation of 
keratinocytes, stimulation of DNA-synthesis, inactivation of other oncogenes, and regulation of 
signaling pathways (Bouvard 1994; Gu 1995; Valle 1995; Chen 1996; Auvinen 1997; Ganguly 2012). 
Little is known about the function of E4, but this viral protein seems to be crucial for the viral 
infection cycle in general, and, in particular, for an arrest of the cell cycle in the G2 phase and 
therefore resembles an E7 antagonist (Davy, Jackson et al. 2005; Wilson, Fehrmann et al. 2005). 
 
1.1.10 Viral morphogenesis and release 
The last step, in which the viral cycle is linked with the host, is represented by the packaging of the 
viral DNA into the new assembled viral capsids in the cell nuclei of the now fully differentiated 
epithelia cells. After amplification of the viral genome, first, the expressed L2, and then L1, 
accumulate within the nuclei at ND-10 bodies (Florin 2002b; Becker, Florin et al. 2004). The 
regulation mechanism, switching from DNA replication to packaging of the DNA into viral capsids is 
triggered by specific processing of viral pre-mRNAs (Graham 2008; Schwartz 2008) but also by an E2-
induced inhibition of early polyadenylation of late mRNAs resulting in transcripts including also the 
late genes L1 and L2 (Johansson, Somberg et al. 2012). The assembly of the viral capsids starts with 
the pentameric arrangement of L1 in the cytoplasm (Fig. 1.4). Then, the L1 pentamers are imported 
into the nucleus based on the interaction of the C-terminal nuclear localization sequence (NLS) of the 
L1 protein with the transport-receptor complex Kapα2/Kapβ1, which prevents a premature 
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cytoplasmic capsid assembly (Nelson 2002; Bird 2008). L2, which is independently imported into the 
nucleus in association with with Hsc70 (Florin 2004), detaches Sp100 from the nuclear bodies (ND-
10) and recruits Daxx to the ND-10 (Florin, Sapp et al. 2002a; Florin 2002b; Becker, Florin et al. 2004). 
At the ND-10, the viral capsids are assembled and packed with viral DNA. For this step, the C-terminal 
region of L1 is essential (Schäfer 2002). E2 triggers the transport of the viral DNA towards the ND-10 
(Day 1998). L2 is not necessarily needed for the DNA packaging, but seems to increase packing 
efficiency significantly (Zhao 2000; Buck 2005; Holmgren, Patterson et al. 2005). Finally, the 
maturation of viruses ends with formation of the characteristic intercapsomeric disulfide bridges, 
and the mature viruses are released together with the top cell layers, which are gradually 
desquamated (Campos and Ozbun 2009). 
 
1.1.11 The HPV late protein L2 (HPV16 L2) 
The HPV16 L2 protein plays a key role during infection with papillomaviruses. Both, the uptake of 
viruses and the assembly of new viruses after successful infection directly depend on L2. L2 is a 
multifactorial protein featuring different regulatory functions after the disassembly of the viral 
capsids in endosomes. From this step on, L2 represents the only interaction partner accompanying 
the viral DNA into the nucleus. L2 thereby functions as regulator in endosomal sorting, intracellular 
membrane passaging, and cytoplasmic and nuclear transport. After that, L2, with its highly specific 
distribution in the nucleus (PML-NBs) and interaction with transcription factors, might trigger 
transcription of viral and cellular genes (reviewed in Spoden 2012 (submitted)). 
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Fig. 1.5: Important sequence motifs within the HPV16 L2 protein sequence. 1 Surface exposed L2 regions (orange), 32-51, 
69-81, 212-231, 279-291, and 362-381, especially conserved L2 sequence regions (orange), 1-12 and 56-81, described by 
(Kawana 1998). 2 Receptor or cell surface binding site (yellow), 13-31, described by (Roden 2000; Yang, Day et al. 2003a). 3 
Furin cleavage site (red), 8-11, described by (Richards, Lowy et al. 2006) and cyclophilin B interaction sites (red), 97-103 and 
409-417, (Bienkowska-Haba, Williams et al. 2012). 4 DNA binding domains (green), 1-13 and 454-462, described by 
(Bousarghin 2003). 5 Membrane destabilizing region (grey), 454-500, (Kämper, Day et al. 2006), sorting nexin17 interaction 
site (grey), 254-257, (Marusic, Ozbun et al. 2012). 6 Syntaxin 18 interaction site (blue), 43-47, described by (Bossis 2005), β-
actin interaction site (blue), 25-45, (Yang 2003b), dynein interaction site (blue), 456-461, (Florin, Becker et al. 2006; 
Schneider 2011). 7 Nuclear localization sites (NLS, magenta), nNLS: 8-12, mNLS: 300-330, cNLS: 440-445 (HPV11), described 
by (Becker 2003; Finnen, Erickson et al. 2003), nuclear export signal (NES, magenta), 462-471, (Becker 2003). 8 DAXX 
interaction sequence (black), 390-420, (Florin 2002b; Becker 2003), L1 binding domain (black), 412-455, (Finnen, Erickson et 
al. 2003), SUMOylation site (black), 35, (Marusic 2010). 
 
The HPV16 L2 protein comprises 473 amino acids and has a molecular weight of about 52 kDa. 
Sequence analysis of different HPV types show several strongly conserved regions (aa 1-12 and 56-
81, Fig. 1.5, Kawana 1998)). With regard to the protein structure of L2, most of the data is based on 
single particle reconstruction of L2 monomers within viral capsids together with L1 pentamers by 
transmission electron microscopy. Thereby, the N-terminal part of L2 at position 60-120 seems to be 
accessible on the surface of the virus capsids (Liu 1992; Kondo 2007). The N-terminus itself folds back 
into the capsid (Yang, Day et al. 2003a; Day 2008a). Additional surface exposed regions of L2 were 
localized at positions 32-51, 69-81, 212-231, 279-291, and 362-381 (Kawana 1998). The ability of L2 
to bind to the cell-surface is attributed to a region at position 13-31 (Roden 2000; Yang, Day et al. 
2003a). Infection studies with HPV6, 16, and 18 PsVs showed that monoclonal antibodies against a 
synthetic peptide of the HPV sequence 108-120 blocked infection of VLPs (Kawana 1999; Kawana, 
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Kawana et al. 2001). Interestingly, the antibody also detects intact HPV16 VLPs, indicating that the 
L2-antigen is located on the surface of the virions. However, there was no production of neutralizing 
antibodies after immunization with VLPs containing this peptide (Slupetzky 2007). 
After cell binding of the viruses and structural rearrangement of the L1/2 capsid, the N-terminus of 
L2 is accessible and cleaved by furin based on an interaction sequence at position 9-12 (Richards, 
Lowy et al. 2006). L2 also interacts with cyclophilin B (interaction sequence 97-103 and 409-417), 
which induces a conformation change of L2 and is important for endosomal L1/L2 dissociation 
(Bienkowska-Haba 2009; Bienkowska-Haba, Williams et al. 2012). After endocytosis, the virus capsid 
is disassembled. The L2 contains two DNA binding domains (aa 1-13 and 454-469, Bousarghin 2003). 
A complex of L2 and DNA is believed to escape the late endosomes by a membrane destabilizing 
region of L2 at position 451-464 (Kämper, Day et al. 2006) and a sequence motif (position 254-257) 
enabling interaction with sorting nexin 17 (Marusic, Ozbun et al. 2012). An interaction site for β-actin 
at position 25-45 allows for intracellular transport of the L2/DNA complex (Yang 2003b). The 
cytoplasmic L2 also contains a sequence motif at position 40-44, which enables L2 interaction with 
the ER receptor syntaxin 18, therefore allowing nuclear entry of the HPV genome (Bossis 2005; 
Laniosz 2007). In this respect, also two basic sequence regions were identified as classical nuclear 
localization signals (NLS) at the N-terminus (aa 1-12, nNLS) and the C-terminus of L2 (aa 456-461, 
cNLS) (Darshan, Lucchi et al. 2004; Mamoor, Onder et al. 2012). In addition to the terminal nuclear 
localization signals, a non-classical and broader central nuclear localization signal (aa 296-316, mNLS) 
was characterized, containing four arginines, which were indispensable for nuclear transport of L2 
(Mamoor, Onder et al. 2012). In a BPV1 model, L2 is characterized as an adapter between the viral 
DNA bound at the C-terminal DNA binding side (position 454-462) and karyopherins, which are 
bound at the N-terminal nuclear localization site of L2, allowing for nuclear import of the viral 
genome via nuclear pores (Fay 2004). L2 also contains a nuclear export sequence at position 462-471 
(Becker 2003).  
Additional cytoplasmic interaction partners of L2 are represented by the dynein subunits 
DYNLT1/Tctex-1 and DYNLT3, which facilitate intracellular transport of the L2/DNA complex (Florin, 
Becker et al. 2006; Schneider 2011). After the L2-dependent localization of the viral DNA at PML-NBs 
upon L2 interaction with DAXX (position 390-420, Florin 2002b; Becker 2003), L2 promotes 
expression of the early genes and may also regulate late gene expression by direct interaction with 
the viral E2 protein and repression of its transcriptional activation functions. L2 also interacts with 
the transcription factors TBX2/3 inducing transcriptional repression (Schneider et al. 2012, 
submitted), and recruits viral E2, L1 and several cellular proteins to the ND-10 (Day 1998; Heino 
2000; Florin, Sapp et al. 2002a; Florin 2002b; Becker 2003; Florin 2004). The nuclear import of 
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expressed L2 depends on the L2 interaction with Hsc70 based on an interaction sequence at position 
456-461 (Florin 2004). During HPV morphogenesis, high L2 expression levels result in the loss of 
detection of the transcriptional transactivator Sp100 (Florin 2002b) and PML-concentration of the 
transcriptional co-repressor DAXX (Florin 2002b; Becker 2003). Interestingly, PML, SP100, and DAXX 
are usually modified by the small ubiquitin-like modifier SUMO (Zhong 2000a; Van Damme 2010). 
SUMOylation was also reported for HPV16 L2 at position 35 (Marusic 2010). The SUMO modification 
of L2 results in L2 stabilization, inhibits the interaction of SUMOylated L2 with L1, and increases the 
general SUMOylation level of cellular proteins.  
 
1.2 The cellular SUMO apparatus 
The human genome comprises about 30,000 genes, which is a comparably small number with regard 
to the complexity of the human organism. It was noticed early that the number of genes allowing 
expression of the respective proteins was by far not enough for formation of the complex tissue 
structures, network and signaling systems and the regulation of the whole system from the single cell 
stage to an adult human. The idea that one gene codes for one mRNA and finally one protein, which 
then fulfills one special function was abandoned very soon. Even on level of the genes, it was 
discovered that mechanisms like alternative splicing already lead to the expression of several 
modified forms of a protein group. Then, it was found that even fully translated proteins can be 
subjected to further modification, termed post translational modification (PTM). These PTMs lead to 
a modified function of the target protein, like e.g. alternative protein-protein interaction, different 
localization, or modification of the activity of the target protein. In most cases, specific amino acids of 
the fully synthesized target proteins are modified by various molecules like phosphate, acetate, 
lipids, or sugars. In some special cases, the target proteins are even modified with complete 
polypeptides in reversible as well as in non-reversible interaction. Conjugation of target proteins with 
ubiquitin (ubiquitination) generally, but not always, targets the ubiquitinated protein for degradation 
by the 26S proteasome (Hofmann 2001; Weissman 2011) Thereby, ubiquitin is usually attached to 
lysine side chains of the target proteins resulting in ‘branched’ ubiquitin-protein conjugates 
(Hochstrasser 1996).  
Within the last decades, a large number of proteins was discovered sharing a high sequence 
similarity with ubiquitin. They were termed ubiquitin-domain proteins (UDPs), which are not 
conjugated to other proteins, or ubiquitin-like modifiers (UBLs), which are able to conjugate with 
target proteins and thereby alter the function of target proteins (Hochstrasser 2000; Jentsch 2000; 
Ohsumi 2001). One group of UBLs is represented by the SUMO proteins (small ubiquitin-like 
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modifiers). SUMO proteins are found in all eukaryotic kingdoms and share a very high conservation 
from yeast to humans (Hanania 1999). In invertebrates, only a single SUMO gene exists (SMT3), while 
for vertebrates four SUMO genes were identified: SUMO1, SUMO2/3, and SUMO4 (Kamitani 1998). 
The founding member SUMO1 is also known as PIC-1, sentrin, or GMP1 (Boddy 1996; Matunis 1996; 
Okura 1996). Human SUMO1 shares a ~50% sequence identity with the homologues SUMO2/3 and 
with SMT3. The two homologues SUMO2 and SUMO3 share a 97% sequence identity. The function of 
SUMO4 is still under debate (Guo 2004; Owerbach 2005). Although the SUMO proteins posses only a 
limited overall primary sequence homology to ubiquitin (18%), they nevertheless feature the 
characteristic ubiquitin-fold tertiary structure with a tightly packed globular fold with β-sheets 
wrapping around one α-helix (Fig. 1.6)(Bayer 1998).  
 
 
Fig. 1.6: Structure homology of SUMO1 and ubiquitin. Although SUMO proteins only share a primary sequence homology 
of about 18% with ubiquitin, there is a very high structural homology of the backbones of SUMO1 (blue) and ubiquitin (red) 
in structural alignments underlining the relationship of the two proteins. The homology modeling was performed with the 
Swiss-PdbViewer 4.0.1 based on the pdb structures ‘1Z5S’ (SUMO1) and ‘3UGB’ (ubiquitin). 
SUMO proteins also differ from ubiquitin by addition of a family-specific, unstructured amino 
terminal extension of up to 22 residues, which probably serves as a further interaction interface. The 
majority of SUMO1 exists in the conjugated form, while SUMO2/3 normally exists as free monomers, 
which can be rapidly recruited for conjugation after cellular stress. Consistent with the difference of 
the primary sequences, SUMO1 and SUMO2/3 are bound to distinct substrates. The covalent SUMO 
conjugation to target substrates is also termed SUMOylation and is described for a very large number 
of SUMO target proteins (Seeler 2003). The SUMO targets or substrates can be found in almost all 
protein families including proteins regulating the genome integrity/structure, transcription factors 
and cofactors, nuclear pore proteins, signal transduction proteins, proteins located at the nuclear 
bodies, but also cytoplasmic and, most interestingly, viral proteins. SUMO2 and 3, but not SUMO1, 
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comprise an internal SUMOylation site allowing formation of poly-SUMO chains, usually as a stress 
response, with SUMO1 as possible chain end (Saitoh 2000; Johnson 2004; Vertegaal 2010). 
In addition to the covalent SUMOylation, which is methodically comparable to ubiquitination, a 
noncovalent modification of several SUMO interaction partners has been discovered recently 
(Kerscher 2007). While the covalent SUMO conjugation depends on a SUMO conjugation motif (SCM, 
Fig. 1.7, A), the noncovalent interaction is induced via a SUMO interacting motif (SIM) within the 
target protein (Fig. 1.4, B) and is also included in regulation of SUMOylation. Both types of SUMO 
modification of target molecules are described separately in the following sections. In general, it 
seems clear that the possible interplay of both SUMOylation and SUMO interaction dramatically 
expands the regulatory potential of the SUMO apparatus dramatically, since one SUMO may be 
covalently bound to one target protein via a SCM, while it targets another protein via SIM-based 
interaction (Gareau 2010, Fig. 1.7). This could also be one plausible reason for the fact that so many 
SUMO-regulated cellular mechanisms are described, although only a very small number of direct 
SUMO conjugates has been reported so far. This phenomenon is termed the SUMO enigma.  
 
 
Fig. 1.7: Overview of the different SUMO modification mechanism of SUMO targets. A During SUMOylation, the SUMO 
substrate is covalently attached to the C-terminal double glycine of the mature SUMO. The attachment is based on the 
formation of an isopeptide bond between an acceptor lysine (K) in the conserved SUMO conjugating motif (SCM) of the 
SUMO substrate and the C-terminal double glycine motif of the mature SUMO proteins. B SUMO interaction describes the 
noncovalent interaction of a SUMO target with SUMO via SUMO interacting motifs (SIMs) featuring a (V/I/L) X (V/I/L) (V/I/L) 
consensus motif. C Combination of SUMOylation and SUMO interaction may induce crossinteraction between SUMO 
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1.2.1 SUMO conjugation 
The SUMOylation pathway involves the covalent attachment of SUMO to a substrate by formation of 
an isopeptide bond linking the C-terminal carboxyl group of the SUMO with an ε-amino group of an 
acceptor lysine residue (Johnson 2004; Kerscher 2006; Capili 2007; Geiss-Friedlander 2007) (Fig. 1.8). 
 
Fig. 1.8: SUMOylated proteins. Schematic view of the isopeptide bond between the carboxy group at the C-terminal end of 
the double-glycine motif of the mature SUMO and the ε-amino group of the receptor lysine within the SUMO target 
molecules (SUMO substrates). 
 
 Before the conjugation is performed, in analogy to ubiquitin or other UBLs, the immature SUMO 
proteins are subjected to an activation step by cleavage by SUMO-specific proteases (SUSPs) to 
generate the mature SUMO form. Mature SUMO proteins feature a C-terminal double-glycine motif 
required for efficient adenylation by a heterodimeric SUMO E1 enzyme (note that the E1/E2/E3 
enzymes involved in SUMOylation are not related to the early (E-) genes of HPVs). The SUMO 
adenylate is linked to a conserved cysteine on a SUMO E1 protein to establish an E1~SUMO thioester 
and then further transferred to a conserved cysteine of a SUMO E2 protein (Ubc9) generating an 
E2~SUMO thioester, which can already be transferred to the receptor lysine residues of some of the 
SUMO substrates. However, in most cases, an E3 protein ligase catalyzes this process in a two step 
reaction to promote specificity and improve the release of SUMO from the E2~SUMO complex for 
transfer to the SUMO substrates (Reverter 2005; Hoeller 2007). Compared to ubiquitination, which is 
based on several E2 enzymes and hundreds of E3 enzymes, the substrate specificity during 
SUMOylation only depends on one E2 and a few E3 enzymes. Examples of proteins with an E3 ligase 
function, which mostly also contain SIMs, are the Ran-binding protein 2, protein inhibitor of STAT 
(PIAS) proteins, and the polycomb protein 2 (Pc2) (Pichler 2002; Seeler 2003; Rytinki 2009; Merrill, 
Melhuish et al. 2010). The SUMO conjugation can be reversed by deconjugation of SUMO from the 
substrates by the same SUMO-specific proteases (SUSPs) involved in maturation of the SUMO 
proteins (Mukhopadhyay 2007). The specificity of SUMO proteases arises from the distinct 
  Introduction 
  19 
subcellular localization of the proteases, which also feature specificity for some of the SUMO 
substrates as well as SUMO isoforms (Gong 2000; Kim 2000; Nishida 2000). 
For SUMOylation of the SUMO target, a ψKX(D/E) consensus motif (SUMO conjugation motif, SCM) 
within the substrate region containing the acceptor lysine was identified (ψ denotes a large 
hydrophobic residue (Rodriguez 2001)). The SCM is mostly localized at rather exposed positions in 
extended loops or intrinsically disordered regions. The residues of the motif directly interact with the 
Ubc9 of the SUMO E2 Ubc9 complex (Sampson 2001). Therefore, the short motif adopts an extended 
conformation enabling the acceptor lysine to fit into a hydrophobic groove of Ubc9, while 
electrostatic and hydrogen bonding between Ubc9 and the neighboring residues around the lysine 
mediate recognition of the sequence motif by E2 surface residues (Bernier-Villamor 2002; Lin 2002). 
This interaction is necessary to center the substrate within the active site of E2 and results in an 
increased rate of catalysis linking SUMO with the SUMO substrates (Yunus 2006). 
In some cases, SUMOylation depends on extended consensus motifs containing additional elements. 
The respective consensus motifs are described as phosphorylation-dependent SUMO motifs (PDSMs, 
mostly ψKX(D/E)XXSP) or negatively charged amino acid-dependent SUMO motifs (NDSMs) 
(Yamashita 2004; Shalizi 2006; Yang 2006). Phosphorylation generally seems to enhance 
SUMOylation, as was found for phosphorylation of heat shock factors after induction of cell stress 
(Hietakangas 2003). The enhancing effect is based on an interaction of the phosphorylated serine of 
the SUMO target with a basic patch on the E2 surface (Mohideen 2009). NDSMs comprise C-terminal 
negatively charged residues. Akin to the phospohrylated serines in PDSMs, here, the negatively 
charged residues interact with the basic patch on the E2 (Yang 2006). 
 
1.2.2 SUMO interaction 
The noncovalent interaction between SUMO and SUMO substrates is mediated by the SIM, as was 
initially identified by two-hybrid screening and biophysical studies (Minty 2000; Song 2004; Hannich 
2005; Kerscher 2007). The known SIMs share a hydrophobic core with a (V/I/L) X (V/I/L) (V/I/L) 
consensus motif flanked by acidic residues. The interaction is facilitated by an induced parallel or 
antiparallel β-strand conformation of the SIM region, which extends the β-sheet of the SUMO 
interaction surface and directs the hydrophobic core of the SIM into a hydrophobic pocket on the 
SUMO surface stabilized by H-bonding (Song 2005). The acidic residues apparently serve as first 
interaction platform and determine the polarity of the SIM-SUMO complex based on H-bonding or 
electrostatic interaction with conserved basic residues on the SUMO surface. Most SIMs, e.g. the 
SIMs of the base excision repair enzyme thymine DNA glycosylase (TD), promyelocytic leukaemia 
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protein (PML), or the transcription factor DAXX show no specificity for a particular SUMO isoform 
(Bernardi 2007; Geiss-Friedlander 2007; Kerscher 2007), but some do, like e.g. the ubiquitin-specific 
protease 25 (USP25) and the transcription regulators MCAF1 and COREST1 (Sekiyama 2008; Ouyang 
2009). The majority of SIM structures were analyzed in complexes with SUMO, so most molecular 
determinants of the SIM enabling SUMO specificity remain unknown. 
In some cases, SIM-mediated SUMO interaction is enhanced by phosphorylation of special serine 
residues, which are located c-terminally of the phospho-SIM (Stehmeier 2009). Usually, the serines 
are phosphorylated by the ubiquitously expressed and constitutively active casein kinase 2 (CK2), as 
was reported exemplarily for PML and PIAS proteins (Duncan 2008). The phosphorylated serines, 
now featuring a net negative charge due to the phosphate group, are believed to interact with basic 
residues on the SUMO surface (Stehmeier 2009). 
 
1.2.3 Targeting of the cellular SUMO apparatus by human pathogens 
Viruses and pathogens are obliged to escape or endure antiviral defense to facilitate productive 
infection. Besides antibody and cell-regulated acquired immunity and interferon mediated innate 
immunity, the viruses are also opposed to the so called intrinsic immunity as the first antiviral 
defense barrier. It is not very surprising that over long time periods, also viruses and other 
pathogens, with their very fast developing genomes, evolved multiple strategies to exploit the 
cellular SUMO apparatus. In general, the hot spot for interaction of the viruses with the host cell 
SUMO system seems to be represented by the PML-NBs (Day 1998; Everett 2001; Florin 2002b; 
Everett 2007; Tavalai 2008; Van Damme 2011). The PML-NBs are mainly comprised of PML and the 
chromatin organizer Sp100, which are both SUMOylated and recruit several antiviral factors like the 
transcription repressor DAXX, and the tumor repressors Rb and p53 to the PML-NBs (Swindle 1999; 
Zhong 2000a; Zhong 2000b; Day 2004; Shih 2007). The PML (promyelocytic leukemia) protein is the 
major component of PML-NBs and exists in at least seven isoforms which are essential for formation 
of PML-NBs and function as growth and transformation suppressors (Le, Yang et al. 1996). Sp100 
(speckled protein of 100 kDa) is also a permanent PML-NB component participating in chromatin 
remodeling and designated as transcription regulator (Seeler, Marchio et al. 1998; Bottomley, Collard 
et al. 2001). Multifunctional DAXX (death domain-associated protein 6) represents a transcription 
corepressor recruiting transcriptional repressors like histone deacetylase 1 (HADAC1), HADAC2, DNA 
methyltransferase 1 (DNMT1), or ATRX (α-thalassaemia/mental retardation syndrome X-linked)(Li, 
Leo et al. 2000; Hollenbach, McPherson et al. 2002; Xue, Gibbons et al. 2003; Ishov, Vladimirova et al. 
2004; Muromoto, Sugiyama et al. 2004). The assembly of PML-components in PML-NBs is involved in 
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apoptosis, regulation of transcription and antigen targeting and represents the innate antiviral 
defense barrier, which represses viral replication in the host. In most cases, in the early phase of 
infection, the viruses manage to associate, modulate, or even destroy the PML-NBs or degrade PML-
associated factors, which finally leads to a deactivation of the antiviral function of PML-NBs and is 
best analyzed for adenoviruses and herpesviruses (Wimmer 2012). A collection of results indicating 
an interaction of a large collection of proteins expressed in pathogens with the cellular SUMO 
apparatus is given in Table 1.1.  
As for papillomaviridae, it is known that the viral E1 and E2 proteins interact with Ubc9 and are 
SUMOylated (Yasugi 1997; Rangasamy 2000a). E1 SUMOylation seems to be regulated by the protein 
inhibitor of STAT (PIAS) family of E3 ligases. HPV E2 is SUMOylated in vitro and in vivo with a 
preference for SUMO-2/3 conjugation in vivo. Thereby, an exogenous overexpression of SUMO-2/3 
with Ubc9 significantly stabilizes E2 protein levels, whereas there is no stabilization with SUMO1 (Wu 
2007; Wu 2009). E2 stabilization does not depend on covalent attachment of SUMO-2/3 to the viral 
protein, since inactivation of the predominantly modified lysine residue does not lead to a modified 
stabilization level. One can conclude that in these systems, stabilization is not triggered by simple 
competition between ubiquitin and SUMO for covalent attachment sites, but rather by a regulation 
based on SUMOylated secondary targets.  
Also the HPV16 L2 is covalently modified by SUMO1 and, preferentially, by SUMO2/3 at lysine 35, 
which leads to stabilization of L2 (Marusic 2010). In this context, remarkably, only non-SUMOylated 
L2 can interact with the major capsid protein L1. For HPV16, the viral L2 protein seems to induce a 
short-lived change in the general SUMOylation status of host cell proteins by specifically upregulating 
endogenous SUMO-2/3 modification. Intriguingly, just during keratinocyte differentiation, expression 
of SUMO-2/3 and Ubc9 is significantly upregulated, whereas SUMO-1 levels remain unaltered 
(Deyrieux 2007). It seems that the level of viral E2 and L2 protein effectively modifies the levels of 
the host cell SUMOylation enzymes, which are directly coupled with the differentiation process in 
infected skin keratinocytes and antiviral defense. 
With regard to noncovalent interaction of pathogenic proteins with SUMO, 2-hybrid experiments 
identified a bit more than a handful of viral proteins interacting with SUMO (Wimmer 2012). From 
this selection, four viral proteins, ICP0 of the herpes simplex virus (Boutell 2011), ORF61 of the 
varicella zoster virus (Wang, Oliver et al. 2011), IE2 of the human cytomegalovirus (Kim 2010), and 
E3L of the vaccinia virus (Gonzalez-Santamaria, Campagna et al. 2011) were able to interact with 
SUMO via one or more SIMs.   
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Table 1.1: A selection of pathogens interacting with the cellular SUMO apparatus. 
Family  Pathogen  Protein  Features  References  
Adenoviridae  avian adenovirus chicken embryo 
lethal orphan CELO  
Gam-1  de-regulation of SUMOylation (Chiocca 2002; Colombo 
2002) 
 human adenovirus HAdV5 E1A, E1B interaction with Ubc9, affects 
polySUMOylation, SUMO substrate 
(Hateboer 1996; Endter 
2001; Endter 2005; 
Yousef 2010) 
Herpesviridae  α-Herpesviridae: herpes simplex 
virus HSV-1 
 
ICP0 links SUMOylation with ubiquitin-
dependent protein turnover, SUMO 
interaction 
(Boutell 2011) 
 α-Herpesviridae: varicella-zoster 
virus VZV 
ORF61 links SUMOylation with ubiquitin-
dependent protein turnover, SUMO 
interaction 
(Kyratsous 2009; 
Reichelt 2011; Wang, 
Oliver et al. 2011) 
 β-Herpesviridae: human 
cytomegalovirus HCMV  
IE1 
IE2  
SUMO substrate  
SUMO substrate, SUMO interaction 
(Spengler 2002; 
Sadanari 2005; Kim 
2010) 
 γ-Herpesviridae: Epstein Barr virus 
EBV  
Zta, Rta SUMO substrate  (Adamson 2001; 
Hagemeier 2010; 
Murata 2010) 
 γ-Herpesviridae: Kaposi’s sarcoma-
associated herpesvirus KSHV  
B-bZIP, 
Lana2 
SUMO substrate  (Izumiya 2005) 
Papillomaviridae  human and bovine papillomavirus 
HPV and BPV  





 HPV16 L2 SUMO substrate (Marusic 2010) 
Poxviridae  vaccinia virus VV  E3L  
A40R  
SUMO substrate, SUMO interaction  
SUMO substrate 
(Rogan 2000; Palacios 
2005; Gonzalez-
Santamaria, Campagna 
et al. 2011) 
RNA viruses  Bunyviridae: Hantaan virus HTNV, 
Tula virus TULV, Seuol virus SEOV  
N, NP  SUMO interaction  (Kaukinen 2003; Lee 
2003; Maeda 2003) 
 Coronaviridae: Severe acute 
respiratory sydrome SARS-CoV  
N  SUMO substrate, interaction with 
Ubc9  
(Li 2005) 
 Filoviridae: Ebola Zaire Virus EBOV  VP35  induces SUMOylation  (Chang 2007) 
 Flaviridae: Dengue virus DENV  env  interaction with Ubc9  (Chiu 2007) 
 Orthomyxoviridae: Influenza Virus NS1, PB1, 
M1, NS2  
SUMO substrate  (Pal 2010; Pal 2011; Wu 
2011; Xu, Klenk et al. 
2011) 
 Paramyxoviridae: 
Parainfluenzavirus PIV5  
P  SUMO substrate  (Sun 2011) 
 Picornaviridae: Enterovirus EV71  3C  SUMO substrate  (Chen 2011) 
 Retroviridae: Human 




SUMO substrate, SUMO 
interaction, interaction with Ubc9 
SUMO substrate 
(Gurer 2005; Jaber 
2009; Zamborlini, Coiffic 
et al. 2011) 
 Retroviridae: Human T-cell 
leukemia virus HTLV-1 
Tax SUMO substrate (Lamsoul, Lodewick et 
al. 2005; Kfoury, 
Setterblad et al. 2011) 
Extra/intracellular 
bacteria  
Yersinia spec  Yops  SENP-like  (Cornelis 2001) 
 Lysteria monozytogenes  LLO  Ubc9 modulation/degradation (Citro 2010; Ribet, 
Hamon et al. 2010) 
 Clostridium perfringens  PFO  Ubc9 modulation/degradation (Citro 2010; Ribet, 
Hamon et al. 2010) 
 Streptococcus pneumoniae  PLO  Ubc9 modulation/degradation (Citro 2010; Ribet, 
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1.3 Electron Paramagnetic Resonance (EPR) Spectroscopy 
1.3.1 The history of EPR 
Electron paramagnetic resonance (EPR) spectroscopy today represents a powerful tool for 
investigation of molecular structure and dynamics, as well as of the local distribution of 
paramagnetic centers (Schweiger 2001). Since its discovery in Kazan in 1944, EPR spectroscopy 
developed from a discipline for studying basic physical properties of condensed matter to a 
sophisticated and acknowledged research method for addressing a very broad collection of problems 
which emerge in most different research fields. Thus, over years, EPR spectroscopy manifested its 
place as a very special technique in material science and biophysics, which can also be attributed to 
three major benefits within the last four decades: i) the seminal work of Freed and others to 
theoretically describe the EPR effect in context of the analysis of molecular dynamics (Goldman 1972; 
Hwang 1975; Schneider 1989), ii) the onset of pulse EPR spectroscopy (Milov 1984; Höfer 1986), and 
iii) the possibility to perform distance measurements in the biophysically relevant range between 1 
and 8 nm (Milov 1984; Martin 1998; Pannier 2000; Jeschke 2002). For biophysicists, EPR is a powerful 
alternative or complement to neutron scattering, nuclear magnetic resonance (NMR), or Mößbauer 
spectroscopy, which allow comparable investigations.  
In general, the EPR method is based on the interaction of an electron spin of a paramagnetic center 
with an external magnetic field B0
.. Since naturally occurring paramagnetic systems are relatively 
seldom (examples are complexes of proteins with paramagnetic transition metals like e.g. Cu2+, Co2+, 
Ni1/3+, Mn2+, Fe3+ (Calle 2006)), without further efforts, the research field of EPR would be rather 
limited. However, just this limitation, the lack of naturally abundant paramagnetic species, 
simultaneously allows for the very promising artificial introduction of paramagnetic species into EPR 
samples. The apparent disadvantage leads to a very high specificity of EPR towards covalently 
attached spin labels or noncovalently introduced spin probes compared with e.g. NMR on 1H-nuclei 
(Kocherginsky 1995; Hubbell 2000). 
In the following section, the reader is familiarized with most common theoretical aspects of EPR and 
with the experimental EPR techniques, which were used here, with special focus on the respective 
problems addressed by each EPR technique. For a more detailed introduction to these techniques, 
the reader is referred to Atherton (1993) and Schweiger (2001). 
 
1.3.2 EPR radicals and site-directed spin labeling (SDSL) 
For EPR experiments, in general, the correct choice of the respective spin label or spin probe is of 
highest importance to extract a maximum of information from EPR measurements. For interaction 
studies including covalently attached spin labels to target proteins, common nitroxide radicals like 
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PROXYL IAA (3-(2-iodoacetamido)-PROXYL) or MTSSL (1-Oxyl-2,2,5,5-tetramethylpyrroline-3-methyl) 




Fig. 1.9: Chemical structure of the EPR spin probes used in this study. Chemical structure of common nitroxide spin 
probes: PROXYL IAA (3-(2-iodoacetamido)-PROXYL), MTSSL (1-Oxyl-2,2,5,5-tetramethylpyrroline-3-methyl), and Fremy’s Salt 
(potassium nitrosodisulfonate, NDS). 
 
The spin probes were covalently attached to the target proteins by site-directed spin labeling (SDSL) 
based on the presence of sulfhydryle (SH) groups, which occur within the amino acid side groups of 
cysteines contained within the target protein (Berliner 1982). An example is given for the covalent 




Fig. 1.10: Chemical structure for the attachment of MTSSL to a target protein. The stable radical MTSSL is covalently 
attached to a receptor cysteine. Thereby, a disulfide bond is generated between the label and the sulfhydryl group of the 
cysteine. 
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In principle, intrinsically abundant cysteines can be labeled as well as artificially introduced cysteins. 
Mutation experiments, which allow the insertion of cysteines at almost every position within the 
protein, therefore enable selective labeling throughout the whole primary sequence of the protein. 
In brief, the labeling reaction includes reduction of the target protein to prepare free and accessible 
sulfhydryl (SH) groups. In a one step reaction, the label is covalently attached to the reduced SH 
groups of the target protein by incubation of the sample protein with the respective spin label.  
 
For EPR experiments based on electrostatic interaction of the spin probe with HPV16 viruses, Fremy’s 
Salt (NDS) was used (Fig. 1.9). Here, the electrostatic interaction of the negatively charged NDS ions 
with stretches of several closely neighbored positively charged amino acids (arginines and lysines) 
within the target L1 and L2 capsid proteins of HPV16 pseudoviruses results in rather defined loci with 
a very high concentration of paramagnetic FS ions. Thus, FS can be noncovalently “attached” to 
positively charged amino acid patches of the target molecules. L2 comprises two patches of 
positively charged amino acids, which are represented by the nNLS and the cNLS at the N- and C-
termini of the protein. L1 comprises only one stretch of positively charged amino acids at its C-
terminus. 
 
1.3.3 EPR spectroscopic methods and their information content 
Characterization of the spin label is routinely performed based on continuous wave (CW) EPR at any 
temperature and on echo-detected (ED) EPR at low temperatures. The measurements give a 
fingerprint of the radical including especially electronic but also geometric information about the 
radical center (Fig. 1.11). 
Based on determination of the rotational motion by simulation of CW EPR, detailed information 
about molecular dynamics of the labeled molecule is accessible in the range of 10 ps - 1 µs. In a 
straightforward application, the change (or non-change) in rotational mobility can be used to prove 
(or rule out) whether a target molecule is attached to membranes or whether there is an interaction 
of two proteins (Beier and Steinhoff 2006; Musse, Boggs et al. 2006; Volkov, Dockter et al. 2009; 
Homchaudhuri L. 2010; Haimann, Akdogan et al. 2011; Kattnig, Bund et al. 2012). Furthermore, CW 
EPR spectra, also in combination with ED EPR measurement characterizing the T2 relaxation time, 
report on the immediate chemical environment (polarity, proticity) in the range of several solvation 
layers (up to 2 nm) around the paramagnetic center (Plato 2002; Junk, Jonas et al. 2008). Also 
information about closely located, dipolar coupled nuclei (mostly N or P atoms) can be obtained 
(Bund, Boggs et al. 2010). 
Additional pulse EPR measurements expand the accessible information content to a further extent. 
With hyperfine sublevel correlation (HYSCORE) spectroscopy and pulse electron-nuclear double 
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resonance (ENDOR), hyperfine couplings with surrounding magnetically active nuclei are detected 
and geometrically characterized, since the measurements are performed in frozen solution 
(Schweiger 2001). 
One of the main achievements is represented by the establishment of a pulse method detecting 
dipole couplings between the unpaired electron spins of the spin labels, allowing for biophysical 
structure determination (Milov 1984; Martin 1998; Pannier 2000; Jeschke 2002; Schiemann, Piton et 
al. 2007; Schiemann and Prisner 2007; Schiemann, Cekan et al. 2009). In this context, double 
electron-electron resonance (DEER) allows distance measurements via the ωdd r
-3 dependence (ωdd 
= dipolar coupling frequency, r = interspin distance). The limited EPR frequency range allows for a 





Fig. 1.11: Schematic summary of the information content of EPR spectroscopic methods on nitroxide radicals. CW EPR 
measurements (together with T2 detection in ESE experiments) deliver information about the direct vicinity of the spin 
label, including dipolar coupling to neighboring nuclei, but also dynamics of the label. Thus, e.g. membrane anchoring or 
protein-protein interactions can be addressed. The accessibility of the spin label to solvent molecules even allows for 
identification of helical regions. With pulsed EPR techniques like HYSCORE, information about potential nuclei, which 
interact with the spin label, can be obtained. Examples are special nitrogen nuclei involved in metal coordination or the 
protein backbone. DEER measurements allow for biophysical structure determination. With DEER, both intramolecular 
distances between two spin labels within the same molecule as well as intermolecular distances between different 
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1.3.3.1 Continuous wave (CW) EPR 
 
In liquid solution, the description of nitroxide radicals by the general anisotropic spin Hamilton 
operator is only based on the electron-Zeeman interaction and the hyperfine coupling to the 
magnetic 14N nucleus (I = 1)(Atherton 1993). The fast motion of the spin probe results in an averaging 
of the g- and hyperfine (A-) tensors to isotropic values and the resonance condition for the irradiated 
microwave is described by: 
 
IisoeSnit maBgE +==∆ 0βω  
 
Thus, the interaction with the nitrogen (I = 1) leads to three allowed transitions and the typical three-
line nitroxide spectrum (Fig. 1.12). 
 
 
Fig. 1.12: Splitting of the energy levels of a free electron spin in a magnetic field. The arrows indicate the allowed 
transitions excited by the micro wave. 
The effect of rotational motion and chemical environment on X-band CW EPR spectra is now 
explained in detail. The rotational correlation time τc  represents a measure for the rotational 
diffusion of the spin probe molecules and can roughly be categorized in the following regimes: i) fast 
motion (τc ≤ 100 ps), ii) intermediate motion (100 ns > τc  > 1 ns), and, iii) rigid limit (τc ≥ 1 µs, Fig. 1.13, 
A). In general, the rotational motion can be isotropic or anisotropic. The latter case is very often 
observed when spin labels are attached to larger molecules. 
The nitroxide spectra are also influenced by effects based on the local environment of the 
paramagnetic centers. Figure 1.13 B depicts the basic principal axis system of electron-Zeeman and 
hyperfine tensors to describe the spectra. The electronic structure of the nitroxide is directly changed 
by different levels of polarity and/or proticity (pH, Fig. 1.13, C). The formation of H-bonds in polar 
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surrounding leads to an increased electron spin density at the nitrogen π-orbital (Fig. 1.11, D). This is 
reflected by changes of the hyperfine coupling parameter aiso : 
aiso (hydrophilic/polar) > aiso(hydrophobic/apolar) 
 
 
Fig. 1.13: Information from nitroxide CW EPR spectra. A The effect of rotational dynamics on CW EPR spectra: i) fast 
rotation with τc~10 ps leading to the typical, averaged three-line spectrum. The isotropic giso represents the center of the 
central line. The spacing between the lines is dominated by aiso, ii) intermediate motion with 100 ns > τc >1 ns, and iii) rigid 
limit with τc ~1 µs. B Principal axis system of electron-Zeeman and hyperfine tensors (collinear). C Influence of the chemical 
environment on CW EPR spectra. Hydrophilic or polar molecular surroundings lead to an increased electron spin density at 
the nitroxide 14N nucleus and an increased aiso and line splitting compared with hydrophobic and non-polar environments. D 
H-bonding in polar/hydrophilic environments (Figure based on Hinderberger, 2011). 
 
1.3.3.2 The electron spin echo (ESE)-detected EPR experiment 
One of the simplest pulse EPR experiments is based on detection of the primary echo, which 
describes the re-appearance of magnetization of the initial magnetization after a pulse sequence of 
(π/2)-τ-(π)-τ-echo. Based on this sequence, ESE-detected EPR is a technique where the pulse 
sequence is repeated at every magnetic field position during a sweep of the magnetic field (Fig. 1.14, 
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A). Finally, the echo intensity is plotted against the magnetic field to give the standard ESE-detected 
EPR spectrum depicted in Fig. 1.14, B. 
 
Fig. 1.14: A ESE pulse sequence with sweep of the magnetic field B0 and the pulse interval time τ. B Typical ESE-detected 
EPR spectrum. 
 
1.3.3.3 Nanoscale distance measurements with DEER 
In this type of pulse EPR measurements, the double electron-electron resonance (DEER) effect of the 
dipole interaction between two spins is used to deduce information about the distance distribution 
between electron spins in a system based on the r-3 dependence of the dipolar coupling frequency 
ωDD (Martin 1998; Pannier 2000; Jeschke 2002). One of the pulse EPR experiments, in which the 
dipolar coupling effects are efficiently isolated from other effects in the spin system, is the 4-pulse 
double electron-electron resonance (DEER) experiment described in the following. The pulse scheme 
of the typical 4-pulse DEER method is illustrated in Fig. 1.15, A. 
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Fig. 1.15. A DEER pulse sequence including the characteristic measurement parameters. B Excitation (vpump) /observation 
(vobserve) positions in the echo-detected EPR spectra selected for 4-pulse DEER experiments. 
 
Thereby, detection of the refocused echo is used, which bears the advantage of a dead time-free 
detection, and was actually developed in Mainz (Martin 1998). The echo intensity of the refocused 
echo is recorded as a function of the pump pulse position d2. The resulting spectrum contains the 
information of the dipolar coupling of the two spins. In a more detailed view, observer and pump 
spins are manipulated separately from each other by selection of two different microwave 
frequencies depicted in Fig. 1.15, B. Here, an ‘observer’ experiment with a refocused echo is 
performed on spins ‘A’ with frequency mw1 (vobserve ), while on spins ‘B’ a π (pump) pulse is applied 
with the resonance frequency mw2 (vobserve ). The irradiation time of the pump-pulse is varied 
between the position of the primary echo (which is not detected, but dephases again) and the last π-
pulse of the observer sequence. Spins ‘B’ are thus inverted by the π-pulse. This results in a changed 
magnetic field at the position of the ‘A’ spins. Therefore, the precession of the ‘A’ spins changes and 
magnetization features a phase difference of tDDDD ωφ =∆ . Finally, the intensity of the refocused 
echo is recorded as a function of the pump pulse position d2. 
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The distance range that is accessible by DEER measurements is limited at the lower end to ~ 1.5 nm 
by the technical excitation bandwidth of the mw pulse generators at X-band frequencies. Spins, 
which are closer than 1.5 nm feature stronger dipolar couplings with frequencies > 35 MHz, which 
significantly exceed the excitation bandwidth (but can often be detected in broadenings of the low-
temperature CW EPR spectra). The limitation at the upper end is directly determined by the dipolar 
evolution time and allows for detection of a theoretical maximum distance of ~ 8 nm with common 
EPR spectrometers. Larger distances only contribute to the homogeneous background signal. A 
typical, background-corrected DEER time trace and the resulting distance distribution are shown in 
Fig. 1.16, A and B, respectively. The modulation depth is defined as the depth of the intramolecular 
oscillation after background correction and is a direct measure of the number of interacting spins. 
 
 
Fig. 1.16: A DEER time trace after removal of the experimental background obtained for a mixture of two rigid nitroxide 
biradicals. The measured spectrum (black) contains contributions of two oscillations with different dipoar frequency ωDD. B 
The corresponding distance distribution is obtained after direct intergral transformation of the time trace in A and shows 
two peaks correlated to the two dipolar coupling frequencies. Note that a higher dipolar coupling frequency is correlated to 
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1.4 Motivation and Aim 
The minor capsid protein L2 of the human papillomavirus (HPV) type 16 fulfills a multiplicity of 
important functions during the HPV16 life cycle including interaction with furin during cell binding of 
the HPVs, facilitation of viral disassembly, endosomal escape, and transport of the L2-DNA complex 
towards the PML-NBs, but also regulation of transcription of viral proteins in late infection phase and 
stabilization of the freshly assembled L1/L2 capsids just before release of new HPVs after succesfull 
infection. However, little is known about the interaction of L2 with cellular factors just after nuclear 
entry of the L2-DNA complex, which represents a key situation in counteracting antiviral defense 
systems bundled in PML-NBs of the target cell, but at the same time taking benefit from the host 
replication machinery by colocalization with the same PML-NBs to establish viral replication. 
The aim of this work was to unravel the complex L2 interaction mechanism with cellular target 
proteins, which regulates the transport of the viral DNA into subnuclear structures known as PML-
NBs, replication of viral DNA, viral transcription, and also morphogenesis of new viral particles. An 
additional challenge was to purify the HPV16 L2 protein and to establish new experimental methods, 
to characterize HPV infection and, in particular, to make the model system of a virus accessible to a 
very special technique like electron paramagnetic resonance (EPR) spectroscopy. Thereby, the special 
focus was on the interaction of HPV16 L2 with one of the most abundant proteins in PML-NBs, the 
small ubiquitin-like modifiers (SUMOs). SUMOs are indispensible for functionality of a number of 
PML-NB associated cellular factors featuring also antiviral functions but also play a role to establish 
infectivity for some viruses. Also, L2 interacts with the host SUMO apparatus, as we were able to 
reproduce covalent SUMOylation of L2, which was reported before, but additionally identified a 
noncovalent interaction of L2 with SUMO proteins, which is based on a conserved SUMO-interacting 
motif (SIM) at L2 position 286-289. The identified SIM was indispensible for infectivity for HPV16 
L1/L2 PsVs. Although PsVs lacking the SIM did not show any detectable aberrations in cell binding 
and endocytosis, there was no nuclear transport of the L2-DNA complex and no colocalization of L2 
or DNA with PML-NBs, explaining the complete loss of infectivity of SIM deficient PsVs. However, the 
L2 SIM seems to be crucial for additional tasks of L2 in the context of PML NBs, which most obviously 
include regulation of the activity of several PML-NB-associated host factors involved in viral defense 
and viral replication, as it was already observed for DAXX or Sp100. 
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  2. Materials and methods 
 
2.1 Materials 
2.1.1 Laboratory equipment 
Tab. 2.1: Laboratory equipment. 
equipment type manufacturer 
analytical balance Mettler AE 100 Mettler 
blot chamber Trans Blot Cell BioRad 
centrifuge Sorvall RC-5B Du Pont instruments 
centrifuge Megafuge 1.0 Heraeus 
centrifuge Laborfuge 400R Heraeus 
centrifuge Biofuge Pico Heraeus 
centrifuge Biofuge fresco Heraeus 
electric pipettes Pipetus®-akku Hirschmann Laborgeräte 
electrophoresis chamber (DNA) n.a. LMS GmBH Labortechnik 
electrophoresis chamber (protein) n.a. BRL Life Technologies 
ELISA reader Multiscan RC models 351 Thermo Labsystems 
FACS FACScan Becton Dickinson 
fluoeescence microscope Axiovert 200M ZEISS 
gel documentation Transillumination BioDocAnalyze Biometra 
heat block (rotation) Thermomixer Comfort Eppendorf 
heat block (static) Blockthermostat BT1303 HLC 
incubator (cell culture) Heraeus 6000 Heraeus 
incubator (E. coli) n.a. WTC Binder 
laboratory balance BL1500S Sartorius 
light microscope Wilovert S AFL Hund Wetzlar 
luffing incubator Rocky Heraeus 
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luminometer (plate format) Tristar LB941 Berthold Technologies 
luminometer (tube format) Lumat LB9507 Berthold Technologies 
magnetic stirrer/heater IKAMAG REC-G Janke & Kunkel 
micro wave Micromat AEG 
pH-meter pH Level 2  InoLab 
pipettes P10, P20, P100, P200, P1000 GISLON 
power supply (DNA gels) Gene Power Supply GPS200/400 Pharmacia 
power supply (protein blotting) PowerPack P25 Biometra 
power supply (protein blotting) PHERO-stab.500 Biotec-Fischer 
power supply (protein gels) ECPS3000/150 Pharmacia 
power supply (protein gels) Standard Powerpack P25 Biometra 
rotor SW40, SW55, SW60, 70Ti Beckmann 
rotor GS 3, GSA, HB-4 Du Pont Instruments 
shaking device Certomat R B.Braun 
shaking device Certomat HK B.Braun 
shaking device (over head) Reax2 Heidolph 
shaking incubator Certomat Sartorius 
sonifier Sonifier 250 Branson 
sterile flow NU-440-400E (Class II) Biological safety cabinets 
thermocycleer T-Gradient Biometra 
ultra centrifuge L8-70M Beckmann 
UV transilluminator TFX-35-MC Vilber Lourmat 
vortexer MS1 Minishaker JK 
water bath W12D Peter Huber GmbH 
 
EPR CW-spectrometer (X-band): 
- MiniScope MS200 with TE102 rectangular resonator, mt magnettech GmbH Analysemesstechnik, 
Berlin; 
- Temperature Controller HO2, mt magnettech GmbH Analysemesstechnik, Berlin; 
- Frequency Counter Model 3200, XL-Microwave Inc. Oakland (CA) USA. 
EPR pulse-spectrometer (X-band): 
- Bruker Elexsys 580 EPR spectrometer with a Bruker Flexline split-ring resonator ER 4118X_MS3, 
Bruker biospin GmbH, Wikingerstraße 13, Mühlburg, Karlsruhe, Germany; 
- Closed cycle cryostat, ARS AF204, customized for CW and pulse EPR, ARS, Macungie, PA, USA; 
- Temperature controller, Lake Shore Cryotronics, Inc., 575 McCorkle Blvd, Westerville, OH 43082- 
8888, USA; 
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- Frequency counter & X-band magnet, Bruker biospin GmbH, Wikingerstraße 13, Mühlburg, 
Karlsruhe, Germany; 
- Vacuum pump, Pfeiffer Vacuum GmbH, Berliner Straße 43, 35614 Asslar, Germany. 
 
All plastics laboratory materials were purchased from Falcon/Beckton Dickinson, Greiner, or Sarstedt. 
Glass ware was obtained from Schott. Further lab equipment is listed in Tab. 2.2. 
 
2.1.2  Chemicals 
Standard chemicals were purchased from Acros, Alexis Biochemicals, AppliChem, Becton Dickinson, 
Fluka, GE Healthcare, Gibco BRL, Invitrogen, Merck, Pharmacia-LKB Biotechnology, Roche, Roth, 
Serva or Sigma Aldrich. Dialysis membranes were purchased from Millipore and nitrocellulose 
membranes from Schleicher & Schüll. Concentratrors were purchased from Sartorius. 
 
2.1.3 Ready-to-use reagents and kit systems 
Tab. 2.2: Ready-to-use reagents and kit systems. 
product vendor description 
3-(2-iodoacetamido)-PROXYL Acros EPR label for site-directed spin labeling (SDSL) 
5,5'-dithiobis-(2-nitrobenzoic acid), DTNB Thermo Scientific quantification of thiols 
BioRad Protein Assay BioRad protein quatification 
BODIPY®507/545IA Invitrogen fluorescence labeling 
Cell Culture Lysis Reagent Promega cell lysis reagent 
Click-iT® EdU Imaging Kit Invitrogen Edu staining for immunofluorescence 
cOmplete protease inhibitor Roche protease inhibitor tablets 
Cytotoxicity Detection KITPLUS (LDH) Roche cytotoxicity assay 
Fluoprep bioMérieux fixation reagent for preparation of microscopic slides 
Glutathione SepharoseTM 4B GE Healthcare protein purification 
His60 Ni Superflow resin Clontech protein purification 
Hoechst 33342 Sigma Aldrich DNA staining 
jetPEITM Polyplus transfectionTM DNA transfection 
JetPEITM DNA transfection reagent Polyplus transfectionTM DNA transfection 
KOD hot start DNA polymerase Novagen PCR polymerase 
LipofectamineTM 2000 Invitrogen DNA transfection 
LipofectamineTM RNAiMAX Invitrogen RNA transfection 
Mammalian 2-Hybrid Assay Kit Stratagene mammalian protein interaction screening 
MATra-A Reagent IBA GmbH RNA transfection 
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methanetiosulfonate spin label (MTSSL) Alexis Biochemicals EPR label for site-directed spin labeling (SDSL) 
NucleoBond® Xtra Midi Macherey und Nagel plasmid DNA preparation from E. coli 
peqGOLD Gel Extraction Kit Peqlab preparation from DNA from agarose gels, PCR or restrictions 
peqGOLD Plasmid Miniprep KitI Peqlab plasmid DNA preparation from E. coli 
peqGOLD Pwo Polymerase Peqlab PCR polymerase 
Protein A/G PLUS Agarose Santa Cruz Biotechnology immuno precipitation 
PureProteomeTM Magnetic Beads Millipore immuno precipitation 
Quant-iTTM PicoGreen® Invitrogen DNA quantification 
ubiquitin agarose Sigma Aldrich ubiquitin binding assay 
Western LightningTM Plus-ECL Perkin Elmer Inc. Western Blot detection (ECL) 
β-Gal Triggering Reagent p.j.k substrate for luminescence measurements 
β-Gal-Juice PLUS p.j.k substrate for luminescence measurements 
 
2.1.4 Antibodies 
2.1.4.1 Primary antibodies 
Tab.2.3: Primary antibodies. 
antibody species  clone/specification dilution manufacturer 
anti-FLAG mouse monoclonal M2 WB 1:10000 Sigma Aldrich 
anti-Gal4 rabbit monoclonal A-712 WB 1:2000 Santa Cruz Biotechnology 
anti-GFP mouse monoclonal Jl-8 WB 1:10000 Clontech 
anti-HIS mouse monoclonal MMS-156R WB 1:5000 Covance 
anti-L1 mouse monoclonal 33L1-7 IF 1:10 M. Sapp 
anti-L1 rabbit monoclonal K75 IF 1:400, WB 1:1000 M. Sapp 
anti-L1 mouse monoclonal 16L1312F WB 1:300 M. Sapp 
anti-L2 mouse monoclonal 33L2-1 IF 1:500, WB 1:300 M. Sapp 
anti-PML rabbit polyclonal SC5621 IF 1:500 Santa Cruz Biotechnology 
anti-SUMO rabbit monoclonal A-712 WB 1:250-1:500 Boston Biochem 
anti-β-actin mouse monoclonal AC-15 WB 1:10000 Sigma Aldrich 
anti-γ-tubulin rabbit monoclonal T3195 WB 1:10000 Sigma Aldrich 
 
2.1.4.2  Secondary antibodies 
Tab.2.4: Secondary antibodies for immunofluorescence microscopy. 
antibody species  conjugate dilution manufacturer 
anti-mouse goat Alexa Fluor 488 1:400 Invitrogen 
  Alexa Fluor 546 1:400  
  Alexa Fluor 647 1:125  
anti-rabbit goat Alexa Fluor 488 1:250 Invitrogen 
  Alexa Fluor 546 1:250  
  Alexa Fluor 647 1:125  
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Tab.2.5: Secondary antibodies for Western Blot. 
antibody species  conjugate dilution manufacturer 
anti-mouse goat horseradish peroxydase 1:5000 Dianova 
anti-rabbit goat horseradish peroxydase 1:10000 Dianova 
anti-goat rabbit horseradish peroxydase 1:8000 Dianova 
 
2.1.5 Standard buffers and solutions 
DNA loading dye, 10 x:   0.42% (w/v) xylene cyanol 
     0.2% (w/v) OrangeG 
     50% (v/v) glycerole 
 
SDS-PAGE protein loading dye, 1 x: 50 mM Tris pH 6.8 
(based on Lämmli)   2% (w/v) SDS 
     20% (v/v) glycerol 
     0.1% (w/v) bromphenole blue 
     5% (v/v) β-mercaptoethanol 
 
SDS-PAGE protein loading dye, 5 x: 250 mM Tris HCl pH 6.8 
     8% (w/v) SDS 
     30% (v/v) glycerol 
     0.2% (w/v) bromphenole blue 
     10% (v/v) β-mercaptoethanol 
 
SDS-PAGE running buffer, 10 x:  0.25 M Tris pH 8.0 
     1.92 M glycin 
     1% (w/v) SDS 
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SDS-PAGE solution A:   30% (v/v) acrylamid 
(based on Lämmli)   0.8% (v/v) bisacrylamide 
 
SDS-PAGE solution B:   1.5 M Tris-HCl ph 8.8 
(based on Lämmli)   0.4% (w/v) SDS 
 
SDS-PAGE solution C:   0.5 M Tris-HCl ph 6.8 
(based on Lämmli)   0.4% (w/v) SDS 
 
TAE buffer, 10 x , pH 8.0:  400 mM Tris 
(for DNA agarose gels)   200 mM sodium acetate 
     10 mM EDTA 
 
Western Blot transfer buffer:  25 mM Tris 
     192 mM glycin 
     20% (v/v) methanol 
 
PBS/Tween:    1 x PBS 
     0.1% (v/v) Tween 20 
 
Stripping buffer:   62.5 mM Tris HCl pH 6.8 
(for nitrocellulose membranes)  2% (w/v) SDS 
     0.1 M β-mercaptoethanol 
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Ponceau S protein stain:  0.1% (w/v) Ponceau S 
     3% (v/v) trichloro acetic acid 
 
2.1.6 Enzymes 
Enzymes used for standard restriction of DNA were purchased from New England Biolabs and used 
according to the manufacturer’s protocol. T4-DNA ligase was purchased from Fermentas. 
Benzonase® and LysonaseTM were purchased from Sigma Aldrich and Novagen. 
 
2.1.7 DNA plasmids 
2.1.7.1 DNA plasmids for L2 and SUMO1/2 protein expression and purification 










mammalian Ampicillin C-term His-
tag, his 
beads 
Tetracyclin vector was provided by G. Spoden 
pLexsyI-neo2 
his10 L2 wt 
(codonopt) 
L. tarentolae Neomycin N-term His-
tag, his 
beads 
Tetracyclin 16L2 was isolated by NdeI/KpnI-HF 
restriction from pcDNA3.1 NdeI L2 and 
inserted into the NdeI/KpnI-HF restricted 
target vector pLexsyI-nleo2 his10 
(codonopt), which was produced  by 
insertion of the BglII/NcoI isolated DNA 
fragment from pLexsyI-bleo2 his10 
(codonopt) into the BglII/NcoI restricted 
target vector pLexsyI-neo2 
pLexsyI-bleo2 
his10 L2 wt  
(codonopt) 
L. tarentolae Bleomycin N-term His-
tag, his 
beads 
Tetracyclin 16L2 was isolated by NdeI/KpnI-HF 
restriction from pcDNA3.1 NdeI L2 and 
inserted into the NdeI/KpnI-HF restricted 
target vector pLexsyI-bleo2 his10 
(codonopt), which was produced with 




E. coli Kanamycin C-term His-
tag, his 
beads 
IPTG purchased via addgene.com, ID25101, 
Mikolajczyk et al. 
pet28a pro 
SUMO2 
E. coli Kanamycin C-term His-
tag, his 
beads 
IPTG purchased via addgene.com, ID25102, 
Mikolajczyk et al. 
pGEX-6p-1 
SUMO1 
E. coli Ampicillin GST-tag, 
glutathione 
beads 
IPTG SUMO1 was isolated by BamHI/XhoI 
restriction from pEGFP-CI-SUMO1 and 
inserted into the BamHI/XhoI restricted 
target vector pGEX-6p-1 
pGEX-6p-1 
SUMO2 
E. coli Ampicillin GST-tag, 
glutathione 
beads 
IPTG SUMO2 was isolated by BglII/NotI 
restriction from pLexsy SUMO2 and 
inserted into the BamHI/XhoI restricted 
target vector pGEX-6p-1 
pet19b L2 wt E. coli Ampicillin N-term His-
tag, his 
beads 
IPTG 16L2 was isolated by NdeI/XhoI restriction 
from pcDNA3.1 NdeI L2 and inserted into 
the NdeI/XhoI restricted, de-
phosphorylated target vector pet19br 
pcDNA3.1 
Hygro (-) his10 
L2 wt 
mammalian Ampicillin N-term His-
tag, his 
beads 
constitutive 10xhis16L2 fragment was isolated by 
BglII/KpnI restriction from pLexsyI-neo2 
his10 L2 wt (codonopt) and inserted into 
the BamHI-HF/KpnI-HF restricted target 
vector pcDNA3.1 Hygro (-) 
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pcDNA3.1 (+) 
L2 wt his6 
mammalian Ampicillin C-term His-
tag, his 
beads 
constitutive L2-his6 was isolated with BglII/NotI 
restriction from pLexsyI-neo2-L2 his6 
inserted into a BglII/NotI restricted pCMV-
HA target vector. Then, L2-his6 was 
isolated by EcoRI/NotI restriction and 
inserted into the EcoRI/NotI restricted 
target vector pcDNA3.1 (+) 
pcDNA3.1 (+) 
L2 C22S his6 
mammalian Ampicillin C-term His-
tag, his 
beads 
constitutive vector was produced by mutagenesis PCR 
based on pcDNA3.1 (+) L2 wt his6 
pcDNA3.1 (+) 
L2 C28S his6 
mammalian Ampicillin C-term His-
tag, his 
beads 
constitutive vector was produced by mutagenesis PCR 
based on pcDNA3.1 (+) L2 wt his6 
pGEX-6p-1 16 
L2 wt 
E. coli Ampicillin GST-tag, 
glutathione 
beads 
IPTG A BamHI-16L2-EcoRI DNA fragment 
produced by PCR based on the pUF 16L2 
vector was restricted with BamHI/EcoRI 
and inserted into the BamHI/EcoRI 
restricted target vector pGEX-6p-1 
 
2.1.7.2 DNA plasmids for mammalian 2-hybrid interaction assays 
Tab. 2.7: DNA plasmids for mammalian 2-hybrid interaction assays. 
vector resistance characteristics vector origin 
pAD-SV40T Ampicillin positive interaction with p53 original vector 
pAD-TRAF Ampicillin negative interaction wiith 
p53 
original vector 
pBD-p53 Ampicillin positive interaction with 
SV40T 
original vector 
pCMV AD Ampicillin original vector for expression 
of the prey protein 
original vector 
pCMV AD-16L2 wt Ampicillin expression of HPV16 L2 as 
prey protein 
L2 was isolated by EcoRI/NotI restriction 
from pCMV HA 16L2 and inserted into the 
EcoRI/NotI restricted target vector pCMV 
AD 
pCMV AD-SUMO1 Ampicillin expression of SUMO2 as prey 
protein 
vector was provided by G. Spoden 
pCMV AD-SUMO2 Ampicillin expression of SUMO2 as prey 
protein 
vector was provided by G. Spoden 
pCMV BD Ampicillin original vector for expression 
of the bait protein 
original vector 
pCMV BD-16L2 wt Ampicillin expression of HPV16 L2 as 
bait protein 
vector was provided by G. Spoden 
pCMV BD-SUMO1  Ampicillin expression of SUMO1 as bait 
protein 
vector was provided by G. Spoden 
pCMV BD-SUMO1 ΔGG Ampicillin expression of SUMO1 ΔGG-
stop as bait protein 
SUMO1 ΔGG was produced by PCR 
restricted with BamHI/PstI and inserted into 
the BamHI/PstI restricted target vector 
pCMV BDS 
pCMV BD-SUMO2 Ampicillin expression of SUMO2 as bait 
protein 
SUMO2 was isolated by NotI/BamHI 
restriction from pCMV AD SUMO2 and 
inserted into the NotI/BamHI restricted 
target vector pCMV BD 
pCMV BD-SUMO2 ΔGG Ampicillin expression of SUMO2 ΔGG-
stop as bait protein 
SUMO2 ΔGG was produced by PCR 
restricted with BamHI/PstI and inserted into 
the BamHI/PstI restricted target vector 
pCMV BDS 
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2.1.7.3 DNA plasmids for further L2 and SUMO1/2 characterization 
Tab. 2.8: DNA plasmids for further HPV16 L2 and SUMO1/2 characterization. 
vector resistance characteristics vector origin 
pEGFP CI Kanamycin expression of GFP 
protein in mammalian 
cells 
original vector 
pEGFP CI SUMO1 Kanamycin expression of GFP-
SUMO1 fusion protein in 
mammalian cells 
vector was provided by G. Spoden 
pEGFP CI SUMO1 ΔGG Kanamycin expression of GFP-
SUMO1 ΔGG fusion 
protein in mammalian 
cells 
SUMO1 ΔGG was isolated by BamHI/PstI 
restriction from pCMV BD SUMO2 and 
inserted into the BglII/PstI restricted target 
vector pEGFP CI 
pEGFP CI SUMO2 Kanamycin expression of GFP-
SUMO2 fusion protein in 
mammalian cells 
vector was provided by G. Spoden 
pEGFP CI SUMO2 ΔGG Kanamycin expression of GFP-
SUMO2 ΔGG- fusion 
protein in mammalian 
cells 
SUMO2 ΔGG was isolated by BamHI/PstI 
restriction from pCMV BD SUMO2 and 
inserted into the BglII/PstI restricted target 
vector pEGFP CI 
pUF AAV #893 16L2 K35R Ampicillin expression of HPV16 L2 
K35R in mammalian cells 
vector was provided by G. Spoden 
pUF AAV #893 16L2 wt Ampicillin expression of HPV16 L2 
wt in mammalian cells 
original vector, Leder et al., 2001 
pcDNA 3.1 (+) 16L2 wt Ampicillin expression of HPV16 L2 
wt in mammalian cells 
vector was provided by G. Spoden 
pcDNA 3.1 Hygro (-)  Ampicillin original vector used to 
adjust DNA to a faixed 
total amount 
original vector 
pcDNA 3.1 Hygro (-) 16L2 
K35R (ΔSCM) 
Ampicillin expression of HPV16 L2 
K35R (ΔSCM) in 
mammalian cells 
vector was produced by mutagenesis PCR 
based on pcDNA 3.1 Hygro (-) 16L2 wt 
pcDNA 3.1 Hygro (-) 16L2 wt Ampicillin expression of HPV16 L2 
wt in mammalian cells 
vector was provided by G. Spoden 
pcDNA3.1 (+) Ampicillin original vector used to 
adjust DNA to a faixed 
total amount 
original vector 
pcDNA 3.1 Hygro (-) 16L2 286-
9AAAA (ΔSIM) 
Ampicillin expression of HPV16 L2 
286-9AAAA ( ΔSIM) in 
mammalian cells 
vector was produced by mutagenesis PCR 
based on pcDNA 3.1 Hygro (-) 16L2 wt 
pcDNA 3.1 Hygro (-) 16L2 
295/6AA (ΔPHOS) 
Ampicillin expression of HPV16 L2 
TS296/6AA in 
mammalian cells 
vector was produced by mutagenesis PCR 
based on pcDNA 3.1 Hygro (-) 16L2 wt 
 
2.1.7.4 DNA plasmids for preparation of HPV16 pseudoviruses (PsVs) 
Tab. 2.9: DNA plasmids for preparation of HPV16 pseudo virions (PsVs). 
vector resistance characteristics vector origin 
pSHELL 16L1/L2 286-9AAAA 
(ΔSIM) 
Ampicillin expression of HPV16 
16L1/L2 286-9AAAA 
(ΔSIM) 
L2 ΔSIM was isolated by NheI/EcoRV 
restriction from pcDNA 3.1 Hygro (-) 16L2 
286-9AAAA (ΔSIM) and inserted into the 
XbaI/EcoRV restricted target vector pSHELL 
16L1/L2 wt 
pSHELL 16L1/L2 K35R (ΔSCM) Ampicillin expression of HPV16 
16L1/L2 K35R 
L2 ΔSCM was isolated by NheI/EcoRV 
restriction from pcDNA 3.1 Hygro (-) 16L2 
K35R (ΔSCM) and inserted into the 
XbaI/EcoRV restricted target vector pSHELL 
16L1/L2 wt 
pSHELL 16L1/L2 TS295/6AA 
(ΔPHOS) 
Ampicillin expression of HPV16 
16L1/L2 TS295/6AA 
(ΔPHOS) 
L2 ΔPHOS was isolated by NheI/EcoRV 
restriction from pcDNA 3.1 Hygro (-) 16L2 
295/6AA (ΔPHOS) and inserted into the 
XbaI/EcoRV restricted target vector pSHELL 
16L1/L2 wt 
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pSHELL 16L1/L2 wt Ampicillin expression of HPV16 
16L1/L2 wt 
original vector 
pUF3 AAV #893 16L1 wt Ampicillin expression of HPV16 L1 
wt 
original vector, Leder et al., 2001 
pcDNA 3.1 (+) Luciferase Ampicillin luciferase expression original vector, Schneider et al., 2011 
 
2.1.8 PCR primers, DNA oligonucleotides, siRNAs 
Tab. 2.10: Mutagenesis primers, sequencing primers, DNA oligonucleotides, and siRNAs. DNA or RNA oligonucleotides 
were purchased from Sigma, biomers, or eurofins. 
mutagenesis primers sequence 
16 L2 3’-Stop KpnI 5‘-TTT GGT ACC TCA GGC GGC CAG GCT CAC GTC-3´ 
16 L2 K35R forward 5´-GCA CAG GCC CGC CCT GGC GGC GAG GAG GAC CGG CAT CAG G-3´ 
16 L2 K35R reverse 5´-CCT GAT GCC GGT CCT CCT CGC CGC CAG GGC GGG CCT GTG C-3´ 
L2 C22S forward 5‘-CTG TAC AAG ACC AGC AAG CAG GCC GG-3´ 
L2 C22S reverse 5‘-CTG GGT GGC GCT GGC CCT CTT GGT CC-3´ 
L2 C28S forward 5‘-CAG GCC GGC ACC AGC CCC CCC GAC ATC-3´ 
L2 C28S reverse 5‘-CTT GCA GGT CTT GTA CAG CTG GGT GG-3´ 
L2 ΔPHOS forward 5‘-G CAC AGG CCC GCC CTG GCG GCG AGG AGG ACC GGC ATC AGG-3‘ 
L2 ΔPHOS reverse 5‘-CCT GAT GCC GGT CCT CCT CGC CGC CAG GGC GGG CCT GTG C-3‘ 
L2 ΔSIM forward 5‘-CGA CCC CGA CTT CCT GGA CGC CGC CGC CGC CCA CAG GCC CGC CCT GAC C -3´ 
L2 ΔSIM reverse 5‘-GGT CAG GGC GGG CCT GTG GGC GGC GGC GGC GTC CAG GAA GTC GGG GTC G-3´ 
NdeI-16 L2his forward 5‘-ATT CAT ATG AGG CAC AAG AGG AGC GCC-3´ 
SUMO1 ΔGG forward 5‘-ATT GGA TCC ATG TCT GAC CAG GAG GCA AAA C-3´ 
SUMO1 ΔGG reverse 5‘-AGC CTG CAG TCA CGT TTG TTC CTG ATA AAC TTC AAT C-3´ 
SUMO2 ΔGG forward 5‘-ATT GGA TCC ATG GCC GAC GAA AAG CCC AAG G-3´ 
SUMO2 ΔGG reverse 5‘-AGC CTG CAG TCA CGT CTG TTG GAA CAC ATC-3´ 
  
sequencing primers sequence 
BGH reverse 5´-TAG AAG GCA CAG TCG AGG-3´ 
CMV forward 5´-CGC AAA TGG GCG GTA GGC GTG-3´ 
pGEX reverse 5´-CCG GGA GCT GCA TGT GTC AGA GG-3´ 
pMK1-5´ pUF3 forward 5´-AAG CTG CGG AAT TGT ACC CG-3´-3´ 
pUF reverse 5´-ACA GAT GGC TGG CAA CTA GAA GG-3´ 
T7 forward 5´-AAT ACG ACT CAC TAT AGG-3´ 
  
oligonucleotides sequence 
his10-L2 forward 5´-GA TCT GCC ATG GGC CAC CAC CAC CAC CAC CAC CAC CAC CAC CAC AGC AGC GGC CAC ATC GAC GAC GAC GAC AAG CAT ATG C-3´ 
his10-L2 reverse 5´-CA TGG CAT ATG CTT GTC GTC GTC GTC GAT GTG GCC GCT GCT GTG GTG GTG GTG GTG GTG GTG GTG GTG GTG GCC CAT GGC A-3´ 
  
siRNAs sequence 
SUMO1 siRNA CAAAGAAUCAUACUGUCAAtt 
SUMO2 siRNA #1 GUUGGAAAUGGAGGAUGAAtt 
SUMO2 siRNA #1 GAGGCAUACACCACUUAGUtt 
luciferase siRNA (GL3) CUUACGCUGAGUACUUCGAtt 
control siRNA AllStars Negative Control siRNA (Quiagen) 
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2.1.9  Synthetic L2 peptides 
The synthetic L2 SIM peptides used for this work were purchased from GenScript (USA). Quantity was 
about 1-4 mg with >95% purity, N-terminal acetylation, and C-terminal amidation. 
Tab. 2.11: Synthetic L2 SIM peptides. 
name sequence 
L2 SIMCys APDPDFLDIVALHRPACTSRRT 
L2 SIM APDPDFLDIVALHRPALTSRRT 
L2 CysSIM ICPDPDFLDIVALHRPALTSRRT 
 
2.1.10 Cell strains, cultures, and additives 
2.1.10.1 Mammalian tissue cultures 
HeLa:  Human cervix carcinoma cell line, HPV18 positive (Scherer, Syverton et al. 1953). 
HaCaT:  Human, spontaneously immortalized epithelial cell line (Boukamp, Petrussevska et al. 
  1988). 
HEK293/T/TT: Cell line derived from the human embryonic kidney cell line 293, without or with one 
  or two copies of the large T-Antigen from SV40 (Graham, Smiley et al. 1977; Pear, 
  Nolan et al. 1993; Buck 2004). 
Tab. 2.12: Human cell culture additives. 
product manufacturer characteristics 
0.05% Trypsin/0.02% EDTA Gibco detachment of cells 
Ciprofloxacin (2 mg/ml) Fresenius Kabi cell medium additive 
Dulbecco’s Modified Eagle Medium (DMEM) Gibco cell culture medium 
fetal calf serum (FCS) Gibco cell medium additive 
Hygromyvin B Roth selection antibioticum for HEK293TT cells 
nonessential amino acids (100 x) PAA Laboratories cell medium additive 
Penicillin/Streptomycin Invitrogen cultivation antibiotics 
 
2.1.10.2 Bacteria culture 
Tab. 2.13: Bacteria strains. 
strain resistances special features manufacturer 
Bl21-CodonPlus(DE3)-RIL Cam Cam: for rare codons additional plasmid Novagen 
NEB 5-alpha chemically 
competent cells 
- for cloning experiments and DNA preparation New England Biolabs 
rosetta 2 DE3 Cam Cam: for rare codons additional plasmid, 2: codon bias Novagen 
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rosetta-gami 2 DE3 Tet, Str, Cam Cam: for rare codons additional plasmid, Tet: selectible S-
S bonds, 2: codon bias 
Novagen 
rosetta-gamiB DE3 Kan, Tet, Cam Cam: for rare codons additional plasmid, Tet: selectible S-
S bonds, B: expression control 
Novagen 
SoluBL21 - specialized for soluble protein expression Genlantis 
TG1 Phage Display 
Electrocompetent Cells 
- for cloning experiments and protein expresssion Lucigen 
XL10-Gold Ultracompetent 
cells 




E. coli strains were routineously cultivated in LB (Luria Bertani) medium. For solid growth media, 
1.5% (w/v) agar was added before preparation of the plates. 
 
LB (Luria Bertani) medium:  0.5% (w/v) yeast extract 
     1% (w/v) trypton 
     1% (w/v( NaCl 
     pH 7.0 
 
low salt LB medium:   0.5% (w/v) yeast extract 
     1% (w/v) trypton 
     0.5% (w/v( NaCl 
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2.1.11 Molecular weight markers 
DNA was routineously characterized on agarose gels using the GeneRulerTM  1 kB DNA Ladder 
(Fermentas) (Fig. 2.1). 
 
Fig. 2.1: DNA ladder for agarose gelelectrophoresis (GeneRulerTM  1 kB DNA Ladder, Fermentas). 
 
For protein SDS-PAGE the Page RulerTM Prestained Protein Ladder was used (Fermentas, Fig. 2.2). 
 
Fig. 2.2: Prestained protein ladder for SDS-PAGE (Page RulerTM Prestained Protein Ladder, Fermentas). 
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2.2 Methods 
2.2.1 Working with DNA 
2.2.1.1 Fragmentation of DNA with restriction endonucleases 
A typical amount of 1 to 5 µg DNA was mixed with ultra pure water, reaction buffer, BSA, and the 
restriction endonuclease(s) and incubated for 1-2 h at 37 °C or the temperature of maximum 
enzymatic activity (Table 2.14). 
Tab. 2.14: Reaction mix for enzymatic DNA restriction. 
DNA target insert 
sample volume 20 µl 40 µl 
DNA 1 µg 5 µg 
10 x reaction buffer 2 µl 4 µl 
BSA (1 mg/ml) 2 µl 4 µl 
enzyme 2 µl max 4 µl max 
H2O ad 20 µl ad 40 µl 
 
2.2.1.2  Isolation of DNA fragments by agarose gel electrophoresis 
After DNA restriction with restriction endonucleases or to check DNA plasmids, the DNA was diluted 
in an appropriate volume of H2O, mixed with 10 x loading dye, and loaded onto 0.8-2.5% (w/v) 
agarose gels (containing about 0.5 µg/ml ethidium bromide) prepared with TAE buffer. The gels were 
run at 90 V (10 V per cm agarose gel). 
 
TAE buffer: 
40 mM Tris 
20 mM acetic acid 
1 mM EDTA. 
 
2.2.1.3 Preparation of DNA from agarose gels 
The isolation of DNA products from agarose gels was performed with a peqGOLD Gel Extraction Kit 
according to the manufacturer’s protocol. 
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2.2.1.4 Ligation of DNA fragments 
The DNA fragments were mixed with T4 DNA ligase reaction buffer and T4 DNA ligase and incubated 
for 1 h at 37 °C, over night at 16 °C, or over the weekend at 4 °C. The reaction was stopped and the 
enzyme was inactivated by incubation for 15 min at 65 °C.  
Tab. 2.15: T4 DNA ligation. 
DNA 45 µl (gel isolated DNA) 
10 x ligase buffer 5 µl 
T4 DNA ligase 5 µl 
 
2.2.1.5 Transformation of competent E. coli cells 
50-100 µl chemically competent E. coli cells were thawed on ice and mixed with 20-30 µl of the pre-
cooled and inactivated DNA ligation mix. The DNA content should not exceed about 200 ng DNA. The 
sample was incubated for 30 min on ice followed by a 30 - 60 s heat shock at 42 °C depending on the 
sample volume. The sample volume was filled up with LB medium to give a final volume of 1 ml and 
incubated for 1 h at 37 °C.  
 
2.2.1.6 Plating of E. coli cells on LB agar plates   
After transformation or longer storage of E. coli cultures, aliquots or the whole transformation mix 
were transferred onto LB agar plates (LB/ 1.5% (w/v) agar) containing antibiotics for selection (Table 
2.16). Small culture aliquots (up to 100 µl) were directly applied onto the plate. To apply larger 
amounts of cells, the culture was centrifuged for one min at 6,000 g. The cell pellet was resuspended 
in residual 50-100 µl culture medium and applied onto the plate. The plates were incubated bottom 
up at 37 °C over night. 
Tab. 2.16: Selection antibiotics used for E. coli cultures/agar plates. 
antibiotics ampicillin kanamycin tetracyclin chloramphenicol streptomycin 
final concentration 100 µg/ml 50 µg/ml 12.5 µg/ml 34 µg/ml 50 µg/ml 
 
2.2.1.7 Preparation of starter bacteria cultures 
After transformation of E. coli cells and plating on LB agar plates, single bacteria colonies were used 
to inoculate starter bacteria cultures. After cultivation for 10-16 hours at 37 °C, the cultures 
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produced enough cell material for DNA plasmid preparation or to inoculate large scale bacteria 
cultures for expression of recombinant proteins.  
 
2.2.1.8 Plasmid DNA preparation 
Mini plasmid DNA preparations for characterization of DNA by restriction enzymes were performed 
with a peqGOLD Plasmid Miniprep Kit according to the manufacturer’s protocol based on starter 
cultures, which were incubated over night at 37 °C. Midi scale plasmid DNA preparations were 
performed with a NucleoBond® Xtra Midi kit (Macherey und Nagel) based on 100-200 ml cultures, 
which were prepared by 1:1000 dilution of starter cultures, and incubated over night at 37 °C. After 
incubation, the cells were centrifuged at 6,000 g. Cell lysis and DNA isolation were performed 
according to the manufacturer’s protocol. The amount of isolated DNA (A260) and purity (A260/A280) 
was determined with a UV spectrophotometer.  
 
2.2.1.9 Standard polymerase chain reaction (PCR) 
PCR reactions were prepared according to a standard protocol in thin walled PCR tubes (Tab. 2.17). 
Tab. 2.17: Standard PCR reaction mix for amplification of target DNA. 
PCR component amount 
template DNA 100 ng 
forward and reverse primer (10 µM or 10 pmol/µl) 1.5 µl 
dNTP mix (10 mM) 1 µl 
10 x PCR buffer 5 µl 
Pwo polymerase 1 µl 
H2O ad 50 µl 
 
The PCR was performed according to a standard thermocycler protocol (Tab. 2.18). 
Tab.2.18: Thermocycler program for standard PCR amplification of target DNA. 
time temperature step 
5 min 95 °C denaturation 
1 min 95 °C denaturation 
1 min Tm-5 °C annealing 
30 s - 120 s/Kb 65-72 °C elongation 
5 min 65-72 °C final elongation 
 
30-40 x 
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2.2.1.10 Mutagenesis PCR 
Mutagenesis PCR was performed to selectively introduce DNA mutations into a DNA region of 
interest. Here, the usage of two complementary DNA primers containing the mutation(s) leads to a 
replication of the entire DNA plasmid and insertion of the mutations into the replicated DNA. 
Mutagenesis PCR was performed based on the peqGOLD Pwo-DNA-Polymerase kit, the Phusion® 
Site-Directed Mutagenesis Kit (Finnzymes, ThermoScientific), or the Stratagene Pfu DNA polymerase 
kit (Tab. 2.19). 
. 
Tab.2.19: Mutagenesis PCR reaction mix. 
PCR component amount 
10 x PCR buffer 5 µl 
dsDNA template 5-50 ng 
forward and reverse primer (10 µM or 10 pmol/µl) 1.5 µl 
dNTP mix (10 mM) 1 µl 
Pfu Turbo DNA polymerase 1 µl 
H2O ad 50 µl 
 
The reaction protocol was changed according to the specificities of a mutagenesis PCR. Here, less 
final DNA is needed, since no subcloning steps are needed afterwards and the number of repeated 
steps is lowered to 20. In contrast, the elongation time has to be expanded because the whole 
plasmid is replicated during PCR (Tab. 2.20). 
Tab.2.20: Thermocycler program for mutagenesis PCR. 
time temperature step 
5 min 95 °C denaturation 
1 min 95 °C denaturation 
45 s 52-60 °C annealing 
2 min/Kb 68 °C elongation 
5 min 65-72 °C final elongation 
 
After the PCR, the template DNA was digested by DpnI restriction for 3 h at 37 °C. Finally, 2-5 µl DNA 
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2.2.2 Cultivation of human adherent cells 
2.2.2.1 Cultivation of cell lines 
Human HeLa, HaCaT, HEK293, HEK293T, and HEK293TT cells were used. Cell cultivation was always 
performed under sterile conditions. Cell incubation was performed at 37 °C and 5% CO2. The cells 
were cultivated in single layer flasks in Dulbecco’s modified Eagle Medium (DMEM) containing 
nonessential amino acids, 10% (v/v) fetal bovine serum (FCS), and Pen/Strep (Roth). For improved 
selection of HEK293TT cells, 200 µg/ml Hygromycin B were added to the medium once a week. 
Passaging of the adherent and confluent cells was performed by removal of the cell medium and a 
washing step with PBS/2.5 mM EDTA. Incubation with 0.05% Trypsin/0.02% EDTA (2-10 min, 37 °C) 
was used for detachment of the cells. Then, the cells were resuspended in an adequate amount of 
cell medium for trypsin neutralization and separated by repeated pipetting. Finally, the cells were 
either transferred into new cell medium for further cultivation or counted for precise plating for 
following experiments.  
 
2.2.2.2 Cell counting using the Neubauer chamber 
Cell counting was performed with 10 µl of freshly detached and separated cells in a Neubauer 
chamber. The sum of the cells of the four large squares was divided by 400 to obtain the cell 
concentration in millions of cells/ml. 
 
2.2.2.3 Cultivation of new cells 
After 30 to about 50 passages, some cell lines develop significantly slower growth speed and/or 
differences in morphology. In order to establish maximum constant conditions for the experiments, 
new cells were used after 2-3 months of cell cultivation. Therefore, cell stocks, which were stored in 
cryo vials in liquid nitrogen in 90% FCS/10% DMSO, were thawed as quickly as possible and mixed 
with DMEM/10% FCS to get a final volume of about 10 ml. Then, the cells were centrifuged for 5-10 
min at 300 g at RT. The supernatant containing the toxic DMSO was discarded. The remaining cell 
pellet was resuspended in DMEM/10% FCS and transferred into a cultivation flask containing 
additional culture medium for further cultivation. 
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2.2.2.4 Preparation of frozen cell aliquots 
The following protocol was used for preparation of five cell stocks from one big culture flask. For 
storage of cell stocks, freshly cultivated cells were brought to a late logarithmic growth phase (about 
70-80% confluency) in a large culture flask. Then, the cells were detached and separated as described 
before. The cells were taken up in DMEM/10% FCS and centrifuged 5-10 min at 300 g and RT. The 
supernatant was discarded and the cells were resuspended in 5 ml pre cooled 90% FCS/10% DMSO. 
Afterwards, 1 ml aliquots of the cell suspension were transferred into cryovials. The vials were stored 
for three days in freeze boxes containing isopropanol at -80 °C to guarantee a slow and linear 
decrease of temperature. Finally, the vials were transferred into liquid nitrogen storage dewars. 
 
2.2.2.5 DNA transfection 
For (co-) transfection of DNAs into mammalian tissue cells, different standard transfection kits were 
used. HeLa and HEK293(T) cells were transfected with Lipofectamine 2000 (LF2000). DNA 
transfection was performed according to the manufacturer’s protocol. Briefly, the appropriate 
amount of LF2000 (75% of the recommended amount was used) was incubated with DMEM for 5 
min. The DNA was also pre-diluted and incubated in DMEM. After addition of the LF2000 to the DNA 
solution, the mixture was incubated for 20 min at RT. Meanwhile, the cell medium was changed. 
Then, the transfection mixture was applied onto the cells. After 4 h, the culture medium was 
changed again. Protein expression was allowed to proceed for 24 h until the cells were harvested or 
another working step was performed. HEK293TT and HaCaT cells were transfected with MaTra 
transfection reagent. Analog to transfections with Lipofectamine 2000, separate mixtures of MaTra 
reagent and DNA in DMEM were prepared and incubated for 5 min. Then, the mixtures were unified 
and incubated for 20 min. After a medium change, the transfection mixture was added onto the cells 
and the cell flask was placed on magnet plates for 15 min at RT followed by standard incubation at 37 
°C. An optional medium change was performed 5 h post transfection. 
 
2.2.2.6 siRNA transfection 
For siRNA-based knockdown experiments, specific double stranded siRNAs (20-25 nucleotides) were 
used for degradation of the mRNA of the corresponding protein of interest. Therefore, transfection 
of siRNAs was performed with Lipofectamine RNAiMAX according to the manufacturer’s protocol. 
Briefly, siRNA and Lipofectamine RNAiMAX were prepared in separate tubes together with DMEM. 
Then, the preparations were mixed and incubated for 15 min at RT. Meanwhile, a medium change 
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was performed. Hereafter, the transfection mixtures were added onto the cells and transfection was 
performed for 24-48 h. The final siRNA concentration was adjusted to 30 nM. For standard siRNA 
transfection, 50,000-100,000 cells (HeLa and HaCat) were cultivated in 24-well format. Depletion of 
the target proteins was characterized by immunodetection or with fluorescence measurements for 
GFP-fused protein targets. 
 
2.2.2.7 Cell harvest 
The cell medium was discarded and the cells were washed with PBS/2.5 mM EDTA. Then, 0.05% 
Trypsin/0.02% EDTA (2-10 min, 37 °C) was used for detachment of the cells. Hereafter, a fourfold 
excess of DMEM/10% FCS was used for neutralization of the trypsin. The cells were centrifuged for 5-
10 min at 300 g at 4 °C. The supernatant was discarded and the cells were resuspended in 10 ml PBS 
containing protease inhibitors. After an additional centrifugation for 5-10 min at 300 g at 4 °C, the 
supernatant was discarded again and the cell pellet was frozen for at least 1 h at -80 °C until follow 
up experiments were performed. 
 
2.2.3  Cultivation of Leishmania tarentolae 
Expression of recombinant HPV16 L2 protein was partly performed with the LEXSinduce2 Eucaryotic 
Protein Expression kit (Jena Biosciences) based on Leishmania tarentolae. The system combines the 
features of eukaryotic protein expression and modification machinery with prokaryotic robustness. 
The system offers high success rates for protein expression, large-scale compatibility, and 
mammalian-type post translation modifications (PTMs) like e.g. N-glycosylation. The following 
chapters describe the experimental outline for recombinant protein expression based on the LEXSY 
system. 
 
2.2.3.1 Cultivation of Leishmania tarentolae cell lines 
For this work, the L. tarentolae original strain T7-TR was used. The aerobic LEXYSY host and 
expression strains were cultivated in the dark at 26 °C as suspension culture in LEXSY BHI complex 
medium. For cultivation, hemin was added as well as penicillin and streptomycin to inhibit bacterial 
infections. Maintenance of T7 polymerase and TET repressor genes was achieved by addition of 
LEXSY NTC and hygromycin. For preparation of standard growth medium, 500 ml LEXSY BHI medium 
were prepared by dissolving 18.5 g LEXSY BHI powder in 500 ml H2O and autoclaving for 15 min at 
121 °C. Then, 2.5 ml Pen-Strep (200 x stock), 1 ml Hemin (500 x stock), 500 µl LEXSY NTC (1000 x 
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stock), and 1 ml Hygromycin (1000 x stock) were added. For selection of recombinants, bleomycin 
(100 µg/ml) or neomycin (50 µg/ml) was added from 1000 x stock solutions. Thereafter, the cells 
were cultivated as continuous suspension culture with regular dilutions of 1:5 to 1:20. Best results 
were achieved by 1:10 dilutions of 10 ml cell cultures on Monday, Wednesday, and Friday with 
ventilated tissue culture flasks. Large-scale cultivation was performed in Erlenmeyer flasks in an 
incubator at approximately 140 rpm (culture volumes: 50-1000 ml). 
 
Standard BHI growth medium: 
3.7% (w/v) LEXSY BHI powder 
50 units/ml penicillin and streptomycin 
5 µg/ml hemin 
100 µg/ml LEXSY NTC 
100 µg/ml LEXSY hygromycin 
 
2.2.3.2 Cultivation of new cells 
After long-term storage of L. tarentolae glycerol stocks at -80 °C, the cryo-vials were thawed on ice. 
Then the entire content was transferred into 10 ml fresh LEXSY BHI medium with appropriate 
antibiotics. The culture was centrifuged for 5 min at 2,000 g and the pellet was resuspended in 5-10 
ml BHI medium for further cultivation. First dilution was performed when the culture got turbid or 
after maximal four days. 
 
2.2.3.3 Preparation of frozen cell aliquots 
The LEXSY strains were stored at -80 °C in 20% (v/v) glycerol. For preparation of six glycerol stocks 2.4 
ml autoclaved glycerol (80% (v/v)) were mixed with 7.2 ml LEXSY suspension culture from mid growth 
phase (4-8 x 107 cell/ml, OD600 ≈1.2-1.8) in a 15 ml tube. Then, 1.6 ml aliquots were transferred into 2 
ml cryo tubes and incubated for 10 min at RT, then for 1 h on ice, over night at -20 °C, and, finally 
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2.2.3.4 Transformation of the T7-TR host 
For transformation of the LEXSY T7-TR host cells with the respective LEXSY expression plasmids, a T7-
TR culture was diluted 1:3 the day before transfection. On the day of transfection, the OD was 
checked (optimal OD600 ≈ 1.4) and the cells were centrifuged for 5 min at 2000 g at RT. Half of the 
supernatant was removed and the pellet was resuspended in the residual medium. The cells were 
incubated on ice for 10 min. Meanwhile, about 3-8 µg DNA of the SwaI restricted and gel isolated 
expression fragment were pre-incubated in tubes on ice in a total volume of 50 µl H2O. Then, 350 µl 
aliquots of the cell suspension were transferred into the DNA tubes, pipetted up and down 3-4 times 
and further transferred into precooled electroporation cuvettes (d=2 mm) without formation of air 
bubbles. The outer surface of the cuvettes was dried and eletroporation was performed at 450 V and 
450 µF with pulse times of about 5-6 ms. After electroporation, the cuvettes were incubated on ice 
for 10 min. Finally, the transformations were transferred into 5-10 ml fresh LEXSY BHI medium with a 
Pasteur pipette and incubated over night at 26 °C. 
 
2.2.3.5 Selection of transgenic LEXSY T7-TR strains 
In this work, clonal selection was used for establishment of expression strains. Therefore, 1-4 
aliquots à 2 ml of the overnight culture after T7-TR transformation were centrifuged for 5 min at 
2,000 g at 20 °C. The cell pellet was resuspended in 50-100 µl of residual medium before the cells 
were spread carefully on autoclaved nitrocellulose filters placed on top of freshly prepared LEXSY BHI 
agar plates supplemented with the respective selection antibiotics. The plates were sealed with 
parafilm and incubated bottom up at 26 °C. After 5-8 days, small colonies appeared and were grown 
until they reached diameters of about 2 mm after 2-3 additional days. Then, about 200 µl selective 
growth medium were inoculated with cell material (inoculation with sterile pipette tips) and 
incubated for 1-2 days at 26 °C in 96-well plates. The cell clones were expanded into 6-, 12-or 24-well 
cultures. Meanwhile, aliquots of the cell clones were grown to check expression of the target protein 
after induction with tetracycline (10 µg/ml) and expression for at least 48 h. For immunodetection of 
the target protein, the tetracycline induced cell suspensions were centrifuged for 5 min at 2000 g 
before the cell pellets were resuspended in 2.5 x SDS-PAGE loading dye and prepared for SDS-PAGE. 
Strains with maximal expression of the target protein were expanded to 10 ml cultures and used for 
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preparation of BHI agar plates (2 plates): 
prepare 25 ml medium 
17.75 ml 2xLEXSY BHI 
5 ml inactivated FCS 
2 ml 1M Hepes pH 7.4 
250 µl penstrep 
100 µl hemin 
100 µl hygromycin 
50 µl NTC 
50 µl selective antiobiotics (bleomycin or neomycin) 
 
The mixture was incubated at 37 °C. Meanwhile, 2% (w/v) BACTO-Agar (DIFCO) was melted in the 
micro-wave and kept at 55 °C (10 min). For plating, 25 ml agar was mixed with the 25 ml BHI medium 
and 25 ml were distributed per plate. After solidification, the plates were dried for 10 min and sterile 
nitrocellulose membranes were applied onto the BHI agar. Then, the plates were ready for clonal 
selection of the T7-TR transformations. 
 
2.2.3.6 Expression of recombinant protein 
For large scale expression of recombinant protein from L. tarentoae, 90 ml BHI medium containing 
selection antibiotics were inoculated with 10 ml of the respective expression strain. At the point of 
inoculation, protein expression was induced by addition of 10 µg/ml tetracycline. The culture was 
cultivated for 48 h at 28 °C at 140 rpm in an Erlenmeyer flask. Then, the culture was diluted 1:10 into 
900 ml BHI medium containing 10 µg/ml tetracycline (with antibiotics). After additional 48 h of 
cultivation at 28 °C at 140 rpm, the cell suspension was centrifuged in a Sorvall GSH rotor for 10 min 
at 2000 g and 20 °C. The cell pellets were resuspended in 1xPBS and aliquoted into 15 ml tubes for 
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2.2.4 Expression of GST or his fusion proteins in E. coli 
Production of GST or His fusion proteins for protein pulldown assays or affinity purifications was 
performed with the E. coli expression system. For expression of recombinant proteins, the target 
expression vector was introduced into E. coli protein expression strains (Rosetta 2(DE3)) based on the 
standard transformation protocol presented above. Then, a 5 ml over night starter culture (LB 
medium with antibiotics) was inoculated with a single colony. The overnight culture was expanded to 
200 ml and incubated at 37 °C until the OD600 was about 0.6-1. Hereafter, 800 ml LB medium were 
added and protein expression was induced by addition of 1 mM Isopropyl-β-D-thiogalactopyranosid 
(IPTG). Protein expression was allowed to proceed for 4 h at 28 °C for GST-SUMO1/2 and for 16 h at 
16 °C for SUMO1/2-his6. The cultures were centrifuged for 20 min at 4 °C and 6,000 g. The 
supernatants were discarded and the pellets resolubilized in cold PBS and divided into aliquots 
resembling 100 ml cell culture. After an additional centrifugation step, the cell pellets were frozen at 
-80 °C for further applications. 
 
2.2.5 Proteinbiochemical methods 
In this section, standard assays to analyze protein solubilization and purification are described as well 
as follow up experiments for characterization of affinity purified proteins and protein pulldown 
assays. 
 
2.2.5.1 Protein solubilization assay 
To characterize solubilization of HPV16 L2 expressed in different protein expression systems the 
respective cells were harvested according to the standard protocols described above. Lysis of the 
harvested cell pellets was performed by sonication in the respective lysis buffers on ice (at least 5 x 
20 s, 30% duty cyle, 30% output) followed by incubation for at least 20 min at 4 °C. The lysis buffers 
contained well defined amounts of detergents, reduction agents, and salt to stabilize the target 
protein, and were compatible with optional follow-up affinity purification of proteins. To test protein 
solubility, the cell lysates were centrifuged for 10 min at 10,000 g and 4 °C. The supernatants were 
subjected to ultracentrifugation for 1 h at 100,000 g and 4 °C in a 70Ti rotor. The pellet was 
resuspended in a 10% volume (with respect to the total volume of lysate) 2.5 x SDS-PAGE loading 
dye. For SDS-PAGE and immunodetection, comparable amounts of the resuspended pellet and the 
supernatant were characterized to compare the fraction of soluble L2 protein in the UZ supernatant 
with the amount of insoluble L2 protein in the UZ pellet. 
  Materials and Methods 
  57 
2.2.5.2 Native affinity purification of SUMO1/2-his6 
For medium-scale SUMO1/2-his6 purification, 100 ml culture pellets of SUMO1-his6 or SUMO2-his6 
expressed in the E. coli were thawed on ice and lysed in 4 ml his lysis buffer (20 mM Tris pH 8.0, 500 
mM NaCl, 5 mM imidazole, protease inhibitors: aprotinin, leupeptin, pepstatin (all 0.1 µg/ml), 
phenylmethylsulfonylfluorid (PMSF, 0.2 µM)), sodium fluoride (NaF,0.2 µM)). After sonication on ice 
(5 x 20 s, 30% duty cycle, 30% output, large top piece), the lysate was incubated for 30 min (wheel, 4 
°C). Then, the lysate was centrifuged for 20 min at 22,000 g at 4 °C. For the subsequent affinity 
purification based on Ni-NTA beads, 200 µl Ni-NTA slurry (Clontech) were washed with 300 µl H2O, 
equilibrated with 500 µl his lysis buffer in gravity columns (BioRad), and loaded with the lysate. The 
flowthrough was applied onto the column for a second time. The column was washed with 10 ml his 
wash buffer (20 mM Tris pH 8.0, 500 mM NaCl, 35 mM imidazole). Protein elution was performed 
with 800 µl elution buffer (20 mM Tris pH 8.0, 500 mM NaCl, 350 mM imidazole). 
 
2.2.5.3 Denaturing affinity purification of HPV16 L2 expressed in L. tarentolae 
For HPV16 L2 purification from L. tarentolae, denaturing his affinity purification was used. Therefore 
the cells of a 50 ml culture were resuspended in 3.5 ml 1xPBS pH 7.4/ 500 mM NaCl/ 1% Triton X-100. 
The cells were lysed by sonication (4 x 1 min with 1 min breaks on ice, 30% output, 30% duty cycle, 
large sonication tip) and incubated for 20 min at 4 °C. Then ultra centrifugation was performed for 1 
h at 100,000 g and 4 °C. The pellet was resuspended in 6 M guanidine HCl pH 8.0 containing 10 mM 
imidazole by sonication. Then, the lysate was incubated with Ni NTA agarose (Clontech) for 2.5 h at 
RT in the purification column. The residual buffer was discarded by gravity flow and the beads were 
washed with 5 ml 6 m Guanidine HCl pH 8.0/ 30 mM imidazole. For elution of the target protein, 800 
µl 8 M Guanidine HCl pH 4.6/500 mM imidazole were added. The protein content was determined by 
Bradford assaying and SDS-PAGE with 1:10 dilutions of the protein solutions due to the 
incompatibility of concentrated guanidine HCl solutions with SDS-PAGE. 
 
2.2.5.4 Denaturing affinity purification of HPV16 L2 expressed in human cell lines 
Large scale L2 preparation was based on denaturing affinity purification of a L2-his fusion proteins. 
Therefore, a cell pellet obtained after L2 expression in two or three 15 cm plates HEK293 or HEK293T 
cells was thawed on ice and resuspended in 3.5 ml lysis buffer. After sonication (5 x 20 s, 30% duty 
cycle, 30% output, large sonication tip), the lysate was incubated for 30 min at 4 °C in siliconized 
tubes. Then the lysate was centrifuged for 1 h at 100,000 and 4 °C in an SW60 rotor. The supernatant 
was discarded and the pellet was resuspended in 1.5 ml 6 M guanidine HCl (10 mM imidazole) after 
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one freeze-thaw cycle and sonication. The lysate was centrifuged for 20 min at 22,000 g and RT and 
the supernatant was used for denaturing purification. Therefore, 200 µl Ni-NTA beads slurry 
(Clontech) were washed in a polypropylene column (BioRad) with three volumes H2O and 
equilibrated with five volumes guanidine HCl pH 8.0 before the cleared lysate was applied onto the 
column. The flowthrough was applied onto the column, again. Then, the column was washed with 
100 column volumes of guanidine HCl pH 8.0/ 35 mM imidazole. Finally, the target protein was 
eluted with 800 µl guanidine HCl pH 8.0/500 mM imidazole. 
 
Lysis buffer: 
  500 mM NaCl   
  1% (w/v) Triton X-100 
  1 mM DTT  
  50 mM Tris HCl, pH 8.0 
 
2.2.5.5 Bradford assay 
Protein quantification was routinely performed based on a Bradford protein quantification kit 
(BioRad). Therefore, 5 µl protein solution were added to 795 µl H2O. 200 µl ready-to-use Bradford 
reagent were added and the mixture was incubated for 10 min at RT. Finally, the OD595 was 
determined and protein concentration was calculated according to calibration curves obtained with 
BSA. Additionally, protein concentration was checked with a Nanodrop (ND1000) device based on 
the theoretical extinction coefficients of the target proteins (in cm-1 M-1, L2: 0.647, SUMO1/2: 0.25, 
L2 SIM peptides: 0.046). 
 
2.2.5.6 SDS PAGE 
For protein characterization by Coomassie staining or immunodetection, the proteins have to be 
separated according to their molecular weight. This was done by SDS PAGE (sodium dodecylsulfate 
polyacrylamid gel electrophoresis)(Laemmli 1970). One-dimensional separation of proteins is thereby 
realized under denaturating conditions in a gel system containing an upper stuffer gel and a lower 
separation gel. The separation of the proteins theoretically only depends on the molecular weight of 
the proteins without larger contributions of intrinsic protein charges. For standard SDS-PAGE, gels 
  Materials and Methods 
  59 
with a diameter of 1 mm were prepared. First, the separation gel was cast and covered with 1 ml 
isopropanol to provide a planar gel boundary. After polymerization, the ispropanol was discarded, 
and the stuffer gel solution was applied on top of the separation gel together with the gel-comb. 
After polymerization, the gels were either directly used or stored under wet atmosphere at 4 °C. 
 
separation  gel:     stuffer gel: 
10-12% (w/v) acrylamid    5% (w/v) acrylamid  
1% (w/v) SDS      0.1% (w/v) SDS 
1% (w/v) APS      0.8% (w/v) APS 
0.05% (w/v) TEMED     0.04% (w/v) TEMED 
pH 8.8       pH 6.8 
 
Before SDS-PAGE, the protein solutions were mixed with protein loading buffer and heated for 5-10 
min at 95 °C. A maximum volume of 100 µl was applied onto the gels. The gels were run at 200 V/ 75 
mA for 3-4 h or 60 V/ 12 mA overnight in 1x running buffer. After SDS-PAGE, the gels were subjected 
either to protein staining (Coomassie, DirectRed81) or transfer blotting. 
For nondenaturing PAGE (known as clear-native PAGE or CN-PAGE), gel and sample preparation were 
identical with the protocol for SDS-PAGE, but all involved buffers were prepared without SDS and 
reducing agents. 
 
2.2.5.7 Protein staining 
Staining of proteins was performed based on Coomassie Acid-Blue R-250 or Direct Red 81 proteins 
staining (Achilonu and Goldring 2010). The gels were incubated for at least 30 min with the protein 
dye solutions. Then the gel was destained for several hours until background staining was minimized 
and the protein bands of interest were clearly visible. For documentation, the gel was scanned either 
directly or after gel drying on a membrane paper. Therefore, the gel was incubated for 1 h in 6% 
glycerol (v/v) in H2O, placed onto a membrane paper, and dried under vacuum on a 58 °C incubator. 
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staining solution: 
50% (v/v) ethanol 
10% (v/v) acetic acid 
1.5 µmol/ml Direct Red 81 or Coomassie Acid-Blue R-250 
 
destaining solution: 
50% (v/v) ethanol 
10% (v/v) acetic acid 
 
Also colloidal Coomassie blue (CCB) protein staining was used, which allows more sensitive protein 
staining without the use of destainers (Kang 2002). 
 
colloidal Coomassie blue (CCB): 
10 % (v/v) ethanol 
2% (v/v) phosphoric acid 
0.02% (w/v) Coomassie Acid-Blue G250  
5% (w/v) aluminum sulfate 
 
2.2.5.8 Transfer Blot 
In order to perform immunodetection, the proteins, which were seperated by SDS-PAGE, were 
transferred onto nitrocellulose or polyvinylidenfluorid (PVDF) membranes. Therefore, semi-dry 
transfer blotting was performed and the proteins from the gels were transferred onto the blot 
membrane by an electric field, which was applied adjacent to the gel and the membrane. Briefly, the 
gel was placed onto the blot membrane and both of them were packed between additional blot 
paper and sponges. The sandwich was placed into the transfer chamber and transfer was performed 
at 400 mA for 2-3 h or at 150 mA over night in transfer buffer. After transfer blotting, the membranes 
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were stained with Ponceau S for visualization of gel bands and were either directly used for 
immunodetection or dried for long term storage. 
 
2.2.5.9 Ponceau S staining 
The proteins, which were transferred onto the blot membranes by transfer blotting, were stained 
with Ponceau S in order to get a first measure of the protein amount and the position of the specific 
target bands on the gel e.g. when cutting of the blot membrane was necessary. Therefore, the 
membrane was incubated for 30-60 s with Ponceau S solution. Then, the membrane was washed 
with H2O to visualize red protein bands. For further processing of the blot membranes, the Ponceau S 
stain was discarded by incubation of the membrane in 1xPBS for several minutes and the membranes 
were ready for characterization by immunodetection. Ponceau S stained membranes can also be 
dried and stored. For further processing, the dried membranes were re-soaked in transfer buffer. 
 
2.2.5.10 Immunodetection 
Immunodetection was performed to characterize protein amounts in the lower nanogram or 
picogram range. This method is based on a combination of a primary, very target specific antibody 
and a secondary antibody, which is coupled to horseradish peroxidase (HRP). The primary antibody 
specifically binds to an antigen of the protein of interest, while the secondary antibody recognizes an 
antigen of the primary antibody with a very high affinity, which dramatically lowers the detection 
limit. In brief, the blot membranes were incubated with 1xPBS/5% (w/v) low-fat milk for 1 h on a 
shaker to reduce nonspecific antibody binding by blocking of the membrane. After that, the solution 
was discarded and the membrane was incubated for 1 h with the first antibody, which was diluted in 
1xPBS/5% (w/v) low-fat milk. Then, four washing steps, each 10 min, were performed with 
1xPBS/0.1% (v/v) Tween-20. After that, the secondary antibody was applied according to the 
recommended dilution in 1xPBS/5% (w/v) low-fat milk for 1 h on a shaker. Finally, four washing 
steps, each 10 min, with 1xPBS/0.1% (v/v) Tween-20 and two additional washing steps in 1xPBS were 
performed. Then, the blot membranes were incubated for 2 min in a 1:1 mixture of the enhanced 
cheminuminescence (ECL) reagents A and B (Perkin Elmer, Western LightningTM detection). 
Documentation of the ECL reaction on light sensitive films (GE Healthcare) was performed in a 
development chamber for several seconds up to 2-3 days before the films were developed, fixed, and 
ready for visual characterization. The membranes were washed with 1xPBS and either dried for long-
term storage or treated with new antibodies for additional immunodetections. 
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2.2.5.11 Stripping of blot membranes 
In many cases, it is necessary to detach antibodies, which were bound to the membrane during 
immunoblotting, from membranes to allow binding of new antibodies for another immunodetection 
experiment. This is of special importance, when the primary antibodies share the same secondary 
antibody or if the position of the target proteins on the blot is more or less identical. In order to 
remove the “old” antibodies, the membranes were washed with 1xPBS or transfer buffer and then 
incubated with 62.5 µM Tris pH 6.8/2 % (w/v) SDS/0.8 % (v/v) β-mercaptoethanol for 1 h at 55 °C. 
Then, a first washing step with 1xPBS/0.1% (v/v) Tween-20 was performed for 10 min at 22 °C 
followed by two additional washing steps at RT. After that, standard procedure for immunodetection 
was performed and the membranes were blocked with 1xPBS/5% (w/v) low-fat milk before the new 
primary antibody was applied. 
 
2.2.5.12 Spin labeling of proteins for EPR measurements 
For preparation of EPR samples, in the site-directed spin labeling (SDSL) reaction, the respective spin 
label molecules were covalently attached to one or more sulfhydryl groups within the protein of 
interest. In brief, for spin labeling of purified proteins, first, the appropriate amount of protein was 
prepared in low retention 1.5 ml tubes. According to the protein characteristics, a first reduction step 
with DTT or TCEP was performed to break potential intra- or intermolecular disulfide bonds and to 
reduce the target sulfhydryle groups for SDSL. Then, an excess of spin label molecules was added and 
the labeling reaction was performed for 2-24 h. After that, excess label was removed and the protein 
solution was concentrated to obtain the desired concentration of spin labeled protein for EPR 
measurements. 
For preparation of SL-SUMO1/2, 1.5 mg SUMO1 or SUMO2 (520 µM) were incubated with a tenfold 
molar excess of TCEP for 2 h at RT. Then, the sample was divided into two aliquots à 125 µl in order 
to perform two different washing protocols. Aliquot A was incubated with a fivefold excess of Proxyl 
IAA and aliquot B with a 20 fold excess of Proxyl IAA for 2 h at RT in the dark. Preparation A was then 
washed with 5 ml SL buffer in a concentrator (MWCO 5,000) and finally adjusted to a volume of 250 
µl (260 µM). Preparation B was applied onto pre-equilibrated PD10 columns according to the 
manufacturer’s protocol. Based on size exclusion chromatography, excess salt (imidazole) and excess 
label molecules were separated from the target protein. The protein content of the elution fractions 
was determined by Bradford Assay. Finally, the three protein containing peak fractions were pooled 
and applied on concentrators to adjust the sample volume to 250 µl followed by protein 
quantification. Both preparation methods led to successful removal of excess spin label. 
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Labeling of the HPV16 L2 SIM peptide was performed with 0.25 mg SIM peptide (200 µM). Optional 
reduction was achieved with a tenfold molecular excess of TCEP and incubation for 2 h at RT. Then, a 
fivefold excess of Proxyl IAA was added and the sample was incubated for 2 h at RT in the dark. After 
that, the labeling reactions were washed and concentrated in concentrators (MWCO 2,000) and 
brought to a final volume of 250 ml followed by protein quantification. 
 
For labeling of full length HPV16 L2, different labeling techniques were performed. An overview is 
given in Figure 2.3. First, denaturing, non-denaturing or high salt buffer conditions were used for 
experimental setup. Then, the reduction step was modified. Labeling was performed with either no 
reduction at all or reduction with TCEP or DTT followed by subsequent removal of DTT by dialysis or 
buffer exchange in concentrators (no removal needed after reduction with TCEP). For the labeling 
step itself, the incubation times were modified (2-24 h at RT or 4 °C). Also the final buffer exchange 
(removal of excess spin label) and sample concentration step was modified. Both, mini column size 
exclusion chromatography as well as concentrators, were tested. Finally, the samples were 
concentrated in concentrators (MWCO 25,000) or by lyophilization. Labeling was testes with PROXYL 
IAA as well as with MTSL. 
 
Fig. 2.3: HPV16 L2 labeling procedures. Most major labeling parameters were widely modified to allow L2 labeling. 
Thereby, different combinations of L2 preparation for labeling, reduction, the labeling reaction itself, as well as final 
washing and concentration steps were tested. 
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2.2.5.13 Fluorescence labeling of HPV16 L2 SIM peptides 
Fluorescence labeling for FCS measurements was comparable with spin labeling of HPV16 L2 SIM 
peptides. Since the experimental molar target concentrations are in the nano molar scale for 
fluorescence labeling (micro molar scale for spin labeling), smaller amounts of the L2 peptide, 
reduction agent, and fluorescent label were used. In a 50 µl preparation, about 100 µg L2 SIM 
peptide were reduced with a tenfold excess of TCEP for 1.5 h. Then, a threefold molar excess of 
fluorescence label (BODIPY®507/545 IA) was used to perform the labeling reaction at RT in the dark 
over night. Excess label was removed by excessive washing with labeling buffer in concentrators 
(MWCO 2,000). Finally, the peptide concentration was adjusted to about 500 nM. In a last step, the 
protein was diluted in labeling buffer to get the final experimental concentration of about 100 nM for 
FCS measurements. For characterization of the L2 SIM interaction with SUMO1/2, a fivefold excess of 
affinity purified SUMO1 or SUMO2 was added before FCS measurements were performed. 
 
2.2.5.14 Characterization of SH group labeling efficiency with the Ellman’s reaction 
In general, the efficiency of SH group based molecular labeling reactions can be characterized based 
on the Ellmann’s reaction. Thereby, the Ellmann’s reagent (5,5'-dithiobis-(2-nitrobenzoic acid), DTNB) 
reacts with free and reduced sulfhydryl groups and the disulfide bond within DTNB is cleaved to give 
2-nitro-5-thiobenzoate (NTB- ,Fig. 2.4). Then, NTB- ionizes to NTB2-, which can be photometrically 
detected at 412 nm. In contrast, if the SH groups are already covalently linked with the labeling 
molecules, no interaction of DTNB with the SH groups occurs. Therefore, also no NTB- or NTB2- is 
formed and there is no absorption at 412 nm. For characterization of labeling efficiency, 10 µl 
aliquots of the labeling reaction were photometrically analyzed together with negative controls 
lacking the respective labeling molecules after addition of 990 µl DTNB working solution and 
incubation for 5 min at RT. The DTNB working solution was prepared by addition of 50 µl DTNB stock 
solution, 100 µl 1 M Tris pH 8.0, and 840 µl H2O per sample. 
 
 
Fig. 2.4: Ellman’s reaction. The Ellman’s reagent (5,5'-dithiobis-(2-nitrobenzoic acid), DTNB) reacts with free thiol groups. 
Dissociation of the disulfide group gives rise to 2-nitro-5-thiobenzoate (NTB-), which ionizes to NTB2- and can be 
photometrically detected at 412 nm. 
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DTNB stock solution: 
50 mM sodium acetate 
2 mM DTNB 
in H2O 
 
2.2.6 Molecular biological methods 
2.2.6.1 Immunoprecipitation 
Potential (direct and indirect) interactions of L2 and SUMO targets were characterized by 
immunoprecipitation of one protein and co-immunoprecipitation of the potential interaction 
partner. For immunoprecipitation experiments, the target proteins were coexpressed in HeLa cells in 
6 cm plates as described before. After cell harvest, the frozen cell pellets were thawed on ice and 1 
ml lysis buffer (50 mM Tris pH 7.5, 300-500 mM NaCl, 0.1-1% (v/v) Triton X-100) was added. The cells 
were lysed by sonication (3 x 20 s, small sonication tip, 30% output, 30% duty cycle) on ice. Then, the 
lysate was incubated for 20 min at 4 °C on an overhead rotator. After that, the protein specific 
pulldown experiments were performed and are described in the following. 
 
Ip of 3xFLAG-L2 and Co-IP of GFP-SUMO1/2 
The lysates containing 3xFLAG-L2 and SUMO1/2 protein were incubated with 3 µg monoclonal anti-
FLAG antibody for 1 h at 4 °C. Then, 50 µl Protein A/G-Agarose beads (Santa Cruz Biotechnologies) 
were added. The mixture was again incubated for 1 h at 4 °C. The beads were centrifuged for 3 min 
at 600 g at 4 °C and then washed with 250 µl washing buffer (50 mM Tris pH 7.5, 150-300 mM NaCl, 
0.1-0.5% (v/v) Triton X-100, 0.1% (w/v) Na-Deoxycholate, 0.01-0.05% (w/v) SDS). The washing step 
was repeated additional two times until the beads were finally incubated and boiled with 75 µl 2.5 x 
SDS loading dye for 10 min at 95 °C. 
 
 IP of GFP-SUMO1/2 and Co-IP of L2 wt, L2 ΔSIM, L2 ΔPHOS, L2 ΔSCM 
For GFP-precipitation of lysates containing L2 wt, L2 ΔSIM, L2 ΔPHOS, L2 ΔSCM, and GFP-SUMO1/2, 
before immunoprecipitation, an additional preclearing was performed. Thus, 45 µl Protein A/G-
Agarose were added and the lysates followed by incubation at 4 °C for 45 min. Preclearing was used 
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to minimize nonspecific binding of L2 protein to the Protein A/G-Agarose beads in subsequent 
immunoprecipication. After incubation, the precleared lysate was transferred into a new tube and a 
lysate control was stored for SDS-PAGE. The remaining lysate was incubated with about 5 µg highly 
specific anti-GFP antibodies (Jl-8) for 45 min at 4 °C. After addition of 45 µl Protein A/G-Agarose 
beads, the samples were incubated for additional 45 min at 4 °C. Then, as described before, the 
beads were centrifuged for 3 min at 600 g at 4 °C and washed with 250 µl washing buffer. The 
washing step was repeated twice until the beads were incubated and boiled with 75 µl 2.5 x SDS 
loading dye for 10 min at 95 °C. 
 
IP of L2 wt, L2 ΔSIM, L2 ΔPHOS, L2 ΔSCM and Co-IP of GFP-SUMO1/2 
Precipitation of L2 was performed with lysates containing L2 wt, L2 ΔSIM, L2 ΔPHOS, L2 ΔSCM, and 
GFP-SUMO1/2. Before immunoprecipitation, an additional preclearing was performed. 45 µl Protein 
A/G-Agarose beads were added and the lysates followed by incubation at 4 °C for 45 min. After 
incubation, the precleared lysate was transferred into a new tube and a lysate control was stored for 
SDS-PAGE. The remaining lysate was incubated with 45 µl highly specific anti-L2 antibody (L2-1) for 
1.5 h at 4 °C. After addition of 45 µl Protein A/G-Agarose beads, the samples were incubated for 
additional 45 min at 4 °C. As described before, the beads were centrifuged for 3 min at 600 g at 4 °C 
and washed with 250 µl washing buffer. The washing step was repeated twice until the beads were 
incubated and boiled with 75 µl 2.5 x SDS loading dye for 10 min at 95 °C. 
 
2.2.6.2 SUMO1/2-his6 Pulldown 
For SUMO1/2-his6 pulldown experiments, 100 ml culture pellets of SUMO1-his6 or SUMO2-his6 
expressed in the E. coli strain Rosetta 2 (DE3) were thawed on ice an lysed in 4 ml his lysis buffer. 
After sonication on ice (5 x 20 s, 30% duty cycle, 30% output, large top piece), the lysates were 
incubated for 30 min (wheel, 4 °C). Then, the lysates were centrifuged for 20 min at 22,000 g at 4 °C. 
Meanwhile, 100 µl Ni-NTA slurry (Clontech) was washed with 200 µl H2O and centrifuged for 3 min at 
600 g. The supernatant was discarded and the beads were incubated with 200 µl his lysis buffer. 
After centrifugation, the supernatant was discarded again. Then, each 10% of the centrifuged 
SUMO1/2-his6 lysates were incubated with the washed and equilibrated Ni-NTA beads in siliconized 
tubes. After 10 minutes, the samples were centrifuged for 3 min at 600 g and 4 °C. The supernatant 
was discarded. 1 ml his wash buffer was added and the sample was centrifuged again for 3 min at 
600 g and 4 °C. This step was repeated two times, until, finally, 400 µl his interaction buffer were 
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added. After that, a Bradford Assay was performed in order to quantify the amount of purified, Ni-
NTA coupled SUMO1-his6 or SUMO2-his6 protein. The samples were stored at 4 °C for further 
processing. 
 
His lysis buffer: 
20 mM Tris pH 8.0 
500 mM NaCl 
5 mM imidazole 
protease inhibitors 
 
His wash buffer: 
20 mM Tris pH 8.0 
500 mM NaCl 
35 mM imidazole 
protease inhibitors 
 
Meanwhile, a cell pellet obtained after expression HPV16 L2 wt protein in HeLa cells for 24 h on six 6 
cm dishes, was thawed on ice. 3 ml lysis buffer were added before sonication was performed on ice 
(5 x 20 s, 30% duty cycle, 30% output, large top piece). The lysate was incubated for 30 min at 4 °C 
(wheel) and then centrifuged for 20 min at 13,000 g and 4 °C. 50 µl lysate were taken as a control. 
The lysate was divided into three 1 ml aliquots and 50 µl washed his-beads were added. The samples 
were incubated for 1 h at 4 °C (wheel) for preclearing and then centrifuged for 3 min at 600 g. The 
cleared supernatant was isolated, stored at 4 °C, and a 50 µl lysate control were taken. 
For the following his-pulldown experiments, 8 µg Ni-NTA coupled SUMO1- or SUMO2-his6 protein 
were added to the precleared L2 samples. After incubation for 3 h at 4 °C, 50 µl washed his beads 
were added. Then, the samples were centrifuged (3 min, 600 g, 4 °C) and the supernatant was 
discarded before 1 ml wash buffer was added. This step was repeated additional two times. After the 
last centrifugation, the supernatant was discarded and the beads were boiled with 75 µl 2.5 x SDS-
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20 mM Tris pH 8.0 
500 mM NaCl 
1% (v/v) Triton X-100 
protease inhibitors 
 
2.2.6.3 SUMO1/2-GST Pulldown 
GST, GST-SUMO1, and GST-SUMO2 cell pellets were thawed on ice and resuspended in 4 ml GST 
interaction buffer. The cells were lysed by sonication on ice (5 x 20 s, 100% duty cycle, 30% output). 
The cell lysate was incubated for 20 min at 4 °C (wheel). Meanwhile, 200 µl glutathione sepharose 4B 
beads (per cell pellet) were incubated with 1 ml PBS on ice for 30-60 min and centrifuged at 600 g. 
The supernatant was discarded and beads stored on ice for further application. The cell lysate was 
centrifuged for 15 min at 4,800 x g and 4 °C. The supernatant was transferred into 1.5 ml tubes and 
centrifuged again for 20 min at 22,000 g at 4 °C. Then, the supernatant was added to the washed 
glutathione sepharose beads in 15 ml tubes and incubated for 2-3 h at 4 °C (wheel). After incubation, 
the beads were washed with 5 ml GST interaction buffer followed by a 3 min centrifugation at 600 g 
and 4 °C. This step was repeated twice before the beads were transferred into 1.5 ml tubes together 
with 1 ml GST interaction buffer. Finally, a Bradford Assay was performed for quantification of the 
amount of purified and precipitated GST, GST-SUMO1, and GST SUMO2. 
 
GST interaction buffer: 
1 x PBS 
0.5% (w/v) Triton X-100 
1 mM DTT 
protease inhibitors 
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During preparation of GST proteins, three cell pellets obtained upon expression of HPV16 L2 wt in 
HeLa cells for 24 h in 6 cm plates were thawed on ice. 1.2 ml lysis buffer were added before 
sonication was performed on ice (5 x 20 s, 30% duty cycle, 30% output, large top piece). The lysate 
was incubated for 20 min at 4 °C (wheel) and then centrifuged for 20 min at 13,000 g and 4 °C. The 
supernatants were collected in one tube and 60 µl lysate were taken as a control.  
 
Lysis buffer: 
1 x PBS 
0.5% (w/v) Triton X-100 
1 mM DTT 
protease inhibitors 
 
For the following GST-pulldown experiments, 8 µg GST-SUMO1/2 or GST protein alone were added 
to 1 ml L2 lysate and incubated for 2 h at 4 °C. Then 40 µl additional, washed glutathione sepharose 
beads were added to the samples, which were then centrifuged for 3 min at 600 g and 4 °C. The 
supernatant was discarded and 1 ml wash buffer was added. The washing step was repeated four 
times. After the last step, the beads were boiled in 75 µl 2.5 x SDS-PAGE loading buffer. 
 
GST wash buffer: 
1 x PBS 
500 mM NaCl 
1% (w/v) Triton X-100 
1 mM DTT 
0.5% (w/v) sodium deoxycholate 
0.2% (w/v) SDS 
protease inhibitors 
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2.2.6.4 Ubiquitin pulldown 
For identification of potential L2-ubiquitin interaction by coprecipitation experiments, ubiquitin 
pulldown assays were performed based on ubiquitin agarose beads. Therefore, HPV16 L2 and L2 
ΔSIM was overexpressed in HeLa cells in 6 cm plates for 24 h. The cells were harvested and lysed. The 
lysates were incubated with 300 µl equilibrated ubiquitin agarose beads for 1.5 h at RT on a shaking 
device and then washed three times with 500 µl Tris pH 7.5/ 300 mM NaCl/1% (v/v) Triton X-100 
including 3 min centrifugation steps at 600 g and 4 °C. After final centrifugation, the samples were 
boiled in 60 µl 2.5x SDS-PAGE loading buffer followed by characterization of co-precipitated L2 by 
immunodetection.  
 
2.2.6.5 Mammalian 2-hybrid assay 
In this work, also a mammalian 2-hybrid assay (Stratagene) was used to identify a potential 
interaction of HPV16 L2 with SUMO proteins. The kit is based on the expression of two fusion 
proteins. One fusion protein is composed of the first interaction partner together with an activation 
domain (AD), while the second fusion protein comprises the second interaction partner together 
with a DNA binding domain (BD). If activation domain and DNA binding domain get in close contact 
due to interaction of the respective fusion partners, expression of a luciferase reporter gene 
(Photinus pyralis, lat. for American firefly) is activated, which can be photometrically detected.  
In order to perform mammalian 2-hybrid assays, first, the corresponding DNA plasmids were 
constructed for cotransfection and coexpression of the HPV16 L2 or SUMO1/2 fusion proteins in 
HeLa cells. In a first experiment, SUMO1 or SUMO2 fusion proteins containing an activation domain 
were coexpressed together with L2 fusion proteins containing a binding domain. Vice versa, in a 
second experiment, also SUMO1/2 fusion proteins containing a DNA binding domain were 
coexpressed together with L2 fusion proteins containing an activation domain.  
In brief, each three DNA plasmids were transfected into HeLa cells (80-120,000, 12-well plates): i): 
pBD-Sumo1/2, pAD-L2, pFR-luciferase or ii): pBD-L2, pAD-SUMO1/2, pFR-luciferase. After protein 
expression for 24 h, the cells were washed with PBS and lysed with Cell Culture Lysis Reagent 
(Promega) as described above. The lysate was centrifuged and 100 µl were used for luciferase assays 
(15 s measurement time) on the LB941 luminometer (Berthold). The experimental setup also 
contained a positive control (transfection of pAD-SV40 with pBD-p53) and negative controls 
(transfection of pAD-L2 with pBD or pAD-TRAF with pBD-p53). 
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2.2.7 Virological methods 
2.2.7.1 Preparation of HPV16 L1/L2 PsVs 
The preparation of HPV16 pseudovirions (PsVs) was performed based on the protocol of Buck et al., 
2004. The protocol allows for a high-yield production of intact L1/L2 capsids containing a marker DNA 
plasmid. In this work, both wild type L1/L2 PsVs assembled from wild-type L1 and L2 proteins were 
prepared, as well as mutant L1/L2 PsVs containing mutant forms of the HPV16 L2 protein. In 
addition, also PsVs, in which the incorporated viral DNA was labeled with 5-ethynyl-2´-deoxyuridine 
(Edu), were prepared. PsVs prepared this way allow for labeling of the viral DNA with an 
AlexaFluor488 fluorescence label, which specifically binds to Edu molecules attached to the viral DNA 
and allows for characterization of the localization of the viral DNA in fluorescence microscopic 
experiments after PsV infection. The protocols for standard PsV preparation are accessible online at 
the homepage of the National Cancer Institut, U.S. National Institutes of Health 
(http://home.ccr.cancer.gov/Lco/). 
For preparation of PsVs, HEK293TT cells were transfected (MATra) with HPV16 L1/L2 plasmids 
(pSHELL 16L1/L2 or pUF 16L1) and the reporter plasmid (pcDNA 3.1 (+) Luciferase). After 48 h of 
protein expression, the cells were detached with PBS/2.5 mM EDTA and 0.05% Trypsin/0.02% EDTA, 
neutralized with DMEM/10% FCS, and centrifuged for 7 min at 300 g at RT as described before. The 
pellets were resolubilized in PBS/9.5 mM MgCl2 and centrifuged again for 7 min at 300 g at RT. The 
cell pellets were resolubilized in about 700 µl PBS/9.5 mM MgCl2 and transferred into new siliconized 
tubes. Then, 0.5% (v/v) Brij58 and 0.1-0.5% (v/v) Benzonase were added for solubilization of L1/L2 
proteins and to digest nonincorporated DNA. Maturation of PsVs was perfomed by incubation of the 
samples for 24 h at 37 °C with repeated mixing. The samples were cooled on ice and brought to a 
final NaCl concentration of 0.85 M NaCl to stop Benzonase activity and aggregation of the 
pseudoviruses. After 10 min on ice, the preparations were centrifuged for 10 min at 2000 g and 
applied onto an Optiprep® ultracentrifugation gradient for purification of the PsVs. Therefore, 
Optiprep® gradients were prepared by dilution of a 60% (w/v) Iodixanol solution with PBS/9.5 mM 
MgCl2/0.85 M NaCl in 27%, 33%, and 39% (v/v) solutions. For preparation of the gradients, 1.4 ml of 
the Optiprep® solutions were pipetted onto each other in SW55 ultra centrifugation tubes starting 
with the 39% solution. The gradients were incubated for 1 h at RT, frozen at -20°C, and rethawed in 
order to be carefully loaded with the cleared lysates. Then, ultra centrifugation was performed for 4 
h at 50,000 rpm and 16 °C with a SW55 rotor. After that, 300 µl fractions were taken starting from 
the top of the gradients and stored at 4 °C until the fractions were characterized by infection assays 
or immunodetection of the L1/L2 content. Then, 1-3 peak fractions were pooled and 100 µl aliquots 
were frozen at -20 °C for long term storage. 
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For preparation of HPV16 L1/L2 PsVs suited for detection of viral DNA in immunofluorescence 
microscopy, the standard preparation protocol was modified according to Ishii et al., 2010. After DNA 
transfection for 6 h, 100 µM 5-ethynyl-2′-deoxyuridine (EdU) were added to the cell medium (Ishii, 
Tanaka et al. 2010). After that, the preparation protocol was identical to the preparation of standard 
PsVs described above. 
 
2.2.7.2 DNA quantification of PsVs based on picoGreen 
As a control for infection assays and for further PsV-based experiments, the reporter DNA content of 
the PsVs was determined based on the Quant-iTTM PicoGreen® (Invitrogen) DNA detection kit. 
Knowing the DNA content of the respective PsV preparation, the amount of the respective PsVs used 
for follow-up experiments was adjusted to guarantee a fixed total amount of reporter plasmid DNA. 
The assay relies on the high affinity binding of a fluorescent marker molecule to double stranded 
DNA. DNA quantification was performed on a fluorescence plate reader.  
Therefore, 150 µl of a 1:200 dilution of PicoGreen in 1xTE were prepared on a black surface 96-well 
plate. Then, 1-5 µl PsVs were added. For absolute quantification of DNA, a concentration row 
containing pcDNA3.1 (+) control plasmid DNA (100 ng, 10 ng, 1 ng, 0.1 ng per 150 µl) was applied 
onto the plate. The plate was incubated for 10 min at RT in the dark. Then, the fluorescence was 
measured in a plate reader (excitation at 480 nm, emission at 520 nm). Absolute quantification of 
DNA was achieved by comparison of the detected fluorescence intensities with intensities obtained 
for the DNA concentration row.  
 
2.2.7.3 Reporter gene assay 
Infectivity of pseudoviruses was routinely characterized based on luciferase reporter gene assays 
after infection of target cells with PsVs. In this assay, a successful infection of the cells by PsVs leads 
to expression of luciferase, which is an oxido reductase that catalyzes the decarboxylation of luciferin 
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For standard Luciferease assays, 25,000-50,000 HeLa or HaCaT cells were cultivated for 24 h in 24-
well plates. Then, about 1-5 µl PsVs were added onto the cells after a medium change. The cells were 
infected for 24 h. Afterwards, the cells were washed with PBS and lysis of the cells was performed 
with 250 µl 1 x Cell Culture Lysis Reagent (Promega). Cells were detached and further lysed by 
scraping with pipette tips followed by incubation for 15 min at RT. Then, the lysate was centrifuged 
for 2 min at 13,200 g. 100-150 µl cell lysate were prepared on 96-well plates for luciferase 
measurements with the Tristar LB941 luminometer (Berthold). For the measurements, 50 µl 
luciferase substrate buffer were automatically added to the lysates. After automatic mixing and 
incubation for 5 s, the light emission based on the luciferase activity was measured for 5-20 s. 
 
Luciferase substrate buffer:  50 mM Tris/HCl pH 7.8 
     15 mM MgSO4 
     20 mM DTT 
     0.5 mM EDTA 
     0.5 mM Luciferin 
     0.5 mM Coenzyme A 
     0.5 mM ATP 
 
2.2.7.4 Lactate dehydrogenase (LDH) cytotoxicity assay 
Quantification of cells and characterization of cell vitality was performed with LDH cytotoxicity assays 
(Roche Cytotoxicity Detection KitPLUS) in parallel with the corresponding reporter gene assays or other 
experiments. For LDH assays, the same cell lysates (prepared with 1xCell Culture Lysis Reagent 
(Promega)) as for luciferase reporter gene assays were used. The kit system is based on the detection 
of the activity of lactate dehydrogenase (Fig 2.5). First, LDH catalyzes the oxidation of lactate to 
pyruvate with reduction of NAD+ to NADH+H+. In a second step, the buffer substrate tetrazolium 
(faint yellow) is reduced to formazan (red) by the free reduction equivalents NADH+H+. The 
formation of formazan is quantified by photo absorption at 590 nm. 
Therefore, 10 µl cell lysate were prepared in a 96-well plate. Then, 100 µl catalysator/dye solution 
were added and the solution was incubated for 10 min at RT in the dark. The reaction was stopped 
  Materials and Methods 
  74 




Fig. 2.5: LDH cytotoxicity assay. The lactate dehydrogenase (LDH) catalyzes the oxidation of lactate to pyruvate under 
reduction of NAD+ to NADH+H+. In parallel, the free reduction equivalents NADH+H+ reduce the buffer substrate tetrazolium 
(faint yellow) to formazan (red), which can be photometrically quantified at 590 nm (source: www.roche-applied-
science.com) 
 
2.2.7.5 Characterization of PsVs by sucrose gradient ultra centrifugation 
After preparation and purification of HPV16 L1/L2 pseudovirions (PsVs), the PsVs were further 
characterized by sucrose gradient ultra centrifugation based on previous experimental protocols 
(Becker, Florin et al. 2004; Florin 2004). This was done in order to reassure that only intact capsids 
and no larger amounts of capsomers, nonincorporated L1/L2, or broken virus debris were used for 
further experiments. Therefore, 9 ml sucrose gradients (10-60% (w/v) sucrose) were prepared 
containing 5 µg/ml BSA for stabilization of PsVs. Then, 300 µl L1/L2 PsVs were mixed with 2.7 ml 
1xPBS (1:10 dilution) containing 5 µg/ml BSA and applied onto the gradients. Ultra centrifugation was 
performed for 150 min at 4 °C and 36,000 rpm in a SW40 rotor. After that, 700 µl fractions were 
collected from top of the gradient and the peak fractions were determined by immunodetection of 
the L1/L2 content and infection assays. 
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2.2.7.6 Flow cytometry 
Flow cytometry was performed to characterize the ability of mutant HPV16 PsVs to attach to the cell 
surface of human target cells (HeLa and HaCaT), and also to characterize PsV uptake by endocytosis. 
For characterization of virus binding, about 200,000 HeLa or 250,000 HaCaT cells were cultivated for 
24 h in 12-well plates, washed with PBS/EDTA, and detached by trypsination (100 µl). After 20 min, 
400 µl DMEM/FCS were added and the cells were transferred into silikonized tubes. The cells were 
centrifuged for 5 min at 300 g at RT and resuspended in 600 µl DMEM/FCS. Then, infection with 
normalized amounts of PsVs (at least 1 µl) was performed for 15 min. The cells were transferred into 
3 ml DMEM in 15 ml tubes and centrifuged for 5 min at 300 g at RT. The supernatant was discarded, 
the cells resuspended in 400 µl PBS, and transferred into 3 ml PBS in FACS tubes. For L1 antibody 
staining, the cells in the FACS tubes were centrifuged for 5 min at 300 g at 4 °C. The supernatant was 
discarded and the primary L1 antibody (L1 K75, 1:500) was added in 200 µl PBS/0.5% (v/v) and 
incubation was performed for 30 min at 4 °C. Then, 4 ml PBS/0.5% (v/v) FCS were added and the cells 
were centrifuged for 5 min at 300 g at 4 °C. The supernatant was discarded and the secondary 
fluorescence antibody (AlexaFluor488 anti rabbit, 1:250) was added in 250 µl PBS/0.5% (v/v) FCS and 
incubated for 30 min at 4 °C. 4 ml (v/v) FCS were added, the cells centrifuged for a last time at 300 g, 
4 °C for 5 min and finally resuspended in 300 µl PBS/0.5% (v/v) FCS for analysis by flow cytometry on 
a Becton Dickinson FACScan device.  
To characterize endocytosis of PsVs, 200,000 HeLa or 250,000 HaCaT cells were infected with 
normalized amounts of PsVs, transferred into 3 ml DMEM in 15 ml tubes and centrifuged for 5 min at 
300 g at RT. The supernatant was discarded and the cells were resuspended in 3 ml DMEM and 
plated on 12-well plates. This time, the infected cells were incubated for 24 hours to allow 
endocytosis of PsVs. Then, again, L1 antibody staining was performed to allow flow cytometrical 
detection of residual PsVs on the cell surface, which were possibly not endocytosed due to L2 
mutations of the L1/L2 PsVs. Thus, high fluorescence intensities would indicate that the 
corresponding L1/L2 PsVs were not endocytosed by the target cells, as the fluorescence-labeled L1 
would be still accessible to antibody detection, while low fluorescence intensities would indicate 
successful endocytosis of PsVs and L1 inaccessibility for L1 antibodies, since the PsVs were already 
taken up. In control experiments, equal amounts of noninfected cells were treated only with the 
respective primary and secondary antibodies or the secondary antibody, alone, to quantify the level 
of background fluorescence. All measurements were performed with three individual parallel 
samples. 
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2.2.7.7 Preparation of HPV16 PsVs for cell binding assays based on CW EPR 
Cell binding of HPV16 PsVs to target cells was characterized based on Fremy’s salt as a molecular 
marker, which could give an indirect measure for the binding of viruses to target cells. Therefore, 
PsVs were incubated with Fremy’s salt, which theoretically attaches to the positively charged L1 and 
L2 amino acid patches of HPV16 PsVs. By doing so, the marker molecules get in close contact to each 
other and a very high local concentration of Fremy’s salt ions is established. In this milieu, each two 
Fremy’s salt ions react with each other in a disproportionation reaction the molecules lose their 
paramagnetic properties, leading to a continuous decay of the EPR signal intensity. Addition of cells 
or heparin as potential binding partners of PsVs in in vitro experiments could significantly change the 
decay of the EPR signal intensity delivering important information about cell binding of the PsVs and 
structural rearrangement of the L1/L2 capsid. 
The general amount of PsVs used for the experiment was adjusted to reach an equimolar amount of 
positively charged L1/L2 amino acid patches when compared with NDS concentrations (100 µM). 
Further more, the amount of the different PsVs types was adjusted to reach comparable L1/L2 and 
DNA levels. The PsVs were washed with 6 ml 1 x PBS in concentrators (MWCO 50,000). Meanwhile, 
HaCaT cells were harvested and washed with 12 ml 1 x PBS for three times to remove DMEM cell 
medium, which interferes with later EPR measurements. About 2.5 mio cells were finally 
resuspended in 1 x PBS and stored on ice for further application. The washed PsVs were adjusted to a 
final volume of about 30-60 µl. Fremy’s salt was added to the samples to give a final concentration of 
about 100 µM and the preparations were divided into three aliquots. At this time, the interaction 
partners were added to the different PsV aliquots. 5 µl heparin solution and about 10,000-100,000 
cells were used for time dependent cell adhesion experiments. The preparations were mixed and 
transferred into 1.5 mm glass capillaries. Then, time dependent CW EPR measurements were 
performed at 16 °C. 
 
2.2.8 Microscopic methods 
2.2.8.1 Immunofluorescence microscopy 
Immunofluorescence microscopy represents a very powerful tool for investigation of cellular 
localization and potential in vivo interaction of proteins. In this work, both, endogenous proteins of 
host cells, as well as transiently over-expressed proteins or viral proteins introduced into the cells by 
PsV infection, were used for characterization.  
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2.2.8.2 Antibody staining 
For characterization of proteins by immunofluorescence microscopy, HeLa or HaCat cells (80,000-
180,000) were cultivated on coverslips for 24 h and transfected with LF2000 (HeLa) or JetPEI (HaCaT) 
for transient expression of proteins for additional 24 h. The cells were washed with PBS (containing 
protease inhibitors) and then fixed and permeabilized with ice-cold methanol for 10-30 min (<2 min 
for cells containing over-expressed GFP fusion proteins). After that, the cells were washed three 
times with PBS and blocked with PBS/1% (w/v) BSA for 30-60 min at RT. Then, the incubation mix was 
completely discarded from the coverslips and the primary antibody was applied onto the cells in 50 
µl PBS/1% (w/v) BSA for 1 h according to the manufacturer’s guidelines (Tab.2.3). Incubation of the 
cells with the antibody was performed for 1 h in a wet chamber at 37 °C. Then, the cells were washed 
three times with PBS to remove residual antibody and the cells were again blocked for 15 min with 
PBS/1% (w/v) BSA at RT. After that, the secondary fluorescence antibody was applied onto the cells 
in 50 µl PBS/1% (w/v) BSA containing the DNA stain Hoechst 33341 in a dilution of about 1:10,000 
and incubated for 30-45 min at 37 °C in a wet chamber. Finally, the cells were washed three times 
with PBS/1% (w/v) BSA, three times with PBS and dried. Subsequently, the coverslips were placed 
onto a droplet of Fluoprep (bioMérieux) prepared on a microscope slide for fixation. The slides were 
dried in the dark and the stored at 4 °C until microscopic analysis was performed. 
 
2.2.8.3 EdU staining of PsVs after infection 
For immunofluorescence microscopic characterization of viral DNA after infection, PsVs containing 
the DNA marker molecule 5-ethynyl-2´-deoxyuridine (EdU) were used. In order to stain the viral DNA 
after PsV infection, the antibody staining procedure contained an additional step based on the Click-
iT® EdU Imaging Kit (Invitrogen). In brief, the cells were washed in PBS and fixed/permeabilized in 
methanol for 30 min. The cells were washed three times in PBS and blocked in PBS/1% (w/v) BSA. 
Then, in a  first reaction a fluorescence antibody (AlexaFluor®488) was covalently linked to the EdU 
DNA stain in a freshly-prepared solution containing 430 µl 1x Click-iT® reaction buffer, 20 µl CuSO4, 
1.2 µl AlexaFluor®488 azide, and 50 µl reaction buffer additive (in this order). The reaction was 
incubated for 1 h at RT in the dark. From this step on, the cells were treated like cells for standard 
antibody staining after methanol fixation. Thus, after the Click-iT® reaction solution was discarded, 
the cells were washed in PBS and blocked again with PBS/1% (w/v) BSA. Then, the primary antibody 
was added. After washing steps and additional blocking the secondary antibody was applied. The 
cells were washed, the coverslips were dried and fixed on microscopic slides as described before. 
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2.2.8.4  Microscopic documentation 
The imaging of antibody stained microscopic slides was performed on a Zeiss Axiovert 200 M 
microscope and a Zeiss Axiocam digital camera. Digital analysis was based on the Axiovision Software 
4.7. After iterative fast deconvolution of the z-stack images, the final images were exported in *.tif 
format and further revised with the CorelDraw Graphics Suite X4. 
Quantification of colocalization of viral DNA with PML or L2 with PML after infection with wild-type 
or mutant HPV16 PsVs was performed by taking fluorescence pictures with fixed exposure times for 
each detection channel. The pictures were taken as single layer picture focused on PML bodies 
without any changes of brightness and contrast. For further analysis, the pixel-by-pixel colocalization 
module was used to determine the channel intensity boundaries for correct report of colocalizing 
pixels. These boundaries were kept fixed for colocalization analysis of about 80-100 nuclei for each 
PsV type. Therefore, the cell nuclei were marked with selection tools and the corresponding level of 
colocalization was tabulated. For analysis, the %-PML colocalization of viral DNA or L2 per nucleus 
was determined as well as the %-PML colocalization of viral DNA or L2 per total amount of viral DNA 
or L2. 
 
2.2.9 Biophysical methods 
2.2.9.1 Electron paramagnetic resonance (EPR) spectroscopy 
In this work, EPR measurements were performed to characterize direct HPV16 L2 in vitro interaction 
with SUMO1/2 or cell binding of HPV16 pseudovirions. For L2 interaction screening with SUMO1/2, 
continuous wave (CW) EPR measurements were performed as well as pulsed-EPR measurements like 
electron spin echo (ESE) detected EPR experiments and double electron-electron resonance (DEER) 
experiments. Cell binding of PsVs was characterized by CW EPR measurements based on Fremy’s 
Salt. 
 
CW EPR measurements 
In CW EPR measurements, the efficiency of site-directed spin labeling of purified HPV16 L2 and 
SUMO1/2 protein as well as HPV16 SIM peptides was characterized. CW EPR experiments were also 
used to characterize a potential interaction of HPV16 L2 with SUMO1/2. The structural region where 
the spin labeld was attached to the target molecules was classified by an empirical plot of the inverse 
of the second moment (<H2>-1) vs. the inverse of the central linewidth (ΔH0
-1) (Mchaourab 1996; Isas 
2002). <H2>-1 was obtained after simulation of the spectra based on the first moment <H> 
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(geometrical center of the spectrum) and the second moment <H2> (spectral breadth) with 




-1 was directly read from the experimental spectra. Additionally, the binding of PsVs on the 
surface of HaCaT host cells was studied in time dependent experiments by passive observation of 
Fremy’s Salt degradation. 
CW EPR measurements were performed on a MiniScope MS200 spectrometer. Standard 
measurements were performed at 5 °C for interaction assays and characterization of spin labeling 
with a modulation amplitude of 1500 mG and 12 dB attenuation (4096 data points, 30 s sweep time). 
The spectral sweep, as well as video gain and number of scans, were adjusted according to the 
characteristics of each spectrum. Minimum sample volumes were about 15-30 µl with spin label 
concentrations of at least 100 µM. Measurements including Fremy’s Salt were performed at 16 °C 
with a modulation amplitude of 150 mG. 
 
Pulse EPR measurements 
Pulse EPR measurements, particularly DEER measurements, were performed in order to get 
additional information about potential protein-protein interaction by measuring the distance 
between the labels attached to the two interaction partners. DEER measurements also help to 
characterize proteins in terms of potential protein self-aggregation, e.g. via disulfide bridging. In this 
work, ESE measurements and DEER measurements were performed on a Bruker Elexsys 580 EPR 
spectrometer at 50 K in 3 mm quartz capillaries. Sample volumes were at least 40 µl with spin label 
concentration > 100 µM. 
ESE-detected measurements were performed using the Hahn echo sequence π/2-τ- π -τ- echo and a 
1.8 mT field sweep. The interpulse delay timeτ was fixed to 200 ns and pulse lengths were 16 ns for 
the π/2 pulse and 32 ns for the π pulse. The integration gate length was set to 100 ns. 
DEER experiments were performed with a π/2(vobserver)- τ1-π(vobserver)-t’- π(vpump)-( τ1+ τ2-t’)-π(vobserver)-
τ2-echo pulse sequence with a [(+x)-(-x)] phase cycle applied to the π/2 pulse. The time t’ was 
incremented in steps of 8 ns. The time τ1=200 ns was kept constant. τ2 was set to 1.5 μs. The dipolar 
evolution time is defined as t= t’- τ1. Data analysis was performed for t>0 ns. The pump frequency 
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(vpump) was set to the center of the resonator dip that coincides with the maximum of the nitroxide 
EPR spectrum, whereas the observer frequency (vobserver) was set to vpump+70 MHz and coincided with 
the low field local maximum of the spectrum for standard nitroxide labels (shoulder position in Fig. 
2.6). The observer pulse lengths were 32 ns for both π/2 and π pulses. The π pump pulse length was 
12 ns. The width of the integrator gate was 32 ns. 
The measurement time of DEER experiments typically was around 4 hours for standard 
measurements and up to 96 hours for long time measurements. 
 
Fig. 2.6: Spin selection in DEER experiments: Selection of observer and pump spins is based on different frequencies for 
observer and pump pulses. The correlating positions within the ESE spectrum are indicated by arrows for vpump and vobserve. 
The difference of about 70 MHz resembles the difference ΔB between the spectral maximum and the low field local 
maximum of the spectrum (25 G).  
 
2.2.9.2 Fluorescence Correlation spectroscopy (FCS) 
Fluorescence correlation spectroscopy is based on detecting and analyzing the fluorescence light 
emitted by chromophores diffusing through a small and fixed observation volume element V, usually 
formed by a laser focused into the sample of interest using confocal optics. From the measured 
temporal fluctuations of the fluorescence intensity, δI(t), an autocorrelation function  
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corresponding to the probability that a chromophore inside the volume V at time t will be still inside 
V  at time t + τ was evaluated. The measured autocorrelation function shows a decay related to the 
free 3D diffusion and can be fitted to the so-called biophysical model function 
1 1/ 2
* 2
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where N* is the average number of fluorescent molecules in the observation volume V, τD is the 
lateral diffusion time that a molecule stays in this volume, and S=z0/r0 is the ratio of axial to radial 
dimensions of V (S≈6 in our experiment). If the hydrodynamic radius RH of a molecule is much smaller 
than the detection volume (RH<<r0), the diffusion coefficient D can be determined from the diffusion 
time τD as . Based on this, the hydrodynamic radii of the molecules can be calculated 





where kB is Boltzmann’s constant, T is the temperature and η is the viscosity of the solution. 
FCS measurements were performed at RT at a commercial FCS setup (Zeiss, Germany) consisting of 
the module ConfoCor 2 and an inverted microscope model Axiovert 200. A Zeiss C-Apochromat 
40x/1.2 W water immersion objective was used. The BODIPY®507/545 IA fluorescence label was 
excited with an Argon laser at λ=488 nm and emission was collected after filtering with a LP560 long 
pass filter. For detection, avalanche photodiodes were used to enable single-photon counting. An 
eight-well, polystyrene-chambered cover-glass (Laboratory-Tek, Nalge Nunc International) was used 
as sample cell.  
 
2.2.9.3 Fluorescence spectroscopy 
Fluorescency spectroscopy with proteins is based on the fluorescence of intrinsic tryptophan, 
tyrosine, and phenylalanine residues. The total fluorescence intensity is dominated by the 
tryptophan fluorescence, which features a much higher fluorescence quantum efficiency than that of 
the two other amino acids. Another reason is that there is resonance energy transfer from proximal 
phenylalanine to tyrosine and from tyrosine to tryptophan (Tab. 2.21). In this study, fluorescence 
spectroscopy was used to estimate the purity of affinity purified HPV16 L2 protein. Since L2 does not 
contain any intrinsic tryptophan residues, the detection of tryptophan fluorescence in the spectrum 
represents a direct hint for background proteins containing tryptophan. Measurements were 
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performed with 600 µl of a 100 nM protein solution on a spectrofluorometer F777 (Jasco, Tokyo, 
Japan), with excitation at 295 nm (1.5 nm bandwidth). The fluorescence spectrum was recorded from 
240-440 nm. 
Tab.2.21: Fluorescence characteristics of tryptophan, tyrosine, and phenylalanine. 
  absorption fluorescence 
 lifetime /ns wavelength /nm absorptivity wavelength/nm quantum yield 
tryptophan 2.6 280 5,600 348 0.20 
tyrosine 3.6 274 1,400 303 0.14 
phenylalanine 6.4 257 200 282 0.04 
 
 
2.2.9.4 Circular dichroism spectroscopy 
The optical activity of protein to flip circular polarized light around its axis delivers direct information 
about the secondary structure of the target protein. With CD measurements, the content of α-helical 
structures, β-sheets, as well as random coiled structures within the target protein, can be addressed. 
CD measurements were performed on a CARY 61 (Cary, Monrovia, CA, USA) CD spectrometer in a 2 
mm µl quartz cuvette. Protein concentration was about 10 µM. The CD measurements were 
performed with a fixed excitation wave length of 220 nm.  
 
2.2.9.5 Isothermal titration calorimetry (ITC) 
Isothermal titration calorimetry was performed to further characterize the interaction of HPV16 L2 
with SUMO1/2 and to gain thermodynamic parameters to describe the interaction of proteins. 
Therefore, binding of one molecular species to another species is characterized by titration and gives 
direct information about the binding constant, stoichiometry, and energetics. Measurements were 
performed on a MCS isothermal titration calorimeter from MicroCal (Northampton, MA, USA). To 
characterize binding of SUMO2 by L2 protein, SUMO2 was injected (18 x 20 µl, 300 µM) into a cell 
with 1.3 ml of HPV16 L2 solution (5 µM) at 15 °C (interaction buffer: in 50 mM Tris pH 7.5/300 mM 
NaCl). For characterization of the interaction of SUMO1 with the HPV16 L2 SIM peptides, SUMO1 
(300 µM) was injected (5 x 20 µl, 300 µM) into a cell with 1.3 ml 20 µM L2 SIM peptide (interaction 
buffer: 50 mM Tris pH 7.5/150 mM NaCl). 
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2.2.9.6 Molecular dynamics simulation 
Molecular dynamics simulation was performed with the YASARA software (YASARA Biosciences) for 
professional structure modeling of the potential attachment of L2 SIM peptides to SUMO1 or 
SUMO2. Therefore, the L2 peptide sequences were manually edited and implemented into a 
simulation cell together with the crystal-structures of SUMO1 or SUMO2 from known complexes with 
SIM containing SUMO targets. The L2 peptide was brought into close vicinity of the interaction 
surface of the SUMO1/2 molecules and the system was equilibarated for 5-12 ns with the simulation 
parameters given in Table 2.22. Then, simulation was continued by taking snap-shots each 12,500 
simulation steps. The simulated model data was characterized by determination of the root-mean-
square deviation (RMSD) of the respective L2 SIM peptides within the respective SUMO1/2 
interaction complex. 
Tab. 2.22: Simulation parameters for Yasara MD simulations. 
parameter selection/specification 
simulation cell 5.0 A around all atoms 
cell boundaries periodic walls 
force field Amber03 
pH 7.5 
temperature 298 K 
simulation snapshots every 12,500 simulation steps 
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  3. Results 
 
In this work, the interaction of the HPV16 late protein L2 with the small ubiquitin-like modifier 
(SUMO) was characterized with a broad selection of methods. L2 sequence analysis revealed a bona 
fide SUMO interacting motif (SIM) at position 284-289, which might enable noncovalent interaction 
of L2 with SUMO. In immunoprecipitation experiments it was found that L2 interacts with SUMO2, 
while no interaction was found between L2 and SUMO1. In electron paramagnetic resonance (EPR) 
spectroscopic measurements with affinity purified proteins, L2 interacted with SUMO1 and SUMO2. 
Coexpression of L2 with SUMO1 and SUMO2 led to a significant stabilization of wild-type L2. 
Furthermore, overexpressed L2 and SUMO1/2 colocalized at PML-NBs in immunofluorescence 
microscopy. For L2 lacking the SIM, there was no interaction with SUMO, and additionally also no 
colocalization with SUMO in PML-NBs. In order to characterize the physiologic relevance of the SIM-
based interaction of L2 with SUMO, HPV16 L1/L2 pseudoviruses (PsVs) containing mutant L2 were 
prepared and subjected to cell binding and infection assays. The lack of the L2 SIM did not affect cell 
binding, but lead to a complete loss of infectivity compared to wild-type L1/L2 PsVs. Then, the 
subcellular localization of wild-type and mutant L2, as well as localization of the viral DNA, was 
characterized by fluorescence microscopy after infection with L1/L2 PsVs. Infection with wild-type 
L1/L2 PsVs resulted in a strong colocalization of L2 and viral DNA in the PML-NBs of the host cells. 
Remarkably, almost no PML-NB-colocalization of L2 (and viral DNA) was observed after infection with 
mutant L1/L2 ΔSIM PsVs. Our data suggest that the identified L2 SIM is important for the interaction 
of L2 with SUMO in the PML-NBs. This most probably also includes L2 interaction with SUMOylated 
proteins at the PNL-NBs. 
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3.1 Characterization of the interaction of HPV16 L2 with SUMO proteins 
3.1.1 The HVP16 L2 protein sequence comprises multiple SIMs 
In general, there are two ways in which SUMO proteins can interact with target molecules: i) 
SUMOylation based on covalent SUMO modification and ii) SUMO interaction via SUMO interacting 
motifs (SIMs). With regard to HPV16 L2 as SUMO target, it is already known that L2 is SUMOylated by 
SUMO1/2/3 at the L2 K35 lysine residue, which leads to a stabilization of L2 (Marusic 2010). A SIM-
based interaction of L2 with SUMO has not been described yet. Remarkably, SIM-based SUMO 
interaction has already been reported for a very large number of target proteins including several 
viral proteins, which are functionally comparable to HPV16 L2. We searched for SIMs within the L2 
protein sequence and identified 9 potential SIMs which meet the criteria of the classical SIM 
consensus sequence (V/I/L)-(V/I/L)-X-(V/I/L) or (V/I/L)-X-(V/I/L)-X-(V/I/L) (Fig. 3.1) (Minty 2000; Song 
2004; Hannich 2005; Song 2005; Kerscher 2007). 
 
Fig. 3.1: Sequence alignment of potential SIMs within the HPV16 L2 protein sequence. Nine potential SIMs were identified 
based on the classical SIM sequence (V/I/L)-(V/I/L)-X-(V/I/L) or (V/I/L)-X-(V/I/L)-X-(V/I/L). The hydrophobic core of the 
potential SIMs is highlighted in the black frame. At L2 sequence positions 105-109, 284-289, and 428-431, two SIMs overlap 
with each other resulting in a double SIM. SIMs are frequently flanked by negatively charged amino acids (red) and/or 
phosphorylation sites. Potential phosphorylation sites within the L2 sequence were identified using the NetPhos 2.0 
prediction server and underlined for clarity. Positively charged amino acids are shown in blue, negatively charged amino 
acids in red, the hydrophobic core amino acids of the classical SIM in green, and all other amino acids in yellow. 
Three potential SIMs represent double SIM sequences (positions 105-109, 284-289, and 428-431), in 
which two SIMs overlap with each other sharing at least two of the hydrophobic core amino acids. 
Further characteristics of a SIM include the presence of neighboring negatively charged amino acids, 
which induce a first docking of the SIM at the SUMO interaction surface. Additionally, 
phosphorylation sites play an important role in the SIM mediated SUMO interaction. Therefore, 
potential serine, threonine, and tyrosine phosphorylation sites were identified (analysis via NetPhos 
2.0 Server, http://www.cbs.dtu.dk) (Blom 1999). Both, negatively charged amino acids and a 
potential casein kinase 2 (CK2) phosphorylation site were identified in the direct neighborhood of all 
potential SIMs. Thus, for further evaluation of the integrity of the potential SIMs, the conservation of 
the SIMs within the L2 sequences of the different HPV high risk types was checked. 
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3.1.2 Three potential SIMs within the L2 protein are conserved for high risk HPVs 
Specific sequence motifs, like e.g. protein interaction sequences or localization signals, often share a 
very high amino acid conservation between related proteins. The amino acid conservation of the 
identified SIMs was characterized based on an L2 sequence alignment of high-risk HPV L2 proteins 
(Fig. 3.2).  
Fig. 3.2: Sequence alignment of L2 in different high-risk HPV types. Only medium or no conservation is observed for the 
hydrophobic core of the potential SIMs at positions 235-238, 408-411, and 427-431. The potential SIMs at positions 105-
109, 145-148, and 284-289 share a very high conservation of the hydrophobic core residues. The complete sequence region 
around the potential double SIM at L2 position 284-289 is highly conserved. 100% sequence conservation is found for the 
most promising IVAL motif of the potential SIM at position 286-289. Additionally, an almost 100% conservation was found 
for flanking negatively charged amino acids (red) as well as the potential CK2 phosphorylation site at position 295/6 (TS). 
Hydrophobic core amino acids of the classical SIM are shown in green, negatively charged amino acids in red, and positively 
charged amino acids in blue. The multiple sequence alignment was performed with ClustalW2 (http://www.ebi.ac.uk) 
(Larkin 2007; Goujon 2010) and edited with Jalview (http://www.jalview.org) (Waterhouse, Procter et al. 2009). 
 
For the potential SIMs at position 408-411, 427-430, and 428-431, no significant conservation of the 
hydrophobic core was observed. A slightly better conservation of the core region was observed for 
the potential SIM at position 235-238, but here the charged, flanking amino acids and potential 
phosporylation sites were not conserved. As for the SIMs/double SIMs at positions 105-109, 145-148, 
and 284-289, a high conservation of the core hydrophobic amino acids, as well as the flanking 
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charged amino acids and phospohorylation sites, was observed. The highest level of conservation for 
the whole amino acid region containing a potential SIM was found for the double SIM at position 
284-289. This potential double SIM region fulfills all requirements of a classical SIM and thus 
resembles a bona fide SIM. For simplification, the double SIM at position 284-289 will be referred to 
as L2 SIM throughout this work. Nevertheless, also the potential double SIM at position 105-109 
features a very high level of conservation.  
 
3.1.3 L2 interacts with SUMO2 in immunoprecipitation 
The interaction of HPV16 L2 with SUMO1/2 was characterized based on different interaction 
experiments. First, immunoprecipitation was used to elucidate a potential interaction of L2 with 
SUMO1 or SUMO2. Therefore, 3xFLAG-L2 was coexpressed together with GFP-SUMO1, GFP-SUMO2, 
or GFP as control in HeLa cells. After immunoprecipitation of 3xFLAG-L2, coprecipitation of GFP was 
analyzed by immunodetection (Fig. 3.3). Coprecipitation was only observed for GFP-SUMO2 (lane 6), 
while there was no coprecipitation of GFP or GFP-SUMO1 (lanes 4 and 5). Interestingly, in the lysate 
controls (lanes 1-3) and IPs (lanes 4-6), an increased amount of L2 was detected after coexpression 
with GFP-SUMO1 and -2 as compared with the GFP control. This might result from a stabilization of 
L2 by GFP-SUMO1 and even stronger by GFP-SUMO2. 
 
Fig. 3.3: L2 interacts with GFP-SUMO2 in immunoprecipitation. HeLa cells were transiently cotransfected with 3xFLAG-L2 
together with GFP, GFP-SUMO1, or GFP-SUMO2. After 24 h, the expressed proteins were analyzed by immunodetection 
with anti-FLAG (detection of 3xFLAG-L2) or anti-GFP antibodies (lanes 1-3). Residual lysate was subjected to 
immunoprecipitation of 3xFLAG-L2 with an anti-FLAG antibody. Coprecipitation of GFP was analyzed with an anti-GFP 
antibody (Jl-8) and was only observed for GFP-SUMO2 (lane 6). There was no co-precipitated GFP (lane 4) or GFP-SUMO1 
(lane 5). An increasing amount of L2 was observed after coexpression with GFP-SUMO1 and GFP-SUMO2 compared to 
coexpression with GFP, indicating L2 stabilization by GFP-SUMO1 and especially GFP-SUMO2. 
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3.1.4 L2 lacking the SIM does not interact with SUMO2 
For further characterization of the L2 interaction with SUMO, different L2 mutants were created (Fig. 
3.4). In order to check whether the identified SIM at L2 position 284-289 is responsible for the SIM-
based L2 interaction with SUMO2, the amino acids 284-289 of the hydrophobic core of the SIMs 
were mutated to alanines (Fig. 3.4, B). This L2 mutant was termed L2 ΔSIM. To investigate the 
influence of L2 SUMOylation on the L2 interaction with GFP-SUMO2, the lysine at position 35 within 
the SUMO conjugation motif (SCM), which was reported to be the target for SUMOylation (Marusic 
2010), was changed to arginine (K35R, Fig 3.4, A). The L2 ΔSCM mutant lacks the SCM and is not able 
to be covalently modified by SUMO (Marusic 2010). A further L2 mutant, L2 ΔPHOS, was created to 
characterize the influence of phosphorylation of a potential casein kinase 2 (CK2) phosphorylation 
site located in the direct vicinity of the double SIM on protein interaction (Fig. 3.4, C). In this L2 
mutant, the phosphorylation receptors threonine and serine (L2 position 295/6) were replaced by 
alanines to inhibit potential phosphorylation. 
 
Fig. 3.4: Different L2 mutants for characterization of the L2 interaction with SUMO. A Wild-type protein sequence of 
HPV16 L2 with the lysine at position 35, which represents the target for SUMOylation, and the SUMO interacting motif at 
position 284-289. The extended SIM region contains the hydrophobic core region (LDIVAL, position 284-289) and a potential 
CK2 phosphorylation site (TS, position 295/6). In the L2 ΔSCM mutant, the lysine (K) at position 35 was replaced by arginine 
(R). B The L2 ΔSIM mutant was created by replacing the IVAL motif in the hydrophobic core with alanines. C The L2 ΔPHOS 
mutant comprises two alanines instead of the phosphorylation receptors threonine (T) and serine (S) at position 295/6. 
To characterize interaction of the L2 mutants with SUMO2, again, immunoprecipitation experiments 
were performed. Therefore, wild-type L2, L2 ΔSIM, and L2 ΔPHOS were coexpressed together with 
GFP-SUMO2 and characterized by immunodetection (Fig. 3.5). After immunoprecipitation of GFP 
with a Jl-8 antibody, coprecipitation was observed for wild-type L2 (lane 6). Remarkably, there was 
almost no coprecipitation of L2 ΔSIM (lane7), as the L2 ΔSIM band intensity only reached the level of 
the negative control after coexpression of wild-type L2 and GFP (lane 5). Like wild-type L2, also L2 
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ΔPHOS was successfully detected after coprecipitation (lane 8) indicating that mutation of the 
potential phosphorylation site had no effect on the L2 interaction with GPF-SUMO2. 
 
Fig. 3.5: No coprecipitation of L2 ΔSIM after coexpression with GFP-SUMO2. Wild-type L2, L2 ΔSIM, and L2 ΔPHOS were 
coexpressed together with GFP-SUMO2 for 24 h in HeLa cells and analyzed by immunodetection. After Jl-8 
immunoprecipitation of the GFP proteins, coprecipitation of wild-type L2 (lane 6) and L2 ΔPHOS (lane 8) was observed. 
Almost no coprecipitation was detected for L2 ΔSIM (lane 7). The observed L2 ΔSIM band only reached background 
intensity comparable to the negative control with coexpressed wild-type L2 and GFP (lane 5). Note that again the amount of 
detectable L2 was significantly increased upon coexpression with GFP-SUMO2 compared to GFP alone.  
In order to characterize a possible influence of SUMOylation on SIM-based L2 interaction with GFP-
SUMO2, coprecipitation experiments were repeated with coexpression of GFP-SUMO2 together with 
wild-type L2 or L2 ΔSCM, which is SUMOylation deficient. After precipitation of GFP with a Jl-8 
antibody, both, wild-type L2 and L2 ΔSCM, were co-precipitated (Fig. 3.6, A, lanes 3 and 4). 
Interestingly, for L2-precipitation with an L2-specific antibody (L2-1), no coprecipitation of GFP-
SUMO2 was observed (Fig. 3.6, B, lanes 7 and 8), although L2-precipitation was successful. 
Remarkably, in none of the numerous experiments, a coprecipitation of GFP-SUMO constructs was 
observed after L2 precipitation based on the L2-specific L2-1 antibody.  
To check the possible influence of SUMOylation of L2 interaction with SUMO, an additional 
precipitation experiment was performed. Therefore, wild-type 3xFLAG-L2 was coexpressed together 
with GFP-SUMO1/2 ΔGG mutants, which are SUMOylation deficient. In contrast to wild-type GFP-
SUMO1/2 containing the full-length SUMO protein, the SUMO1/2-ΔGG proteins resemble C-
terminally truncated SUMO isoforms. The shortened protein sequence of SUMO1-ΔGG (amino acids 
1-95) ends before the double glycine motif, which is located at amino acid position 96/97 of wild-
type SUMO1. In parallel, the protein sequence of SUMO2-ΔGG (amino acids 1-91) ends at position 91 
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just before the double glycine at amino acid position 92/93 of wild-type SUMO2. Theoretically, both 
SUMO1/2-ΔGG isoforms are not able to participate in SUMO modification of SUMO targets anymore, 
since the necessary double glycine, which serves as target for covalent binding of SUMO with SUMO-
ligands, is missing. Finally, after coexpression of wild-type 3xFLAG-L2 together with GFP-SUMO1 ΔGG 
or GFP-SUMO2 ΔGG and precipitation of 3xFLAG-L2, no coprecipitation of GFP-SUMO1/2 ΔGG was 
observed (Fig. 3.5, C, lanes 5 and 6). Note that there is a comparable amount of detected L2 within 
the lysate controls (lanes 1-3) and IPs (lanes 3-6) after L2 coexpression with the SUMO1/2-ΔGG 
mutants and GFP alone, indicating that there is no L2 stabilization based on GFP-SUMO1/2 ΔGG as it 
was seen for L2 and wild-type SUMO1/2. Immunofluorecence microscopy with overexpressed 
SUMO1/2-ΔGG revealed an exclusively cytoplasmic localization of GFP-SUMO1/2 ΔGG with almost no 
GFP signal within the nucleus (data not shown).  
We were also able to characterize L2 SUMOylation after simple coexpression of L2 together with 
SUMO1/2 (Fig. 3.6, D). While each one additional high molecular L2 band was detected for 
coexpression of wild-type L2 and SUMO1 or SUMO2, which run at the characteristic molecular 
weight of a L2-GFP-SUMO1/2 fusion protein (lanes 2 and 3), in line with the results obtained by 
Marusic et al. 2010, no high molecular L2 bands were detected after expression of L2 ΔSCM (lanes 5 
and 6). Additionally, there were also no high molecular L2 bands detected for coexpression of wild-
type L2 together with GFP-SUMO1/2 ΔGG (lanes 8 and 9). 
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Fig. 3.6: Coprecipitation experiments including SUMOylation-deficient L2 ΔSCM or GFP-SUMO1/2 ΔGG. A Wild-type L2 
was coexpressed with GFP-SUMO2 in HeLa cells for 24 h. After GFP precipitation, both wild-type L2 and L2 ΔSCM were 
successfully co-precipitated (lanes 3 and 4). B Again, wild-type L2 was coexpressed with GFP-SUMO2, but precipitation was 
performed based on an anti L2 antibody (L2-1). No significant coprecipitation of GFP-SUMO2 was observed (lanes 7 and 8). 
C Wild-type 3xFLAG L2 was coexpressed with GFP-SUMO1/2 ΔGG, which cannot be covalently linked to SUMO substrates. 
After precipitation of 3xFLAG L2 with an anti-FLAG antibody, no coprecipitation of GFP or GFP-SUMO1/2 ΔGG was observed 
(lanes 4-5). There was difference in the amount of L2 after coexpression of L2 with GFP or GFP-SUMO1/2 ΔGG in the lysate 
controls and IPs, indicating no L2-stabilization based on SUMO1/2 ΔGG. D Characterization of L2 SUMOylation after 
coexpression of wild-type L2 or L2 ΔSCM together with GFP, GFP-SUMO1, GFP-SUMO2 or together with GFP-SUMO1, -2 
ΔGG. Arrows indicate SUMOylated L2 detected by anti-L2 antibodies. 
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3.1.5 Wild type L2 colocalizes with GFP-SUMO1/2 in PML NBs 
After a SIM-based in vitro interaction of HPV16 L2 and SUMO2 was observed in immunoprecipitation 
experiments, overexpressed L2 and SUMO1/2 were characterized by immunofluorescence 
microscopy. Therefore, HPV16 L2 variants were coexpressed with GFP-SUMO1/2 and the cellular 
localization of the proteins was monitored. Wild-type L2 accumulated in the cell nucleus within larger 
aggregates and almost always colocalized with endogenous PML bodies (Fig. 3.7). For GFP-SUMO1 or 
-SUMO2, an almost 100% colocalization with L2 wt was observed for both SUMO isoforms. In 
general, the majority of overexpressed wild-type L2 colocalized with GFP-SUMO1 or GFP-SUMO2 at 
cellular PML bodies. PML-localization of wild-type L2, GFP-SUMO1, or GFP-SUMO2 was also observed 
in control experiments with separate overexpression of the respective proteins, showing that the 
PML-localization did not depend on coexpression. 
 
Fig. 3.7: Wild-type L2 accumulated in the nucleus and colocalized with GFP-SUMO1/2 at PML-NBs. After coexpression of 
wild-type L2 together with GFP-SUMO1 or GFP-SUMO2 for 48 h in HeLa cells, L2 accumulated in the nucleus and colocalized 
with GFP-SUMO1/2 within larger aggregates at the PML-NBs. PML-localization of L2, GFP-SUMO1, or GFP-SUMO2 was also 
observed after separate overexpression of the respective proteins, indicating that the observed PML-localization did not 
depend on coexpression. 
 
3.1.6 No colocalization of L2 ΔSIM with SUMO1/2 or PML 
Also the subcellular localization of L2 ΔSIM was characterized upon coexpression with GFP-SUMO1/2 
(Fig. 3.8, A). Here, the L2 ΔSIM structures were less distinct and featured a rather diffuse distribution 
all over the cell nucleus compared with the wild-type L2 aggregates. Remarkably, there was almost 
no (or only random) colocalization of L2 ΔSIM with PML-NBs or GFP-SUMO1 or GFP-SUMO2. After 
coexpression of L2 ΔPHOS or L2 ΔSCM with GFP-SUMO1/2, a wild-type like localization of the L2 
mutants was observed (Fig. 3.8, B and C). L2 ΔPHOS and L2 ΔSCM colocalized at PML-NBs together 
with GFP-SUMO1 or GFP-SUMO2. The same L2 localization pattern was observed after separate 
overexpression of L2 ΔPHOS or L2 ΔSCM without GFP-SUMO1/2. 
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Fig. 3.8: No PML-NB localization of L2 ΔSIM. A After coexpression of L2 ΔSIM with GFP-SUMO1 or GFP-SUMO2 for 48 h in 
HeLa cells, a diffuse L2 distribution and no colocalization with GFP-SUMO1/2 or PML-NBs was observed. GFP-SUMO1 and 
GFP-SUMO2 still colocalized at the PML-NBs. B For coexpression of L2 ΔPHOS with GFP-SUMO1 or -2, a wild-type L2 
distribution was observed. L2 ΔPHOS colocalized with GFP-SUMO1 or -2 at PML-NBs. C Also for coexpression of L2 ΔSCM, a 






  Results 
  94 
3.1.7 L2 wt and L2 ΔSCM are stabilized by SUMO1/2 after coexpression in HeLa cells 
In several immunoprecipitations with overexpressed L2 and GFP-SUMO1/2, a significant L2 
stabilization was observed after coexpression with GFP-SUMO1 and especially GFP-SUMO2. Based on 
these observations and previous publications reporting on SUMOylation-based L2 stabilization 
(Marusic 2010), L2 stabilization assays were performed. Therefore, L2 was coexpressed with GFP-
SUMO1, GFP-SUMO2, or GFP for 24 h. Then, cycloheximide (CHX) was added to stop further protein 
synthesis and cell lysates were characterized by immunodetection after 0.5, 1, 2, and 4 hours (Fig. 
3.9, A). Note that the zero time controls were prepared directly before CHX was added to the parallel 
samples. The L2 amounts were quantified by densitometry and plotted against the time (Fig. 3.9, B). 
 
Fig. 3.9: L2 stabilization assay. A After coexpression of L2 together with GFP-SUMO1, GFP-SUMO2, or GFP protein synthesis 
was inhibited by addition of cycloheximide (CHX, 50 µg/ml). Lysates were prepared after 0.5, 1, 2, and 4 hours and 
characterized by immunodetection. The zero time control was prepared directly before addition of CHX to the parallel 
samples. For densitometrical quantification of L2, L2 blots with equal L2 zero time intensities were compared by variation of 
the exposure time during development of the films. B L2 bands were quantified densitometrically, normalized to the L2 
amount of the zero-time controls (including β-actin correction) and plotted against the time. The protein half-life times of 
the different L2 mutants were determined by fitting of linear or exponential decay functions and were summarized in Table 
3.1. 
Without coexpression of GFP-SUMO proteins, the shortest L2 half-life time was detected for L2 ΔSCM 
(0.33 ± 0.2 h, Table 3.1). The half-life time for wild-type L2 was about 0.9 ± 0.2 h, for L2 ΔSIM about 
1.4 ± 0.2 h. In general, coexpression of L2 together with GFP-SUMO1 or GFP-SUMO2 resulted in 
significantly prolonged L2 half-life times. Coexpression of GFP-SUMO2 extended half-life times of 
wild-type L2 and L2 ΔSIM to about 3.2 ± 0.2 h and 5.0 ± 0.2 h (GFP-SUMO1: 2.3 ± 0.2 h and 3.1 ± 0.2 
h). For L2 ΔSCM, especially coexpression of GFP-SUMO1 resulted in a longer L2 half-life time of about 
3.7 ± 0.2 h (GFP-SUMO2: 2.4 ± 0.2 h).  
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Table 3.1: L2 stabilization assay. L2 half-life times for coexpression of L2 with GFP-SUMO1, GFP-SUMO2, or GFP. The half-
life times were determined by linear or exponential fitting of the L2 decay functions of Figure 3.9, B.  
 L2 wt L2 ΔSCM L2 ΔSIM 
GFP 0.9 ± 0.2 0.3 ± 0.2 1.4 ± 0.2 
GFP-SUMO1 2.3 ± 0.2 3.7 ± 0.2 3.1 ± 0.2 
GFP-SUMO2 3.2 2.4 5.0 
 
 
3.1.8 No Interaction of L2 and SUMO1/2 in GST-SUMO or SUMO-his pulldowns 
To characterize a possible interaction of purified SUMO1/2 with overexpressed L2, SUMO1/2 
pulldown experiments were performed. Therefore, GST-SUMO1/2 or SUMO1/2-his6 was immobilized 
on an affinity matrix followed by incubation with L2. Coprecipitation of L2 was characterized by 
immunodetection (Fig. 3.10). No coprecipitation of L2 was observed after incubation with GST, GST-
SUMO1, or GST-SUMO2 (Fig. 3.10, A, lanes 2-4), although an adequate amount of the respective GST 
proteins was immobilized on the affinity matrix (see anti-GST Western Blot and Direct Red 81 protein 
staining, lanes 2-4). GST-pulldown and coprecipitation of L2 was repeated under different buffer and 
washing conditions, but no coprecipitation of L2 was observed. After immobilization of SUMO1/2-
his6 and incubation with L2, again, there was no coprecipitation of L2, since L2 band intensities in the 
lanes with L2 incubation with SUMO1/2-his6 (Fig. 3.10, B, lanes 7 and 8) were comparable with the 
negative control after incubation of L2 with Ni-NTA beads without immobilized SUMO1/2 (lane 6). 
Nevertheless, anti-His Western Blots and Coomassie protein staining indicated immobilization of an 
adequate amount of highly pure SUMO1/2-his6 (lanes 7 and 8). 
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Fig. 3.10: No coprecipitation of L2 after SUMO1/2 immobilization. A GST-SUMO1 or GST-SUMO2 was overexpressed in 
E.coli and immobilized and purified on glutathione sepharose beads. L2 was overexpressed in HeLa cells and the L2 lysate 
was incubated with 8 µg of immobilized GST-SUMO1, GST-SUMO2, or GST. Immobilization of the GST proteins, as well as 
coprecipitation of L2, was characterized by immunodetection with anti-L2 or anti-GST antibodies. Although adequate 
amounts of L2 (lane 1) and GST-SUMO1/2 (lanes 3 and 4) were detected, no coprecipitation of L2 was observed. B 
SUMO1/2-his6 was expressed in E. coli and immobilized and washed on Ni-NTA beads. L2 lysates were prepared after 
overexpression in HeLa cells and incubated with 8 µg of immobilized SUMO1-his6, SUMO2-his6, or Ni-NTA beads. 
Characterization of co-precipitated L2 by immunodetection revealed an equal amount of L2 after incubation with 
immobilized SUMO1 and SUMO2 (lanes 7 and 8), but a comparable L2 amount was also detected in the negative control 
after incubation of L2 with Ni-NTA beads without SUMO1/2 (lane 6). Therefore, the detected L2 bands only represent 
background precipitation of L2 on the Ni-NTA beads. 
 
3.1.9 No interaction of L2 and SUMO in Mammalian-2-Hybrid screening 
In addition to immunoprecipitation experiments, mammalian 2-Hybrid experiments were performed 
to monitor L2-SUMO interaction. Therefore, a bait fusion protein, containing a DNA binding domain 
(BD) and SUMO1/2, and a prey fusion protein, containing an activation domain (AD) and L2 as the 
potential interaction partner, were coexpressed in HeLa cells together with a luciferase reporter 
plasmid. After cell lysis, a luciferase-based reporter gene assay was performed to characterize 
transactivation of the luciferase gene by interaction of L2 with SUMO1 or SUMO2. Transactivation of 
the luciferase gene was only observed for the internal positive control, where a p53-BD fusion 
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protein interacts with a SV40-AD fusion protein (Fig. 3.11). For the combination of L2 fusion proteins 
with SUMO1 or SUMO2 fusion constructs, no transactivation of the luciferase gene was observed, as 
luciferase expression was comparable with the negative or blank controls. The experiment was 
repeated after a switch of L2 and SUMO1/2 within the bait and prey fusion proteins. However, also 
coexpression of BD-L2 together with AD-SUMO1 or AD-SUMO2 fusion proteins did not result in a 
transactivation of the luciferase reporter (data not shown). 
 
Fig. 3.11: No L2 interaction with SUMO1 or SUMO2 in mammalian 2-hybrid experiments. A AD-L2 was coexpressed with 
BD-SUMO1 or BD-SUMO2 in HeLa cells for 24 h followed by quantification of the luciferase expression upon transactivation 
of the luciferase reporter gene. There was no luciferase expression for coexpression of AD-L2 and BD-SUMO1/2, as 
detection levels were comparable to the negative controls (AD-L2 + BD, AD-TRAF + BD-p53) or the blank control without 
protein expression. Luciferase expression was only observed for the positive control of the 2-hybrid system, where 
coexpression of AD-SV40 and BD-p53 resulted in transactivation of the luciferase reporter. B The separate expression of the 
BD-SUMO1/2 and AD-L2 fusion proteins was characterized by immunodetection with an anti-GAL4 antibody for BD fusion 
proteins and anti-L2 for the AD-L2 fusion protein after overexpression for 24 h in HeLa cells. 
 
3.1.10 The L2 SIM is also important for ubiquitin interaction of HPV16 L2 
For the correct reproduction of viruses, a complex and well-regulated interaction with the host cell is 
absolutely necessary. Thereby, interaction with the cellular SUMO apparatus is regularly observed, 
but very often also ubiquitination or phosphorylation trigger the viral pathway. Based on these 
findings and the remarkable structural homology of SUMO proteins with ubiquitin, in the following 
experiment, a potential interaction of HPV16 L2 with ubiquitin was investigated by coprecipitation 
experiments with ubiquitin agarose beads. Therefore, cell lysates with overexpressed HPV16 L2 or L2 
ΔSIM were incubated with ubiquitin-coupled agarose beads and incubated for 1.5 h at RT. After 
washing of the beads, potential co-precipitated L2 protein was characterized by immunodetection 
(Fig. 3.12). Only wild-type L2 was co-precipitated with ubiquitin agarose. There was no 
coprecipitation of L2 ΔSIM. 
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Fig. 3.12: No coprecipitation of L2 ΔSIM with ubiquitin agarose. Wild-type L2 and L2 ΔSIM were overexpressed for 24 h in 
HeLa cells in two parallels. L2 lysates were incubated with ubiquitin-coupled agarose beads and L2 coprecipitation was 
analyzed by immunodetection. While a strong L2 coprecipitation was observed for wild-type L2, there was no 
coprecipitation of L2 ΔSIM. 
 
3.2 Structural and functional analysis of SUMO-interaction deficient L1/L2 ΔSIM PsVs 
3.2.1 HPV16 L1/L2 ΔSIM PsVs are noninfectious 
After characterizing the interaction of L2 with SUMO proteins after overexpression, the main focus 
was on the functional relevance of the L2 SIM in the context of HPV16 virions and infection. 
Therefore, wild-type L1/L2 PsVs and also L1/L2 ΔSIM PsVs were prepared. Infection of HeLa or HaCaT 
cells with L1/L2 wt, L1/L2ΔPHOS, or L1/L2 ΔSCM PsVs resulted in comparable luciferase expression 
levels (Fig. 3.13, A). Remarkably, luciferase expression was significantly decreased after infection with 
L1/L2 ΔSIM PsVs. Control infection with L1 VLPs did not result in significant luciferase expression. 
To check whether the loss of infectivity of the L1/L2 ΔSIM PsVs was based on incorrect incorporation 
of L1 or L2 ΔSIM into the PsVs during capsid assembly, the L1 and L2 content of the PsV was 
quantified by immunodetection (Fig. 3.13, B). All PsV preparations contained an equal level of L1 and 
L2. For L1 VLPs, no L2 was detected, as L1 VLPs completely lack viral L2. 
For comparable characterization of the infectivity of the different PsVs, the amount of PsVs was 
adjusted according to the DNA content of the respective PsV preparation to establish a constant level 
of reporter DNA for each PsV type. Reporter DNA quantification revealed an equal DNA level for all 
PsVs (Fig. 3.13, C). Thus, putative artifacts stemming from different reporter gene contents of the 
PsVs during infection assaying can be excluded.  
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Fig. 3.13: L1/L2 ΔSIM PsVs are noninfectious. A HeLa or HaCaT cells were infected with L1/L2 PsVs or L1 VLPs for 24 h. 
Infectivity was characterized based on expression of a luciferase reporter gene, which was incorporated into the PsVs/VLPs 
during virus assembly. Infection with wild-type PsVs, as well as L1/L2 ΔPHOS or L1/L2 ΔSCM, resulted in comparable 
luciferase expressions. Remarkably, after infection with L1/L2 ΔSIM PsVs, no luciferase expression was detected. There was 
also no luciferase expression after infection with L1 VLPs. B Immunodection of L1 (anti-L1, 312F antibody) and L2 proteins 
(anti-L2, L2-1 antibody) revealed an equal amount of L1 and L2 for all PsVs/VLPs. C The reporter DNA content of the 
respective PsVs/VLPs was analyzed based on the Quant-iTTM picogreen® DNA quantification kit (Invitrogen). All PsVs/VLPs 
contained comparable amounts of reporter DNA. 
 
3.2.2 Correct assembly of L1/L2 ΔSIM PsVs 
L1/L2 ΔSIM PsVs were subjected to an additional ultracentrifugation step on a 10-60% (w/v) sucrose 
gradient to analyze the content of larger L1/L2 aggregates, isolated capsomers, or nonassembled 
L1/L2 within the PsV preparation, which could cause loss of infectivity of L1/L2 ΔSIM PsVs 
preparations. Therefore, after ultracentrifugation, the PsV fractions were characterized by 
immunodetection (Fig. 3.14). All PsV gradients contained well detectable amounts of L1 and L2 
protein (for L1 VLPs only L1 was detected). Maximum L1 and L2 intensity was detected for fractions 
12-14, which represented the peak fractions for all PsV gradients depicting intact PsVs. Within the 
last fractions, there were no larger amounts of aggregated viral debris or L1/L2 aggregates. As for L1 
VLP, the L1 maximum was not as distinct as for the other PsVs and also the bottom fraction 16 and 
17 contained larger amounts of L1. This could be an indication that L1 VLPs were not as uniform in 
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size and structure as the other PsVs. Additionally, in all gradients, there was no L1 or L2 detected in 
one of the first fractions, which is a good mark that all L1 and L2 was incorporated into the PsVs. 
Infection assays with the pooled PsVs peak fractions after sucrose gradient ultracentifugation 
confirmed the results obtained before: Infection with wild-type PsVs and L1/L2 ΔSCM PsV led to 
comparable levels of luciferase expression, again, indicating full functionality and infectivity of the 
PsVs. No luciferase expression was detected for the L1/L2 ΔSIM PsVs and also for L1 VLPs (data not 
shown). 
 
Fig. 3.14: Correct assembly of L1/L2 ΔSIM PsVs. To characterize the correct assembly of L1/L2 ΔSIM PsVs, the purified PsVs 
were subjected to an additional ultracentrifugation (150 min at 36,000 rpm and 4 °C) to detect possible L1/L2 aggregates, 
isolated capsomers, or non-assembled L1/L2, which could cause the loss of infectivity of L1/L2 ΔSIM PsVs preparations. The 
fractions were characterized by immunodetection with anti-L2 (L2-1) and anti-L1 (312F) antibodies. The highest L1/L2 
amounts were detected in the peak fractions 12-14. There was no larger amount of non-assembled L1/L2, which would be 
detectable in the first fractions of the gradient. There were also no larger L1/L2 aggregates within the last fractions, 
indicating that the majority of PsVs within the respective preparation were intact and not disrupted allowing formation of 
even larger L1/L2 aggregates. There was no detection of any clear peak fractions for L1 VLPs, possibly indicating a larger 
polydispersity. 
 
3.2.3 L1/L2 ΔSIM PsVs show a wild-type phenotype in electron microscopy 
After characterization of PsV assembly by sucrose gradient ultracentrifugation, the PsVs were 
additionally characterized by Transmission Electron Microscopy (TEM) to directly visualize the capsid 
structure and to check for any defects for L1/L2 ΔSIM PsVs, which could cause loss of infectivity. All 
PsVs investigated here featured a wild-type phenotype with typical spherical capsids with a diameter 
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of about 55 nm (Fig. 3.15). In general, the mutations within the L2 capsid proteins (L2 ΔSIM, L2 
ΔPHOS, L2 ΔSCM) did not lead to a visible defect of the capsid structure of the assembled L1/L2 PsVs. 
Additionally, also staining of the reporter DNA with 5-ethynyl-2´-deoxyuridine (EdU) during PsV 
preparation, which allows for a fluorescence microscopic characterization of PsV infection, did not 
visibly alter the capsid structure of the respective PsVs (data not shown). 
 
 
Fig. 3.15: L1/L2 ΔSIM PsVs show a wild-type capsid structure in electron microscopy. PsVs were streaked on copper grits, 
stained with uranylacetate, and washed with PBS. TEM pictures were made on a 300 kV High Resolution Cryo-TEM. A 
comparable amount of intact viral cpasids with diameters of about 55 nm were detected within all PsV/VLP preparations 
(scale bar: 100 nm). There were no visible structural defects of the viral capsids due to virus assembly based on L1 and L2 
ΔSIM, L2 ΔPHOS, or L2 ΔSCM. The pictures were taken by Philip Arnold (AG Markl, Johannes Gutenberg University, Mainz). 
 
3.2.4 L1/L2 ΔSIM PsVs bind to HeLa and HaCaT cells and are endocytosed 
Loss of infectivity of L1/L2 ΔSIM PsVs could by provoked by several factors. To exclude aberrations 
during cell binding and endocytosis of L1/L2 ΔSIM PsVs, the attachment of the PsV onto target cells 
and viral uptake by endocytosis was characterized by flow cytometry. To test cell binding of PsVs, 
HeLa and HaCaT cells were infected with L1/L2 PsVs for 15 min. Then, the PsVs were labeled with an 
anti-L1 antibody in combination with an AlexaFluor488 secondary fluorescence antibody for 
detection in flow cytometry (Fig. 3.16, A and B).  
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Fig. 3.16: Wild-type cell binding and endocytosis of L1/L2 ΔSIM PsVs. HeLa cells (A) or HaCaT cells (B) were infected with 
L1/L2 PsVs. Cell binding and endocytosis of the PsVs/VLPs was characterized by flow cytometry based on detection of viral 
L1 with a primary anti-L1 antibody (L1-7), which was coupled with a secondary fluorescence antibody (AF488). For 
characterization of cell binding, the target cells were incubated with PsVs/VLPs for 10 min, washed, and subsequently 
prepared for quantification of the L1 fluorescence by flow cytometry. Here, high L1 fluorescence intensities were reached 
for all PsVs/VLPs, indicating that equal amounts of viruses were able to bind to the target cells. To check whether cell-
bound PsVs/VLPs were also able to be endocytosed, target cells were again infected for 10 min, but this time flow 
cytometry was performed after a 24 h incubation of the target cells with the cell-bound viruses to allow endocytosis. All 
PsVs/VLPs seemed to be endocytosed, as there was no L1 fluorescence stemming from residual surface-bound viruses. 
Here, the L1 fluorescence was at the same level as within negative controls with non-infected HeLa or HaCaT cells. 
 
An equal level of L1 fluorescence was detected for all PsVs/VLPs, indicating that comparable amounts 
of PsVs/VLPs, including L1/L2 ΔSIM PsVs, were attached to the host cells. To analyze endocytosis of 
cell-bound PsVs/VLPs, again, HeLa and HaCaT cells were infected for 15 min. This time, the cells were 
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incubated for additional 24 h to allow endocytosis of the viruses. After fluorescence-labeling of L1, 
the L1 fluorescence was again characterized by flow cytometry. Fluorescence intensities were on a 
background level and comparable with negative controls without PsV/VLP infection of the target 
cells. This is a direct hint that all PsVs/VLPs, also L1/L2 ΔSIM PsVs, were successfully endocytosed 
after cell binding, since there was no detection of L1 fluorescence stemming from residual PsVs/VLPs 
on the cell surface. 
In a novel attempt, the cell binding of PsVs/VLPs was also characterized by standard CW-EPR 
measurements. Therefore, PsVs/VLPs were incubated with Fremy’s Salt (NDS, potassium 
nitrosodisulfonate) to allow electrostatic attachment of NDS to postitively charaged amino acid 
patches of L1 and L2. Then, the L1-/L2-coupled NDS molecules served as a sensor for monitoring the 
cell binding of the NDS-labeled viruses after incubation with target cells by measurement of the time-
dependent decay of the NDS signal in CW EPR measurements. The NDS CW EPR spectra were not 
further analyzed according to spectral parameters, since variations in spectral breadth and/or 
mobility effects were only affected by the sample viscosity due to residual amounts of Optiprep® 
medium, which could not be maintained at exactly comparable levels during preparation of the 
different PsVs for CW EPR measurements but did not significantly interfere with EPR activity of the 
NDS molecules. However, EPR samples were comparable within the same PsV type, since the 
samples used for characterization of effects based on addition of cells or heparin originated from 
each one master sample for each type of PsVs containing PsVs and NDS. NDS within pure buffer 
solution featured highest half-life times. Whenever NDS molecules get in closer contact, like e.g. at 
the positively charged amino acid patches in L1/L2, the half-life time of the NDS molecules decreases. 
For NDS incubation with wild-type L1/L2 PsVs, NDS half-life times of about 45 ± 10 min were 
detected (Fig. 3.17, A). After addition of heparin to the NDS/PsV solution, extended half-life times of 
about 60 ± 10 min were detected, while addition of HaCaT cells led to decreased NDS half-life times 
of about 35 ± 10 min. These trends were also observed for L1/L2 ΔPHOS and L1/L2 ΔSCM PsVs. 
Experiments based on NDS incubation with L1/L2 ΔSIM PsVs and L1 VLPs resulted in slightly longer 
NDS half-life times, also for incubation with heparin or HaCaT cells. Incubation of the NDS/PsV 
solution with a larger amount of HaCaT cells lead to a drastic decrease of NDS half-life times without 
a greater change of the half-life times for samples without HaCaT cells (Fig. 3.17, B). Since addition of 
heparin lead to a stabilization of NDS in all samples, it was checked whether pre-incubation of the 
NDS/PsV mix with even higher amounts of heparin could inhibit the effect of strongly decreased NDS 
intensity provoked by addition of HaCaT cells (Fig. 3.17, C). In fact, after incubation of the NDS/PsVs 
mix with heparin, the NDS half-life times after addition of HaCaT cells were comparable with NDS 
half-life times before addition of HaCaT cells (about 70 ± 10 min).  
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Fig. 3.17: Addition of HaCaT cell induces NDS dissociation in NDS/PsV samples in CW EPR measurements. Different 
PsVs/VLPs were incubated with NDS at equimolar levels of L1/L2 and NDS. The NDS EPR signal intensity was plotted against 
the time for the mixture of NDS and PsVs alone, or after addition of an excess amount of heparin or HaCaT cells. A Addition 
of about 10,000 HaCaT cells per sample lead to reduced NDS half-life times (35 min) when compared with the reference 
sample without cells (40 ± 10 min) or with the sample containing heparin (60 ± 10 min). The same trends were observed for 
L1/L2 ΔSIM PsVs, but here, in general, slightly prolonged NDS half-life times were deduced. B The NDS intensity vanished 
within several minutes when larger amounts of HaCaT cells (~200,000) were added to the NDS/PsV samples. Half-life times 
for the reference samples without HaCaT did not vary significantly from the previous experiment in Fig. 3.17, A. Also, the 
NDS half-life time of the negative control containing only NDS and a comparable amount of HaCaT cells was not shortened 
significantly, indicating only a small background interaction of NDS with the injected HaCaT cells. Again, slightly extended 
NDS half-life times were detected for samples containing L1/L2 ΔSIM PsVs (and L1 VLPs, data not shown). C It was also 
tested whether pre-incubation of PsVs/VLPs with heparin could inhibit the effect of shortened NDS half-life times after 
addition of HaCaT cells. Remarkably, NDS half-life times after addition of HaCaT cells were comparable to the half-life times 
of the mixture of NDS/PsVs with heparin before injection of cells (about 70 ± 10 min). 
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3.2.5 No PML-colocalization of DNA or L2 after infection with L1/L2 ΔSIM PsVs 
Flow cytometry and CW-EPR measurements with Framy’s Salt indicated a wild-type cell binding and 
endocytosis of L1/L2 ΔSIM PsVs. Here, fluorescence microscopy was performed to check for an 
influence of the L2 ΔSIM mutation on the nuclear transport or PML-localization of the L2-DNA 
complex, which could also lead to a loss of infectivity for L1/L2 ΔSIM PsVs. Therefore, L2 and the 
reporter DNA were labeled with different fluorescence dyes to characterize the cellular localization. 
After infection with L1/L2 wt, L1/L2 ΔPHOS, and L1/L2 ΔSCM PsVs, a very strong colocalization of viral 
DNA and L2 was found in the cytoplasm and in the cell nucleus (Fig. 3.18). In the nucleus, a strong 
colocalization of viral DNA and L2 with PML was observed. Remarkably, after infection with L1/L2 
ΔSIM PsVs, no PML-localization of DNA or L2 was observed. Instead, there were large L2 aggregates, 
which were only detectable when focusing out of the plane of the cell nuclei (see arrows in Fig. 3.19). 
Fig. 3.18: No PML-localization of viral DNA or L2 after infection with L1/L2 ΔSIM PsVs. After infection of HeLa cells with 
L1/L2 wt, L1/L2 ΔPHOS, and L1/L2 ΔSCM PsVs, a strong colocalization of viral DNA and L2 was observed in the cytoplasm 
and in the nucleus (see also enlarged pictures of the cell nuclei taken with a laser scanning microscope, LSM). In the 
nucleus, a strong PML-localization of viral DNA and L2 was observed. After infection with L1/L2 ΔSIM PsVs, almost no PML-
localization of viral DNA or L2 was detected. Viral DNA was labeled based on 5-ethynyl-2´-deoxyuridine (EdU) in 
combination with an AlexaFluor488 fluorescence dye. The last column shows an enlarged section of the cell nucleus taken 
by laser scanning microscopy (LSM). 
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Fig. 3.19: L2 ΔSIM aggregates on the cell surface. L2 ΔSIM colocalized with the viral DNA in dense structures at the cellular 
surface after 24 h of infection. Almost no L2 ΔSIM was found within the nucleus (pictures taken on a laser scanning 
microscope, LSM). 
In order to statistically quantify colocalization of L2 or viral DNA with endogenous PML, a pixel-by-
pixel colocalization analysis was performed. Therefore, 80-100 nuclei were selected for each type of 
PsVs and PML-localization of L2 or viral DNA was determined. The PML-colocalizations after infection 
with wild-type viruses were used as 100% reference. Most PML-colocalized L2 was observed after 
infection with L1/L2 ΔSCM PsVs (160%) and wild-type PsVs (100%, Fig. 3.20, A). Almost no PML-
localized L2 was detected after infection with L1/L2 ΔSIM PsVs (7%). Infection with L1/L2 ΔPHOS PsVs 
resulted in a medium colocalization level of L2 with PML (60%). With regard to the viral DNA, 
significant levels of PML-localized viral DNAs were only detected after infection with wild-type or 
with L1/L2 ΔPHOS PsVs (100 and 65%). Almost no PML-colocalization of viral DNA was detected after 
infection with L1/L2 ΔSIM (<1%) and L1/L2 ΔSCM PsVs (13%). 
 
Fig. 3.20: No PML-colocalization of L2 and viral DNA after infection with L1/L2 ΔSIM PsVs. The PML-colocalization of L2 or 
viral DNA per nucleus is given in percent with respect to the colocalization levels detected after infection with wild-type 
PsVs (100% control). Almost no PML-colocalization of L2 or viral DNA was detected after infection with L1/L2 ΔSIM PsVs. 
Infection with L1/L2 ΔSCM PsVs lead to decreased levels of PML-localized viral DNA, but not L2.  
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3.2.6 No destabilization of L2 after infection with L1/L2 ΔSIM PsVs 
To analyze differences in protein stability of viral L2 after infection with mutant L1/L2 ΔSIM PsVs, 
which could be indicative for the differences observed for the localization of L2 ΔSIM, L1 and L2 
stability assays were performed after infection with L1/L2 PsVs. Therefore, the amount of L1 and L2 
was quantified based on immunodetection of L1 and L2 at time points of 1, 8, 24, and 48 h post 
infection (Fig. 3.21, A).  
 
Fig. 3.21: No destabilization of L2 after infection with L1/L2 ΔSIM PsVs. A Comparable L1 amounts were detected after 
infection of HeLa cells with L1/L2 wt and L1/L2 ΔSIM PsVs for the given infection periods (1, 8, 24, and 48 hours, with two 
parallel experiments, each). Slightly less L1 was detected after infection with L1/L2 ΔSCM PsVs. A comparable amount of L2 
was detected after infection with wild-type PsVs and L1/L2 ΔSIM PsVs. For infection with L1/L2 ΔSCM PsVs, L2 detection 
levels were significantly lower (about 20% of the wild-type L2). B The L1/L2 amounts were obtained by densitometrical 
analysis of the L1/L2 Western Blots, normalized according to the β-actin control, and plotted against the infection time. L1 
and L2 half-life times were derived by exponential fitting of the L1/L2 decay curves (with R2 > 0.95 for all fit functions). 
There were no significant differences of the L2 half-life times after infection with L1/L2 wt or L1/L2 ΔSIM PsVs (both about 9 
hours). The small amount of L2, which was detected after infection with L1/L2 ΔSCM PsVs, had a very long half-life time of 
about 13 h. However, assumption of roughly comparable L2 levels at the beginning of infection gave rise to a corrected half-
life time between 3 and 6 hours L2 ΔSCM, which seems to be more realistic due to comparable L1 amounts for infection 
with the different PsVs and normalization of the PsV amounts to gain a balanced L1 and L2 content. Remarkably, after 24 
hours of infection, which also represents the standard infection time, the L2 content was at a comparable level for all PsVs. 
 
The L1/L2 half-life times were determined by exponential fitting of the respective decay curves after 
densitometrical analysis of the L1/L2 bands (Fig. 3.21, B). Equal L1 amounts were detected after 
infection with wild-type and L1/L2 ΔSIM PsVs. A little less L1 was detected after infection with L1/L2 
ΔSCM PsVs. L1 half-life times were almost comparable, but slightly expanded after infection with 
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L1/L2 ΔSIM and L1/L2 ΔSCM PsVs (about 15 h) when compared with wild-type PsVs (about 11 h). In 
contrast, the amounts of detected L2 varied significantly. After infection with wild-type and L1/L2 
ΔSIM PsVs, comparable amounts of L2 were detected, while after infection with L1/L2 ΔSCM PsVs, 
the detectable L2 amount was only about 20% with respect to the wild-type PsVs. L2 half-life times 
were about 9 h for wild-type and L1/L2 ΔSIM PsVs. After infection with L1/L2 ΔSCM PsVs, the residual 
L2 seemed to feature a longer half-life time of about 14 h. However, since the amount of the 
different PsVs used for infection was normalized to guarantee a comparable L1/L2 amount at the 
starting point, a corrected half-life time for L2 ΔSIM was derived with a half-life time of 3-6 h 
implementing a very fast decay of L2 ΔSCM. 
 
3.2.7 Overexpression of wild type L2 does not recover infectivity of L1/L2 ΔSIM PsVs 
In order to check whether overexpression of wild-type L2 could restore infectivity of HPV16 L1/L2 
ΔSIM PsVs, wild-type L2 was overexpressed before infection with L1/L2 wt or L1/L2 ΔSIM PsVs. There 
was no luciferase expression for infection with L1/L2 ΔSIM PsVs after overexpression of wild-type L2 
(Fig. 3.22). Control experiments with transfection of an empty control plasmid before infection with 
wild-type PsVs led to the same luciferase expression as after overexpression of wild-type L2. 
 
 
Fig. 3.22: Overexpression of wild-type L2 does not recover infectivity of L1/L2 ΔSIM PsVs. HeLa cells were transfected with 
wild-type L2 DNA or the same amount of an empty control plasmid. After 24 h, the cells were infected with either L1/L2 wt 
or L1/L2 ΔSIM PsVs for 24 h. Both, in the control experiment and after overexpression of wild-type L2, no luciferase 
expression was observed for infection with L1/L2 ΔSIM PsVs. With respect to wild-type PsVs, the same level of luciferase 
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3.2.8 Overexpression of GFP-SUMO1/2 enhances infectivity of HPV16 PsVs  
To characterize the influence of a modified level of cellular SUMO proteins on HPV infection, 
different amounts of GFP-SUMO1, GFP-SUMO2, or GFP control DNA were transfected into HeLa cells. 
After protein expression for 24 hours, the cells were infected with L1/L2 wt PsVs (Fig. 3.23 A) or L1/L2 
Δ SCM PsVs (Fig. 3.23, B). Interestingly, increasing luciferase expression was observed with increasing 
amounts of transfected GFP-SUMO1 or GFP-SUMO2 DNA for both PsVs types. It is noteworthy that 
especially expression of GFP-SUMO2 seems to increase infectivity of both PsVs types. Additional 
experiments showed that there were no additive effects due to coexpression of GFP-SUMO1 
together with GFP-SUMO2 on infectivity of PsVs. 
 
Fig. 3.23: GFP-SUMO1/2-dependent enhancement of HPV infection. HeLa cells were transfected with different amounts of 
GFP-SUMO1, GFP-SUMO2, or GFP DNA. The total amount of transfected DNA was kept constant by addition of an empty 
control plasmid. After 24 hours of protein expression, the cells were infected with L1/L2 wt (A) or L1/L2 ΔCM PsVs (B) for 24 
hours. Luciferase expression was normalized according to the expression level for the control experiments without 
overexpression of GFP-SUMO1/2. Both, for infection with wild-type PsVs or L1/L2 ΔCM PsVs, a DNA dosis-dependent 
increase of luciferase expression was observed. Especially expression of GFP-SUMO2 led to a 5-7 fold increase of luciferase 
expression. Expression of GFP had no effect on luciferase expression, when compared with control transfections with an 
empty pcDNA 3.1 (+) vector. 
 
3.2.9 SUMO2 siRNA knockdown strongly increases infectivity of HPV16 PsVs 
After checking the effect of overexpression of SUMO proteins on infectivity of HPV16 PsVs, additional 
experiments based on depletion of SUMO proteins were performed. Therefore, endogenous 
SUMO1/2 was depleted by RNA interference after transfection with specific SUMO1/2 siRNAs. First, 
the knockdown of overexpressed GFP-SUMO1/2 was characterized by quantification of the GFP 
fluorescence to ensure functionality of the selected siRNAs (Fig. 3.24, A). 
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Fig. 3.24: Specific knockdown of GFP-SUMO1 or GFP-SUIMO2 by SUMO1/2 siRNAs. HeLa cells were transfected with 
SUMO1, SUMO2, or control siRNA for 24 h followed by transfection of GFP-SUMO1 or GFP-SUMO2 DNA. GFP-SUMO1/2 was 
overexpressed for additional 24 h before the cell lysate was characterized by quantification of the GFP fluorescence in a 
plate reader (A) or by immunodetection of GFP-SUMO1/2 with an anti-GFP (Jl-8) antibody (B). Transfection with SUMO1 
siRNA lead to an almost complete depletion of GFP-SUMO1 while GFP-SUMO2 levels remained comparable to the controls 
with transfection of control siRNA. Transfection with SUMO2 siRNA resulted in a significant depletion of GFP-SUMO2 while 
GFP-SUMO1 levels were at about 60% when compared to transfection of control siRNA. 
An almost total loss of GFP fluorescence was found for overexpression of GFP-SUMO1 after 
transfection of SUMO1 siRNA. Transfection of SUMO2 siRNA had almost no effect on GFP 
fluorescence of overexpressed GFP-SUMO1. Vice versa, an almost total loss of GFP fluorescence of 
GFP-SUMO2 was recorded after transfection with SUMO2 siRNA. Transfection with SUMO2 siRNA 
resulted in an about 40% reduction of GFP fluorescence for GFP-SUMO1. The depletion of the siRNA 
target molecules GFP-SUMO1 and GFP-SUMO2 was also characterized by immunodetection (Fig. 
3.24, B). A significant depletion of overexpressed GFP-SUMO1 was detected after transfection of 
SUMO1 siRNA. Band intensities of GFP-SUMO1 remained almost unaltered for transfection with 
control siRNA and SUMO2 siRNA. As for overexpression of GFP-SUMO2, transfection with SUMO2 
siRNA induced an almost complete loss of GFP-SUMO2 compared to transfections with control siRNA 
and SUMO1. Taken together, the two siRNAs selectively and efficiently depleted expression of the 
respective target proteins GFP-SUMO1 and GFP-SUMO2 after overexpression.  
After the specific siRNA-mediated depletion of overexpressed GFP-SUMO1/2 was confirmed, the 
effect of depletion of endogenous SUMO proteins on infectivity of HPV16 PsVs was characterized 
(Fig. 3.25). Transfection with SUMO1 siRNA resulted in a significant reduction of luciferase expression 
after infection with wild-type and L1/L2 ΔSCM viruses (20 and 30% with respect to the control). 
Remarkably, luciferase expression exceeded the background detection level for infection with L1/L2 
ΔSIM PsVs. Transfection with SUMO2 siRNA led to a strong enhancement of luciferase expression 
(about 600% and 800%) for wild-type and L1/L2 ΔSCM PsVs. However, also lucifease expression upon 
infection with L1/L2 ΔSIM PsVs was significantly increased. 
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Fig. 3.25: SUMO2 depletion increased infectivity of HPV16 PsVs. HeLa or HaCaT cells were transfected with SUMO1, 
SUMO2, or control siRNA followed by infection with L1/L2 wt, L1/L2 ΔSCM, or L1/L2 ΔSIM PsVs for 24 h. Luciferase 
expression levels were corrected according to the LDH and normalized to the expression detected after transfection with 
control siRNA. Note that the 100% control for infection with L1/L2 ΔSIM PsVs (marked with a star) only represents the 
experimental background, since infection with L1/L2 ΔSIM PsVs did not lead to significant luciferase expression. 
Transfection with SUMO1 siRNA significantly reduced luciferase expression after infection with L1/L2 wt or L1/L2 ΔSCM PsV. 
Remarkably, for infection with L1/L2 ΔSIM PsVs, luciferase expression levels for the first time crossed the level of 
background detection. Transfection with SUMO2 siRNA resulted in strongly increased luciferase expression levels for all 
PsVs, including L1/L2 ΔSIM. 
In a control experiment, the possible influence of the siRNA transfection procedure on the following 
expression of a transfected luciferase reporter gene was characterized (Fig. 3.26, A). Luciferase 
expression was at an equal level after transfection of control siRNA and SUMO2 siRNA. As for 
transfection with SUMO1 siRNA, the luciferase intensity was reduced to about 75%. In the positive 
control, transfection of luciferase siRNA successfully reduced luciferase expression to about 30% 
intensity. 
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Fig. 3.26: Effects of siRNA transfection on transcription of the reporter luciferase gene. A HeLa cells were transfected with 
control siRNA, SUMO1 siRNA, SUMO2 siRNA, or luciferase siRNA for 24 h. Then, the cells were transfected with a standard 
luciferase reporter plasmid followed by expression for 24 h and detection of luciferase expression. Transfection with control 
siRNA and SUMO2 siRNA resulted in comparable luciferase expression. SUMO1 siRNA transfection led to slightly decreased 
luciferase expression (75%). Transfection of luciferase siRNA, as a positive control, led to decreased luciferase expression 
levels of about 30%. B HeLa cells were transfected with the luciferase reporter plasmid for 24 h followed by siRNA 
transfection. No changes of the luciferase expression were detected after transfection with SUMO1/2 siRNA when 
compared to transfection with the control siRNA. Transfection of luciferase siRNA in the positive control resulted in a 
luciferase expression of about 30%. 
Additionally, to exclude potential artifacts based on a siRNA influence on transcription of the 
luciferase gene, the experiment was repeated in different order. This time, first, transfection with the 
luciferase reporter DNA was performed for 24 h allowing for a stable transcription and expression 
phase of the luciferase gene. This step was followed by siRNA transfection for 24 h (Fig. 3.26, B). 
Transfection of control siRNA and SUMO1/2 siRNA resulted in comparable luciferase expression 
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3.3 Biophysical interaction studies of HPV16 L2 with SUMO1/2 
The interaction of the HPV16 capsid protein L2 with SUMO1 and SUMO2 was characterized by 
immunoprecipitation, 2-hybrid screening, and fluorescence microscopy as described in the previous 
chapters. To get further information about the interaction with SUMO proteins, additional 
interaction studies were performed using electron paramagnetic resonance (EPR) spectroscopy as 
the main method of this chapter, but also fluorescence correlation spectroscopy (FCS), isothermal 
titration calorimetry (ITC), fluorescence and circular dichroism spectroscopy, and also molecular 
dynamics (MD) simulations. Therefore, adequate amounts of SUMO1/2 and L2 proteins had to be 
produced. 
 
3.3.1 Purification of SUMO1/2 protein by native his tag affinity purification 
Purification of SUMO1 and SUMO2 was performed based on expression of SUMO1/2-his6 fusion 
proteins in E. coli followed by Ni-NTA affinity purification under nondenaturing conditions. 
Quantification of the protein content was performed by Bradford Assaying. Standard protein yields 
were in the range of 1-2 mg SUMO1/2 protein for cell-pellets obtained from a 100 ml culture volume. 
Purified SUMO1/2 was characterized by Coomassie staining and immunodetection (Fig. 3.27).  
 
Fig. 3.27: Affinity purification of highly pure SUMO1/2-his6. SUMO1/2-his6 was overexpressed in E. coli (Rosetta 2 DE3) for 
4 h at 30 °C. Then, the cells were harvested and stored in aliquots at -80 °C. After cell lysis in 20 mM Tris pH 8.0/500 mM 
NaCl/5 mM imidazole, SUMO1/2 his6 was purified in gravity columns with Ni-NTA resin under native conditions. The column 
was washed with the same buffer containing 35 mM imidazole and final protein elution was done with 335 mM imidazole. 
0.1 µg or 8 µg purified SUMO1/2-his6 were characterized by immunodetection with anti-His antibodies or Coomassie 
protein staining. Each one clear band of SUMO1- or SUMO2-his6 was observed without larger detection of background 
proteins. 
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In Coomassie stainings, each one clear protein band was detected for purified SUMO1- or SUMO2-
his6 without detectable contributions of background proteins.  
 
3.3.2 Denaturing purification of HPV16 L2 
3.3.2.1 Full-length and soluble L2 protein after expression in HEK293 cells 
In a first attempt, the expression of HPV16 L2 protein from different protein expression systems was 
analyzed, since early L2 purification experiments did not result in noteworthy L2 amounts. First, 
specialized E. coli expression strains were used to express his10-L2 and GST-L2 fusion proteins 
followed by characterization of the expressed proteins by immunodetection (Fig. 3.28). Despite of 
the well detectable bands for the full length HPV16 L2 proteins, there was a large amount of 
inaccurately expressed or disrupted L2 indicated by a large number of lower molecular weight bands. 
In additional experiments, expression temperature and time was modified to allow for a better 
expression of full-length L2, but did not result in significant improvements.  
 
Fig. 3.28: No adequate expression of L2-his10 or GST-L2 fusion proteins in E. coli. Special E. coli expression strains were 
transformed with L2-his10 or GST-L2 expression vectors. Before induction of protein expression, the cultures were brought 
to an equal cell density. Expression was performed for 2 h at 37 °C. Normalized amounts of the cell suspensions were lysed 
in 2.5 x SDS-PAGE loading buffer and characterized by immunodetection with an anti-L2 (L2-1) antibody including also a non 
induced negative control (first lane for each cell type). 
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L2 was also expressed in Leishmania tarentolae and human HEK293T cells. Pilot experiments showed 
that in both systems significantly more full-length L2 protein was obtained. In order to guarantee 
highest purification performance, first, the solubility of L2 was checked for the different expression 
systems and under different buffer conditions. This was done by ultracentrifugation at 100,000 g and 
characterization of the content of soluble L2 in the supernatant or insoluble L2 in the pellet by 
immunodetection. After expression of L2 in Leishmania tarentolae, cell lysis, and ultracentrifugation, 
the synthesized L2 was in a rather water insoluble state. For none of the native lysis buffers, a 
significant amount of solubilized L2 was detected in the supernatant (Fig. 3.29).  
 
Fig. 3.29: L2 is insoluble after expression in Leishmania tarentolae. L2 expressing cells were resuspended in 1xPBS pH 7.5/ 
500 mM NaCl/ 1mM DTT and the lysate was divided into several aliquots. Before sonification of cells, different detergents 
were added to cell suspension (2% (v/v), LDAO: Lauryldimethylamine-oxide). After incubation for 45 min at 4 °C, the lysates 
were centrifuged for 10 min at 10,000 g. The supernatant was subsequently subjected to ultra centrifugation at 100,000 g 
for 1 h at 4 °C. After centrifugation and resuspension of the pellet, an equal amount of pellet (P) and supernatant (S) was 
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L2 solubility was also checked after L2 expression in HEK293 cells (Fig. 3.29). In the presence of Triton 
X-100, Triton X-114, Dodecylmaltoside, or LDAO, a large amount of soluble L2 was detected (up to 50 
% of the total L2, Fig. 3.30). 
 
Fig. 3.30: High solubility of HPV16 L2 expressed in HEK293 cells. The cells containing HPV16 L2 protein were lysed in 
standard buffer (1xPBS pH 7.5/ 500 mM NaCl/ 1mM DTT) containing different detergents (1 % (v/v)), allowing for L2 
solubilization. After sonification and incubation, the cell lysates were centrifuged at 100,000 x g for 1 h at 4 °C. The same 
amount of supernatant (S) and resuspended pellet solution (P) was characterized by immunodetection. The majority of the 
L2 signal corresponds to insoluble L2, but larger fractions of soluble L2 were detected after incubation with lysis buffers 
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In addition to solubility screening with different detergents, also an influence of the pH on L2 
solubility was checked (Fig. 3.31). There were no significant changes in the ratio of insoluble L2 in the 




Fig. 3.31: No pH-dependence of L2 solubility. The L2 solubilization assay was performed with a standard lysis buffer 
containing 50 mM Tris HCl/350 mM NaCl/ 2% (v/v) Triton X-100/ 1 mM DTT in the pH range of pH 4.5-10. After 
ultracentrifugation at for 1 h at 100,000 g and 4 °C, comparable amounts of the supernatant and the resuspended pellet 
were characterized by immunodetection. 
 
Even higher amounts of soluble L2 were achieved by using LMPG (lysomyristoylphosphatidylglycerol) 
as detergent. Additionally, it was checked whether the L2 solubility depends on the position of the 
polyhistidine affinity tag. Therefore, the solubilization assay was repeated with different composition 
of the lysis buffers. The, L2 solublility was analyzed densitometrically after immunodetection of L2 
(Fig. 3.32). The highest L2 solubilization (50%) was achieved with Tris or phosphate buffers containing 
2% (v/v) LMPG. In contrast, buffers containing Triton X-100 led to solubilization levels of 20-30%. In 
general, L2 fusion proteins containing a C-terminal polyhistidine tag featured slightly increased 
solubility. Taking into account the comparable accessibility of the tags for his antibodies (data not 
shown) and the fact that with the use of a C-terminal L2 his fusion protein, only full length L2 is 
purified in theory, only L2 his6 was used for further experiments. 
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Fig. 3.32: High L2 solubilization with 2% (v/v) Triton X-100 or LMPG. L2 wt, his10-L2, or L2-his6 was expressed in HEK293 
cells. L2 was solubilized either in phosphate buffer pH 7.5 (300 mM NaCl) or Tris buffer pH 8.0 (300 mM NaCl) containing 2% 
(v/v) Triton-X100 or LMPG. After incubation for 45 min at 4 °C, the lysate was centrifuged for 10 min at 13,000 g followed by 
ultracentrifugation of the supernatant for 1 h at 4 °C and 100,000 g. Equal amounts of supernatant and resuspended pellet 
were characterized by immunodetection (A) and densitometry (B). In general, higher total amounts of L2 and especially 
solubilized L2 in the UZ supernatant were found for cell lysis in LMPG containing buffers or for Tris buffers containing Triton 
X-100. The location of the polyhistidine affinity tag did not significantly affect L2 solubilization.  
 
After optimization of L2 solubilization, purification under non-denaturing conditions was performed, 
but did not lead to adequate amounts of purified L2. Most obviously, the reasons for low-yield L2 
purification were low affinity binding of L2 to the Ni-NTA affinity matrix and a yet too small fraction 
of soluble L2. Also adjustment of the imidazole concentration during purification or the use of 
alternative purification tags (e.g. Strep-Tag) did not improve purification results. Further non-
denaturing purification attempts including expression of a maltose binding protein (MBP) fusion 
protein with L2 in E. coli or L2-his6 expression and purification from inclusion bodies in E. coli resulted 
in expression and/or purification of highly fragmented L2, which was not suitable for further 
characterization. 
 
3.3.2.2 High yield L2 purification under denaturing conditions  
All attempts to produce highly pure L2 protein by non-denaturing purification did not result in 
adequate L2 amounts for biophysical characterization. The main problems were low solubility, no or 
very low selective binding of L2 to the His bead matrix (Ni-NTA resin), and fragmentation of L2 during 
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the purification process or the protein expression itself. However, in this work, a method for medium 
scale purification of HPV16 L2 based on his-tag affinity purification under denaturing conditions was 
established, offering adequate and highly pure L2 amounts for biophysical characterization of HPV16 
L2 (100-400 µg L2 per 15 cm plate overexpressing HEK293 cells). Therefore, the L2 pellet was first 
resuspended in lysis buffer containing Triton X-100 to solubilize the maximum amount of cellular 
background proteins. The lysate was subjected to ultracentrifugation to collect the large fraction of 
insoluble L2 in the pellet, which was then denatured in guanidine buffer and purified based on Ni-
NTA affinity purification. Purification of L2 fusion proteins with N- or C-terminal his tag led to well 
detectable L2 bands at about 80 kDa (Fig. 3.33, lanes 4-6).  
 
Fig. 3.33: Purification of HPV16 L2 under denaturing conditions. L2 was expressed in HEK293 or L. tarentolae. The L2 
lysates were prepared in 50 mM Tris pH 8.0 350 mM NaCl, 1 mM DTT, 1% (v/v) Triton X-100. After sonication and 
incubation for 45 min at 4 °C, the lysate was centrifuged for 1 h at 100,000 g and 4 °C. The supernatant containing the 
soluble fraction of L2 and all soluble background protein was discarded. The pellet was resuspended in 6 M Guanidine HCl 
with one freeze-thaw cycle and sonication. The solution was incubated with Ni-NTA-beads for 30 min at RT in a gravity 
column. After washing and elution, the L2 protein was characterized by protein staining with Direct Red 81 and 
immunodetection (anti-L2, L2-1). Adequate amounts of purified L2-his6 or his10-L2 without larger contributions of 
background proteins were detected after L2 expression in HEK293 (lanes 1-2 and 4-5). For purification of L2 expressed in L. 
tarentolae, only a faint L2 band on an intense background of cellular proteins was detected after protein staining (lane 3). 
L2 refolding by ethanol precipitation resulted in well-detectable L2 bands after immunodetection for L2 purified from 
HEK293 (lanes 7-8, no detection of L2 purified from L. tarentolae after refolding). 
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For L2 purified from HEK293 cells, in Direct Red 81 stainings, only the major L2 bands were 
detectable with only very small contributions of background proteins (lanes 1 and 2). As for the 
purification of L2-his6 from L. tarentolae, the major L2 band was hardly visible (lane 3) and there was 
a large level of background protein detection.  
 
3.3.2.3 Characterization of affinity purified HPV16 L2 protein  
After successful purification of HPV16 L2 from HEK293 cells by his affinity purification under 
denaturing conditions, L2 refolding was performed by dialysis in non-denaturing buffer or by ethanol 
precipitation of L2 followed by resolubilization of the L2 pellet in non-denaturing buffer. 
Subsequently, L2 refolding was characterized by immunodetection (Fig. 3.33, lanes 7-9). This led to 
well-detectable, non-fragmented bands for L2 purified from HEK293 cells (lanes 7-8), which were 
comparable to the samples with direct application of L2 in 6 M Guanidine HCl (lanes 4-6). Further L2 
characterization was performed by optical photometry, fluorescence spectroscopy, circular dichroism 
(CD) spectroscopy, and dynamic light scattering (DLS).  
A small but significant fraction of L2 seems to aggregate into larger particles during L2 refolding, 
which was visible in the large content of scattered light at higher wavelengths in UV/Vis spectroscopy 
(Fig. 3.34, A, see dashed marker line). Additional hints for L2 aggregation came from DLS 
measurements. Samples containing refolded L2 had a particle diameter of about 5-6 nm with a very 
high polydispersity index (PDI) of about 0.9, signaling the detection of particles of very different sizes. 
After centrifugation of the L2 sample and characterization of the supernatant, the mean diameter 
was significantly decreased (4 nm). Additionally, there was a higher uniformity for the particles 
within the sample, which was represented by a decreased PDI of about 0.3. 
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Fig. 3.34: L2 aggregation during refolding. A After ethanol precipitation, the L2 pellet was resuspended in Tris buffer and 
characterized by UV/vis spectroscopy. A significant contribution of scattered light at higher wavelengths indicated detection 
of aggregated structures within the sample (see spectral region under the dashed line). Interestingly, the maximum of light 
absorption was shifted toward the absorption maximum of phenylalanine (~275 nm, see arrow). B Dynamic light scattering 
with refolded L2 revealed an apparent L2 particle diameter between 5 and 6 nm. After centrifugation of the sample (20 
min, 22,000 g, 4 °C) and characterization of the supernatant, a decreased mean particle diameter of about 4 nm was 
detected (marked with a star). C The polydispersity index (PDI) was very high for non-centrifuged L2, signaling the detection 
of a very broad distribution of particle diameters. After centrifugation, the PDI was significantly reduced, indicating a larger 
uniformity of detected particles (marked with a star). 
Since there was no information about the level of background proteins, despite estimations based on 
desitometry performed with Coomassie stained SDS gels, the background level of proteins was 
additionally determined in a different way. Therefore, fluorescence spectroscopy was used. The L2 
protein sequence comprises 22 tyrosines and 15 phenylalanines but no tryptophans. Thus, low 
trypthophan fluorescence (350 nm) together with high tyrosine (303 nm) and phenylalanine (282 
nm) fluorescence intensities would indicate a low level of background proteins for highly pure L2 
samples. In fact, for his10-L2, and especially, L2-his6 purified from HEK293 cells, the tryptophan 
contribution was significantly reduced (Fig. 3.35). The maximum fluorescence intensity clearly shifted 
towards the fluorescence maxima of tyrosines and phenylalanines, indicating a very low content of 
background protein for purification of L2 from HEK293 cells (marked with a star). For samples 
containing L2-his6 stemming from L. tarentolae, the fluorescence maximum was clearly located at 
about 340-350 nm. Here, the fluorescence spectrum almost entirely consists of the tryptophan 
fluorescence of background proteins.  
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Fig. 3.35: Low level of background tryptophan fluorescence in purified and refolded L2 samples. The fluorescence 
intensity of tryptophans from background proteins at about 345 nm was significantly reduced for L2 expressed in HEK293 
cells. Only the fluorescence maximum of the 22 tyrosines within the L2 proteins sequence was detected at about 305 nm 
(marked with a star) indicating a high purity of L2. 
 
Additionally, CD spectra of the refolded L2 samples were recorded to obtain information about the 
content of secondary structure elements. The CD spectrum of the purest L2-his6 preparation from 
HEK293 cells contained fractions of all secondary structure elements (Fig. 3.36). It was found that the 
spectrum contained about 55% random coil elements, 25% alpha helical elements, and 20% β-sheet 
elements. This fingerprint could serve as basis for interaction studies with SUMO proteins via the L2 
SIM. The non covalent interaction with formation of induced β-sheet elements could lead to 
measurable changes within the CD spectrum. 
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Fig. 3.36: CD spectrum of HPV16 L2. Simulation of the experimental CD data obtained for HPV16 L2 (black line) with model 
CD spectra based on with home-written MATLAB® software revealed a contribution of about 55 % random coil elements, 25 
% alpha helical elements, and 20 % β-sheet elements.  
 
3.3.3 Noncovalent interaction of HPV16 L2 and SUMO1/2 characterized by EPR 
CW EPR measurements were performed to study the in vitro interaction of purified L2 with purified 
SUMO1 or SUMO2. For these experiments, only one of the interaction partners contains a spin label. 
The smaller SUMO protein was selected for site-directed spin labeling (SDSL), since potential 
interaction with the larger L2 molecule would result in a well detectable slow down of SUMO1/2 
diffusion due to formation of larger SUMO-L2 complexes. Additionally, L2 interaction with SUMO 
should result in the detection of significant changes within the local vicinity of the EPR label attached 
to SUMO proteins. In order to measure distances between SUMO and L2 by DEER measurements, 
SDSL has to be performed for both interaction partners. Therefore, labeling experiments with both, 
































  Results 
  124 
3.3.3.1 Highly efficient spin labeling of purified SUMO1/2 
Site-directed spin labeling of the cysteine residue C52 (SUMO1) and C48 (SUMO2) was performed 
including reduction of the sulfhydryl groups with triscyanoethylphosphin (TCEP) and labeling with 3-
(2-iodoacetamido)-PROXYL (PROXYL-IAA). Excess spin label was removed by buffer exchange with 
PD-10 columns or centricons. The protein containing fractions were pooled, concentrated in spin-
concentrators (MWCO 5,000) and characterized by CW EPR measurements (Fig. 3.37).  
 
 
Fig. 3.37: Highly efficient spin-labeling of SUMO1/2. CW EPR spectra of the EPR samples after site-directed spin-labeling of 
SUMO1/2 were extremely broadened with respect to the control sample with Proxyl IAA. The separation between the 
resolved outer hyperfine extrema of the spectra (2Apar) was about 52.7 G for SL-SUMO1 and about 52.8 G for SL-SUMO2. 
Simulation of the experimental SL-SUMO1 and SL-SUMO2 CW EPR spectra (dashed magenta lines) revealed a content of 
about 3-5% free spin label within the EPR samples. 
 
The CW EPR spectra obtained after site-directed spin-labeling of SUMO1/2 featured an extremely 
broadened line-shape indicating successful labeling of the SUMO1/2 molecules and immobilization of 
the spin labels. The separation between the well-resolved outer hyperfine extrema of the spectra 
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(2Apar) was about 52.7 G for SL-SUMO1 and about 52.8 G for SL-SUMO2. Simulation of the recorded 
EPR spectra revealed a content of free spin label of only about 3-5 % and labeling efficiencies of 
about > 95% for SUMO1 and SUMO2, as well as rotation correlation times of about 11 ns (compared 
with 1 ns for the Proxyl IAA reference). Especially the shape and location of the low field line, which is 
most sensitive for immobilization effects of the label molecule, show the typical pattern of a label 
which is located close to or within an surface helix (Mchaourab 1996; Isas 2002). In fact, the labeling 
positions C52 (SUMO1) and C48 (SUMO2) are both located within a surface helical region (aa 45-55 
for SUMO1, aa 41-51 for SUMO2). 
 
3.3.3.2 SL-SUMO2 seems to self-arrange into SUMO oligomers 
After purification and spin labeling, the SUMO1/2 proteins were again characterized by SDS-PAGE 
and immunodetection to detect possible degradation of SL-SUMO1/2, as well as potential 
oligomerization of SL-SUMO1/2 due to intermolecular disulfide bridging (Fig. 3.38). Especially for 
SDP-PAGE sample preparations of spin-labeled (SL-) SUMO1/2 without addition of reducing agents, 
an increased level of high molecular SUMO2 bands was observed. The number and intensity of the 
high molecular bands was slightly diminished by addition of DTT or TCEP, but only boiling of the SL-
SUMO1/2 samples at 95 °C with addition of β-mercaptoethanol lead to an almost complete reduction 
of high molecular SUMO2 bands. In general, for purified SUMO2 (without SDSL), only the prominent 
band at about 36 kDa was detectable. SL-SUMO1 was not characterized by additional reduction 
assays so far, but standard sample preparation in 2.5 x SDS-PAGE loading buffer did not lead to 
significant detection of high molecular weight bands in immunodetections. 
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Fig. 3.38: High molecular (SL-) SUMO2 aggregates. A Incubation at 65 °C for 6 min resulted in the detection of the main SL-
SUMO2 bands at about 18 kDa, but also in an additional band at about 36 kDa for labeled and nonlabeled SUMO2. These 
bands most obviously represented (SL-) SUMO2 dimers (see black arrowhead). Only for SL-SUMO2, an increased amount of 
additional bands appeared at even higher molecular weights. The most prominent band of the additional, high molecular 
bands was located at about 60 kDa and could represent SL-SUMO2 trimers (open arrow). To test stability of the oligomers 
in the presence of different reduction agents, the samples were also prepared with 1 mM TCEP (B), 1 mM DTT (C), and 10% 
(v/v) β-mercaptoethanol (D). The intensity of the bands at higher molecular weight decreased, especially for sample 
treatment with β-mercaptoethanol and incubation at 95 °C. Here, only very faint bands at 36, 55, and 75 kDa were 
detected. The band at about 60 kDa vanished completely. For sample preparation with TCEP or DTT and incubation at 65 °C, 
the pattern of higher molecular bands was comparable to that without reduction agents, but was less intense.  
 
3.3.3.3 HPV16 L2 interacts with SL-SUMO1/2 
Interaction studies with HPV16 L2 and SUMO1/2 were performed based on spin labeled SUMO1/2 
(SL-SUMO1/2) and the full length L2 protein at different molecular ratios in the range of about 1:1 to 
1:4 (L2:SUMO1/2). The samples were prepared by dissolving the appropriate amount of lyophilized 
or ethanol precipitated L2 in SL-SUMO1/2 solution and incubation for 45 min at RT. Then, CW EPR 
measurements were performed to detect a possible spectral broadening and slow down due to the 
L2 attachment to the labeled SUMO1 or SUMO2 molecules. In fact, a clear L2-dose dependent 
spectral broadening due to a shift of the outer hyperfine extrema was observed after incubation of 
SL-SUMO1 with L2 (Fig. 3.39).  
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Fig. 3.39: L2 interacts with SL-SUMO1. CW EPR measurements were performed at 5 °C after incubation of SL-SUMO1 with 
different amounts of L2. L2 addition lead to the detection of an additional paramagnetic species featuring a significantly 
increased separation 2Apar between the outer hyperfine extrema (60.14 G compared with 52.72 G for SL-SUMO1, alone).  
 
Detailed spectra analysis showed that addition of L2 lead to detection of a second species of spin 
labels with significantly enlarged separation between the outer hyperfine extrema with values about 
60.14 G, a shift of 7.42 G with respect to the samples without L2 (52.72 G). The spectral shape clearly 
changed from that of a typical surface-helix bound label to that of a label bound to a helix at a 
protein interaction interface (Mchaourab, 1999; Isas, 2002). The L2 dose-dependent slow down of 
the spectrum clearly indicated an interaction of HVP16 L2 with SUMO1/2. The same trend was found 
for the measurements of SL-SUMO2 with increasing amounts of L2 (Fig. 3.40).  
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Fig. 3.40: L2 interacts with SL-SUMO2. CW EPR measurements were performed at 5 °C after incubation of SL-SUMO2 with 
different amounts of L2. Like it was shown for SL-SUMO1, also L2 addition to SL-SUMO2 led to the detection of an 
additional paramagnetic species. Interestingly, the separation 2Apar between the outer hyperfine extrema was even more 
pronounced (61.7 G compared with 52.83 G for SL-SUMO2, alone).  
 
This time, the observed second EPR species featured 2Apar values of about 61.7 G, which were 
significantly larger than 2Apar values of about 52.83 G for SL-SUMO2 alone (Δ2Apar ≈ 8.87 G).  
With respect to the mobility of the spin label, a plot of the inverse of the second moment (<H2>-1) vs. 
the inverse of the central linewidth (ΔH0
-1) gives a good empirical indication for the localization of the 
label within the secondary structure elements (Mchaourab 1996; Isas 2002). The inverse of the 
central linewidth (ΔH0
-1) is a direct measure of the mobility of the nitroxide side chains and therefore 
also a measure of the mobility of the local labeling position. The inverse of the second moment 
(<H2>-1) also represents a measure for the mobility of the spin label, but with slightly more weight on 
immobile spectral components emphasizing contributions from the outer hyperfine extrema of the 
spectra. Utilizing both measures in a plot, it can be checked whether the label is positioned within 
buried, contact, or surface regions of the secondary structure elements. For assignment of the 
  Results 
  129 
labeling position of SL-SUMO1/2 in measurements together with L2, the inverse of the central 
linewidth was directly read from the spectra, while the inverse of the second moment was acquired 
by simulation of the spectra with home-written MATLAB® software. For measurements with SL-
SUMO1/2 without L2, the data points were positioned directly within the region of standard spin 
labels attached at positions within helical surface structures of example proteins (Fig. 3.41). With 
increasing amounts of L2 within the sample, especially the inverse of the central linewidth was 
significantly smaller, so that the labels seemed to be positioned at a more immobile helical contact 
region. 
 
Fig. 3.41: L2 addition induces a contact helical surrounding for the spin labels attached to SL-SUMO1/2. The inverse of the 
second moment (<H2>-1) was plotted against the inverse of the central linewidth (ΔH0
-1), allowing for a structural 
characterization of the region where the spin label is attached, based on empirical CW EPR data. The data points acquired 
for CW EPR spectra of SL-SUMO1/2 alone or with small amounts of L2 were located directly within a plot area, which is 
characteristic for a helix surface attachment of the spin label. For measurements with larger amounts of L2, the data points 
were positioned within the plot region characteristic for contact helical attachment of spin labels. 
It was also tested whether the L2 single cysteine mutants were able to interact with SUMO1/2. This 
was of special interest, since for several physiologic L2 features, a formation of a disulfide bridge 
between the SH group C22 and the SH group at position C28 of the L2 amino acid sequence was 
reported to be necessary (Campos and Ozbun 2009; Conway 2009; Gambhira 2009). Both L2 C22S 
and L2 C28S were able to interact with SL-SUMO1 or SL-SUMO2 (Fig. 3.42). A significant loss of 
mobility was represented by large 2Apar values (53-59 G), which were comparable to the spectra of 
wild-type L2 with SL-SUMO1/2. The observed, marginal differences between the spectra stem from 
inaccuracies of protein quantification and normalization for these measurements. 
SL-SUMO1 + L2 
SL-SUMO2 + L2 
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Fig 3.42: L2 cysteine mutants are able to interact with SL-SUMO1/2. CW EPR measurements were performed with wild-
type L2, L2 C22S, and L2 C28S after incubation with SL-SUMO1 (A) or SL-SUMO2 (B) at about equimolar protein ratios. In all 
measurements, significantly enlarged separations 2Apar between the outer hyperfine extremas were observed, indicating 
protein interaction. The splitting was even more pronounced in samples containing L2 C22S or L2 C28S when compared 
with wild-type L2, which was most obviously due to a slightly higher L2 protein concentration. 
 
3.3.3.4 The interaction of L2 with SL-SUMO1/2 is diminished by L2 antibodies 
Furthermore, it was analyzed, whether the addition of a highly selective anti-L2 antibody could lead 
to even more immobilized spectra due to the binding of the larger L2-antibody complex by SL-
SUMO1/2, or whether the antibody competes with the SL-SUMO1/2 proteins for L2 interaction. No 
further immobilization of the spin label was observed. In contrast, there was an increase of mobility 
of the spin label represented by smaller 2Apar values, which reached values detected for the SL-
SUMO1/2 samples without L2 (Fig 3.43). This clearly is a sign that the interaction of L2 with SL-
SUMO1/2 was canceled or at least strongly diminished by the competing L2 antibody.  
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Fig. 3.43: L2-antibody-induced dissociation of L2 and SL-SUMO1/2. EPR samples containing equimolar amounts of L2 and 
SL-SUMO1 (A) or SL-SUMO2 (B) were incubated with a highly specific L2 antibody (L2-1). The CW EPR spectra obtained after 
L2 antibody addition featured significantly decreased 2Apat values (52.8 - 54.5 G) when compared with 2Apat values from 
spectra taken before antibody addition (56.9 – 60 G). In general, the spectra obtained after L2 antibody addition were 
comparable with spectra containing only SL-SUMO1/2, indicating an almost complete inhibition of L2 interaction with 
SUMO1/2. 
 
3.3.3.5 The L2 labeling positions C22 and C28 are inaccessible for spin labeling 
In order to gain more information about L2-SUMO1/2 interaction and to measure DEER distances 
between the interaction partners, in addition to SDSL of SUMO1/2, also HPV16 L2 was subjected to 
SDSL. Here, wild-type L2, as well as the L2 point mutants L2 C22S and L2 C28S, were used. All labeling 
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experiments were based on L2 which was His-affinity purified under denaturing conditions in 6 M 
guanidine HCl. Since first pilot labeling experiments based on the standard protocol, which was also 
used for labeling of SUMO1/2, did not lead to successful L2 labeling, a series of test labeling reactions 
was performed (Fig. 3.44). Here, the most important labeling parameters were modified, e.g. the 
labeling conditions (denaturing vs. non-denaturing), reduction, and final removal of excess spin label, 
as well as washing steps and sample concentration. Most possible combinations were tested with all 
available L2 types (wild-type, L2 C22S, L2 C28S). Additionally, labeling was performed in 4 M NaCl 
buffer to minimize potential electrostatic shielding of L2 structure elements, or in the presence of 
SUMO1/2. Taken together, none of the experiments resulted in correct labeling of L2 protein. The 
“best” labeling reaction resulted in a sample which eventually contained a labeled L2 fraction of 
about 5%. Spectral acquisition could also be complicated by extremely broad spectra due to strong 
immobilization of the label and potential spin-spin interaction for SL-L2 wt, which would theoretically 
contain two spin labels at a <2 nm distance (at L2 position C22 and C28).  
 
Fig. 3.44: Different protocols for L2 spin labeling. For efficient labeling of L2, a large set of protocols was tested including 
modification of the most important experimental parameters like refolding of L2 before labeling, L2 reduction, the general 
labeling conditions (denaturing or non-denaturing), as well as final washing and protein concentration steps. Finally, CW 
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3.3.4 No interaction of HPV16 L2 SIM peptides with SUMO1/2 in EPR 
Since labeling of purified, full length HPV16 L2 was not successful, L2 peptides containing the HPV16 
L2 SIM region were synthesized and used as a target for spin labeling. Labeling of the L2 SIM peptide 
would allow for interaction screening with nonlabeled SUMO1/2 in CW EPR measurements and 
additionally allow detection of DEER distances between the spin labels attached to the L2 SIM 
peptides and the labels attached to SUMO1 or SUMO2 if there is an interaction between the L2 SIM 
peptide with SUMO1 or SUMO2. Synthesis of two types of L2 peptides with different labeling 
position (L2 CysSIM and L2 SIMCys) theoretically allowed for discrimination of the orientation of the 
L2 SIM attachment to SUMO1 or SUMO2. Each peptide contained a single cysteine residue in a 
peripheral region, leaving the hydrophobic core of the SIM untouched (Fig. 3.45).  
 
 
Fig. 3.45: Possible orientation discrimination of the L2 SIM peptide attachment on SUMO1/2. Two types of L2 peptides 
containing the SIM region at position 284-289 were synthesized (Genscript). The CysSIM peptide (amino acid sequence: 
ICPDPDFLDIVALHRPALTSRRT, 23 amino acids) contains a cysteine, which is located near the N-terminus of the peptide. In 
contrast, the SIMCys peptide (amino acid sequence: APDPDFLDIVALHRPACTSRRT, 22 amino acids) comprises the cysteine 
near its C-terminus. Detection of different sets of DEER distances between spin labels attached to the L2 SIM peptides and 
the labels attached to SUMO1/2 allow for discrimination of parallel attachment (A) and (B), or anti-parallel attachment of 
the L2 SIM peptides with respect to the orientation of the neighbored beta sheet of the SUMO1/2 target (C). 
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Labeling of the L2 SIM peptides was performed based on reduction with TCEP and labeling with 
ProxyIAA. Before DEER measurements were performed, first, it was checked whether spin-labeled L2 
SIM peptides would interact with nonlabeled SUMO1/2 in CW EPR measurements (Fig. 3.46). 
 
Fig. 3.46: No immobilization of spin-labeled L2 CysSIM peptides after SUMO2 addition. CW EPR measurements were 
performed at 5 °C. Spin-labeled CysSIM samples featured significantly immobilized spectra (rotational correlation times 
tc~1.4 ns) when compared with control spectra with Proxyl-IAA (tc~1 ps). Interestingly, after addition of increasing amounts 
of SUMO2, no effects of further immobilization caused by a potential interaction of the CysSIM peptide with SUMO2 were 
observed. In contrast, addition of increasing amounts of SUMO2 lead to a less broadened spectral line shape.  
The spectra obtained for SL-CysSIM and SL-SIMCys samples without SUMO showed a significant 
reduction of mobility of the spin label as it was supposed after attachment of the spin labels to the L2 
CysSIM peptide containing 23 amino acids. For g values of [2.0080 2.0049 2.0029] and A values (in 
Gauss) of [2.07 5.67 40.14], rotational correlation times of about 1.4 ns were calculated by simulation 
of the spectra (~1 ps for the Proxyl IAA reference). In a concentration row, the labeled L2 SL-CysSIM 
peptides were incubated with different amounts of nonlabeled SUMO2. An interaction of the short 
peptides with the larger SUMO1 or SUMO2 should result in significant changes of the spin label 
mobility. This was not observed here. Instead, the spectra obtained for SL-CysSIM after SUMO2 
addition were almost identical to the reference spectra without SUMO2. The experiments were also 
performed with addition of SUMO1 and L2 SIMCys peptides (Fig. 3.47). There was no immobilization 
of the spin label due to addition of SUMO1/2 in any of the experiments when compared with the 
reference spectra without SUMO1/2 (dashed lines). 
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Fig. 3.47: SUMO1/2 addition does not induce immobilization of spin-labeled L2 SIM peptides. Spin-labeled SL-CysSIM or 
SL-SIMCys peptides were incubated with a fivefold excess of nonlabeled SUMO1 or SUMO2 and characterized by CW EPR 
measurements at 5 °C. Addition of SUMO1/2 lead to a less broadened line shape of the spectra when compared with 
control spectra without addition of SUMO1 or SUMO2 (dashed lines). 
 
Interaction of SL-SUMO1/2 with L2 SL-CysSIM or SL-SIMCys peptides was additionally characterized 
by ESE-detected pulse EPR measurements and DEER. For ESE-detected EPR spectra, no significant 
differences between spectra containing only SL-SUMO1/2 and those containing SL-SUMO1/2 
together with labeled L2 peptides were observed (Fig. 3.48). There was only a slight narrowing of the 
spectra detected for the labeled L2 CysSIM and SIMCys peptides without addition of SL-SUMO1/2 
(marked with arrows). 
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Fig. 3.48: ESE EPR experiments show no spectra changes upon incubation of spin-labeled L2 SIM peptides with SL-
SUMO1/2. Spin-labeled CysSIM or SIMCys L2 peptides were characterized by ESE EPR measurements at 50 K with or 
without incubation with equimolar amounts of SL-SUMO1 or SL-SUMO2. Spectra with CysSIM or SIMCys alone were 
comparable with reference spectra containing Proxyl IAA and slightly narrowed when compared with spectra taken from SL-
SUMO1/2 samples (see black arrows). There were no significant differences between SL-SUMO1 and SL-SUMO2 spectra. 
Also spectra of SL-CysSIM or SL-SIMCys samples were almost identical. 
 
Samples were further subjected to more selective DEER measurements to check whether small 
fractions of L2 peptides and SUMO molecules interact with each other, leading to detection of DEER 
distances (Fig. 3.49). 
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Fig. 3.49: No detection of DEER distances upon incubation of spin-labeled L2 SIM peptides with SL-SUMO1/2. DEER 
measurements were performed at 50 K with a d2 time of 1.5 µs. A The original DEER time traces were plotted together with 
the respective background functions (dashed lines, homogeneous 3D background, background fitting from 0.5-1.5 µs). B 
After background correction, only one very broad and slight modulation with very small modulation amplitude was 
detected for samples containing SL-SUMO1 and especially SL-SUMO2 (modulation amplitudes 0.05 ± 0.02 and 0.08 ± 0.02). 
Samples including L2 SIM peptides together with SL-SUMO1/2 did not feature enhanced modulation depths or additional 
modulations upon interaction of the L2 peptides with SUMO protein. Remarkably, incubation of SL-SUMO2 with a threefold 
molar excess on nonlabeled L2 did result in a significant increase of modulation depth (0.27 ± 0.05) when compared with 
SL-SUMO2 alone (0.08 ± 0.02, see double arrow). 
 
There were no dominant modulations in any of the original DEER time traces. The time traces 
obtained for SL-CysSIM or SL-SIMCys followed the experimental background (dashed lines) with only 
very small deviations. Analysis of the time traces obtained for SL-SUMO1 and especially SL-SUMO2 
revealed one very broad modulation with very small modulation depth, which could be attributed to 
a very broad distribution of distances around 3.5 nm. Times traces obtained for samples containing 
spin-labeled L2 SIM peptides (SL-CysSIM, SL-SIMCys) together with SL-SUMO1 or SL-SUMO2 decayed 
slightly faster, but the modulation depths were comparable to the modulation depths of SL-
SUMO1/2 samples without L2 SIM petides, indicating that L2 SIM addition did not result in an 
increase of detectable DEER distances between the L2 peptides and SUMO molecules. Most 
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interestingly, addition of a threefold molar excess of full-lenghth, nonlabeled L2 to SL-SUMO2 
resulted in significantly increased modulation depths (0.27 ± 0.05 vs. 0.08 ± 0.02 for SL-SUMO2, 
alone). 
 
3.3.5 Interaction of HPV16 L2 SIM peptides with SUMO1/2 in FCS 
The potential interaction of the HPV16 L2 SIM peptide and SUMO1/2 was additionally characterized 
by Fluorescence Correlation Spectroscopy (FCS). In this method, the size of the smaller interaction 
partner (here the L2 SIM peptide) was determined by measurement of the diffusion rate of a 
fluorophor, which was coupled to the peptide before. Measurements were also performed with the 
addition of the interaction partner SUMO1 or SUMO2 to the L2 SIM. Lower diffusion rates would 
thereby indicate a larger size or hydrodynamic radius of the molecule with the attached fluorophor. 
This would be a direct hint for interaction of the L2 SIM peptide with SUMO1/2. First, the labeling of 
the peptides was performed and characterized. For FCS measurements, the HPV16 L2 SIM peptide 
SIMCys was reduced with TCEP and incubated with the BODIPY®507/545 IA fluorophor. The labeling 
efficiency was tested photometrically by detection of free sulfhydryl groups with Ellmann’s reagent 
(5,5'-dithiobis-(2-nitrobenzoic acid) or DTNB). Absorption was only detected for the samples 
containing reduced CysSIM without addition of BODIPY®507/545 IA (A412nm = 0.25), while for samples 
which were incubated with the fluorophor, no significant absorption was measured. Therefore, it can 
be concluded that almost all SH groups were labeled with BODIPY®507/545. For FCS measurements, 
the fluorescence labeled L2 CysSIM peptides were mixed with a 3-5 fold excess of SUMO1/2.  
The autocorrelation curves for L2 CysSIM peptides together with SUMO1 (shown in red, Fig. 3.50, A) 
or SUMO2 (shown in red, Fig. 3.50, B) showed a significant shift towards higher diffusion times 
compared to the measurements with L2 CysSIM peptides (shown in black).  
Multicomponent fitting of the experimentally detected autocorrelation curves was used for 
determination of the diffusion coefficients and hydrodynamic radii of the observed fluorescence 
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Fig. 3.50: SUMO1/2-induced shift of the autocorrelation curves obtained for FCS measurements with fluorescence 
labeled L2 CysSIM peptides. FCS measurements were performed at RT with BODIPY®507/545 labelded L2 CysSIM peptides 
with or without incubation with a 3-5 fold excess of SUMO1 (A) or SUMO2 (B). After addition of SUMO1 or SUMO2, a 
significant shift of the autocorrelation curves towards higher correlation times was observed (red lines/data points). 
 
Tab. 3.2: FCS parameters for measurements with fluorescence labeled L2 CysSIM peptides with SUMO1 or SUMO2. 
 τD /ns Rh /nm % high molecular weight 
CysSIM  20 0.56  
CysSIM + SUMO1  104 1.9 50% 
CysSIM + SUMO2  100 1.9 25% 
 
Compared with diffusion times of the free L2 SIM molecules (20 ns), addition of SUMO1 or SUMO2 
resulted in significantly slower diffusion rates (~100 ns). Also a remarkable increase of the 
hydrodynamic radius was observed after addition of SUMO1/2 (0.56 nm for CysSIM controls vs. 1.9 
nm after SUMO1/2 addition). Further analysis showed that a fraction of about 50% of the 
fluorophors was bound in higher molecular complexes after addition of SUMO1, while the fraction 
was about 25% after addition of SUMO2. 
 
3.3.6 No interaction of L2 with SUMO1/2 in isothermal titration calorimetry 
In order to confirm the presented results for L2 interaction with SUMO1/2 and to determine binding 
affinities, isothermal titration calorimetry was performed (Fig. 3.51). 
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Fig. 3.51: Isothermal titration calorimetry (ITC) data for the interaction of full-length L2 with SUMO2 (blue) or L2 SIM 
peptides with SUMO1 (black). The top panel shows the ITC thermogram. The bottom panel shows the integrated heat of 
each injection after correction for the heat of dilution. Assuming binding at a molar 1:1 ration, the binding constant was 
about 1 KCa/mol for SUMO2 injection to L2, and about 0.5 KCa/mol for injection of SUMO1 to the L2 SIM peptide, which 
was comparable with the dilution heat upon injection of buffer solution in the control experiment (red). 
For titration of SUMO2 into a sample solution containing full-length L2, a binding constant of about 1 
kCa/mol was determined. For SUMO1 injection into a sample solution containing L2 SIM peptide, a 
binding constant of about 0.6 KCa/mol was obtained, which was comparable with background 
dilution artifacts (see red data points). 
 
3.3.7 The L2 SIM peptide attaches to SUMO1 and SUMO2 in MD simulations 
In order to reproduce L2-SUMO interaction data and to characterize the potential interaction 
interface of the L2 SIM region and the SUMO receptor, MD simulations were performed. Therefore, 
the L2 SIM peptide (amino acid sequence: APDPDFLDIVALHRPALTSRRT) was modeled onto the 
potential SIM receptor grooves on SUMO1 or SUMO2 in parallel or anti-parallel orientation of the L2 
SIM with respect to the sheet-helix motif of the SUMO receptors. After equilibration for several 
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nanoseconds, for each of the four simulations (L2 SIM-SUMO1, L2 SIM-SUMO2, each with parallel or 
anti-parallel orientation), simulation snapshots were taken and the orientation of the L2 SIM 
peptides on the SUMO surface was characterized. For each simulation, the root-mean-square 
deviation (RMSD) was determined to describe conservation of a potential, conserved L2 SIM 
structure, which could be characteristic for the interaction of the L2 SIM peptide with SUMO 
proteins. 
Docking experiments of the L2 SIM peptide onto SUMO1 in parallel orientation resulted in a tight 
fitting of the hydrophobic core residues IVAL into the hydrophobic SUMO1 pocket located near the 
SUMO1 ARG54 (Fig. 3.52). Dipolar interactions were detected between the L2 SIM ASP3 and LYS37, 
ASP5 and LYS39 or ARG54, and ASP8 and ARG54 or LYS46. The RMSD of the L2 SIM peptide was 
about 5.6 Å, indicating no significant stabilization of the L2 SIM structure on the SUMO1 surface. For 
anti-parallel orientation, the L2 SIM region only very superficially attached to the SUMO1 surface. 
The RMSD of the L2 SIM was 6.7 Å, indicating no interaction with SUMO2 under these conditions. A 
potential dipolar interaction was only detected between the L2 SIM ASP5 and LYS35. In contrast, 
after docking of the L2 SIM peptide on SUMO2 in parallel orientation, the peptide was tightly 
associated within the hydrophobic SUMO2 acceptor groove. Also, the directly neighboring peptide 
regions were in close contact to characteristic side chains of SUMO2 surface residues (see black 
arrows). Dipolar interactions were identified between ASP3 of the L2 SIM and LYS33, as well as ASP5 
with ARG50, and ASP8 with LYS35, but also the C-terminal ARG14 with ASP16. Especially the SIM core 
amino acids IVAL were directly located with a hydrophobic surface grove of the SUMO2 receptor 
directly located beneath the SUMO2 ARG50. This characteristic orientation of the L2 SIM was 
significantly stabilized indicated by a low RMSD of the L2 SIM peptide of about 2.2 Å. Docking of the 
L2 SIM peptide to SUMO2 in anti-parallel orientation did not result in a stabilized attachment of the 
peptide on the surface of SUMO2. With increasing simulation time, the L2 peptide moved further 
away from the SUMO2 surface also represented by an increased RMSD of the L2 Sims of about 4.4 Å. 
Additionally, there were only two dipolar interactions of the L2 SIM ASP5 with LYS35 and L2 SIM 
ASP8 with LYS42, which were not present in all simulation snapshots.  
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Fig. 3.52: MD simulations of the L2 SIM peptide interaction with SUMO1/2. A Superposition of L2 SIM structures after 
parallel or anti-parallel docking of the L2 SIM peptide onto SUMO1. Black arrows indicate tight surface attachment of the L2 
peptide. Asterisks denote significant flexibility of the peptide termini. B Superposition of L2 SIM structures after parallel or 
anti-parallel docking of the L2 SIM peptide onto SUMO2. C View on the hydrophobic core of the L2 SIM peptide (amino 
acids IVAL, green) within the hydrophobic groove (left) and the amino acid residues involved in ionic interaction after 
docking to SUMO2 in parallel orientation (right). D RMSD values for the different L2 SIM-SUMO1/2 interaction modi. E 
Amino acids involved in ionic interactions and determination of the central hydrophobic core motif of the L2 SIM.
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  4. Discussion 
 
Human papillomaviruses (HPVs) are a family of nonenveloped DNA viruses, which mostly account for 
benign papillomas. However, several high-risk HPVs, such as HPV16, also cause cervical cancer or 
other epithelial tumors (Walboomers and Snijders 1999; Parkin 2006). After infection of basal cells, 
the life cycle of HPVs fundamentally depends on the differentiation of keratinocytes including 
genome amplification and production of new viruses in fully differentiated epithelial cells. The HPV 
capsid is composed of the major capsid protein L1 and the minor capsid protein L2, which plays a key 
role in several steps during HPV infection, including nuclear transport of the L2-DNA complex, and 
assembly of new viruses (Florin, Sapp et al. 2002a; Florin 2002b; Florin, Becker et al. 2006; Kämper, 
Day et al. 2006; Buck, Cheng et al. 2008; Schneider 2011). For functional regulation of these 
processes, L2 exploits different cellular mechanisms. There is strong evidence that pathogens and 
viruses frequently use the cellular apparatus of small ubiquitin-like modifiers (SUMOs) for regulation 
and establishment of persistent infection (Wimmer 2012). Multiple viral proteins which are 
functionally related to L2 thereby interact with SUMO proteins by both covalent SUMO modification 
(also termed SUMOylation) but also noncovalent interaction based on SUMO interacting motifs 
(SIMs) (Wimmer 2012). It was shown before that also the HPV16 L2 protein is SUMOylated and that 
especially L2 SUMOylation with SUMO2/3 significantly increased L2 stability upon coexpression 
(Marusic 2010). In this context, it was of highest importance to characterize the unknown physiologic 
relevance of L2 SUMOylation, but also to elucidate whether L2 is able to interfere with the cellular 
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SUMO apparatus via SUMO interacting motifs (SIMs) by noncovalent interaction and to characterize 
possible consequences for HPV infection.  
This study provides the first direct evidence that HPV16 L2 directly interacts with SUMO proteins via 
a conserved SIM (amino acids 286-289: IVAL). Incorporation of L2 lacking the SIM region (L2 ΔSIM) 
led to an almost complete loss of infectivity for HPV16 L1/L2 ΔSIM pseudobiruses (PsVs), while 
incorporation of SUMOylation deficient L2 did not influence infectivity of HPV16 L1/L2 PsVs. The lack 
of the L2 SIM had no effect on virus binding and endocytosis, but almost entirely abolished 
colocalization of L2 or the viral DNA with promyelocytic leukemia bodies (PML bodies or ND-10) after 
infection with L1/L2 ΔSIM PsVs, which is characteristic for wild-type L1/L2 PsVs (Day 1998; Florin 
2002b; Schneider 2011). After cellular L2 expression, the lack of the L2 SIM had no effect on nuclear 
import, but led to an inhibition of L2 colocalization with PML. However, since generation of L1/L2 
PsVs also succeeded with L2 lacking the SIM, SIM-based SUMO interaction does not seem to be 
crucial for morphogenesis of new viral particles. 
 
4.1 Covalent SUMOylation has no effect on assembly and infectivity of L1/L2 PsVs 
There is a manifold of examples showing that viral proteins counteract the viral defense system of 
infected target cells by exploiting the cellular SUMO apparatus (Wimmer 2012). Thereby, both 
SUMOylation of viral proteins, but also SIM-based interaction with SUMO, leads to modification, 
delocalization, or even destruction of cellular PML bodies, which are regarded as antiviral centers 
featuring an especially high level of SUMOylated anti-viral proteins like PML, Sp100, DAXX, or ATRX. 
Also the HPV16 L2 protein interacts with components of the PML-NBs, leading to modification and 
reorganization of PML-NBs (Florin 2002b). First, we characterized the ability of L2 to be SUMO 
modified by covalent SUMOylation. After overexpression of L2 together with GFP-SUMO1 or GFP-
SUMO2, clear high molecular weight bands featuring the theoretical weight of GFP-SUMO1/2 
modified L2 were found for wild-type L2, while no such bands were identified after expression of 
SUMOylation deficient L2 lacking the SUMO conjugation motif (L2 ΔSCM). We were additionally able 
to identify a preference of L2 SUMOylation for GFP-SUMO2, while less L2 SUMOylation was observed 
for GFP-SUMO1. Most interestingly, L2 SUMOylation led to stabilization of L2, as half-life times of 
overexpressed L2 ΔSCM were significantly decreased when compared with wild-type L2 after 
coexpression with GFP (0.3 h vs. 0.9 h). This was in line with previous results reporting SUMOylation 
of wild-type L2, especially by SUMO2/3, but not L2 ΔSCM, which had a stabilizing effect on L2 
(Marusic 2010). In this work, the effect of L2 SUMOylation on L2 stability was additionally 
characterized by measuring L2 turn over/degradation after coexpression together with GFP-SUMO1 
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or GFP-SUMO2. As a general trend, coexpression of GFP-SUMO1 or GFP-SUMO2 resulted in 
significantly extended L2 half-life times and enhanced stabilization of all L2 mutants when compared 
with GFP-L2 coexpression without SUMO1/2. There are several possible explanations for L2 
stabilization. First, L2 half-life times could be directly affected by SUMOylation due to altered 
molecular structure and interaction activity of the modified L2. Second, it is plausible that enhanced 
SUMOylation levels due to GFP-SUMO1/2 overexpression could lead to enhanced SUMOylation of 
transcription factors, resulting in increased expression levels. However, this assumption may be 
disqualified at least in some part due to the fact that the stability assay was based on addition of 
cycloheximide (CHX) just before characterization of L2 stability, which represents an inhibitor of 
eukaryotic translation and allows for determination of L2 turnover without artifact stemming from 
transcription or translation. An additional explanation could be that the coexpressed GFP-SUMO1/2 
fusion proteins are dominant-negative for formation of fully-functional anti-viral and L2 degrading 
PML-NBs, which in turn leads to extended L2 half-life times. A further reason for increased L2 
stability could be, that the lysine at position 35, which serves as acceptor during L2 SUMOylation, can 
not longer be targeted by ubiquitin, which could induce L2 degradation. 
By L2 overexpression experiments, also the influence of L2 SUMOylation on morphogenesis of new 
HPV16 PsVs was investigated. Previously, a diffuse L2 localization pattern all over the nucleus for 
wild-type L2 and L2 ΔSCM was reported in immunofluorescence microscopy in the presence of 
endogenous SUMO (Marusic 2010). Conversely, our experiments showed a well defined 
colocalization of L2 with PML and SUMO1/2 at the PML-NBs for wild-type L2 and L2 ΔSCM in HeLa 
and HaCaT cells with or without coexpression of GFP-SUMO1 or GFP-SUMO2. In addition, it was 
reported that SUMOylated L2 does not interact with L1 in pulldown experiments, which could have 
important effects on HPV morphogenesis. In our studies, L2 ΔSCM had no influence on L2-
incorporation into HPV16 L1/L2 PsVs and the mutant L1/L2 ΔSCM PsVs featured a wild-type level of 
incorporated viral DNA and a typical capsid structure. 
This study provides the first results for unraveling the consequences of L2 SUMOylation on HPV 
infection including cellular localization of viral proteins and DNA after infection. SUMOylation is 
obviously not required for the typical localization of the L2-DNA complex at PML bodies after HPV16 
infection, as immunofluorescence experiments showed a clear localization of both, L2 and viral DNA, 
at PML NBs after infection with wild-type HPV16 L1/L2 PsVs or L1/L2 ΔSCM PsVs. Additionally, 
SUMOylation deficiency of L2 had only a slight effect on infectivity. The infection level of L1/L2 ΔSCM 
PsVs was decreased to about 50-70% in many infection experiments when compared with wild-type 
PsVs. This could indicate a small but measureable influence of L2 SUMOylation on HPV infectivity, 
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which could be caused by the lower L2 stability and the decreased half-life time of SUMOylation 
deficient L2 ΔSCM observed after infection and overexpression. 
 
4.2 Two highly conserved SUMO interaction motifs (SIMs) in HPV16 L2 
SUMOylation does not represent the only way for proteins to interact with the cellular SUMO 
apparatus. As a second mechanism, also a noncovalent interaction of proteins with SUMO via SUMO 
interacting motifs (SIMs) was frequently observed (Minty 2000; Song 2004; Hannich 2005; Kerscher 
2007). Since SUMOylation is also linked with SIM-based SUMO interaction, as it was already observed 
for PML-NB associated proteins like DAXX and Sp100 (Johnson 2004) but also during regulation of 
SUMOylation by SIM-containing E3 ligases (Gareau 2010), we searched for potential SIMs within the 
L2 protein sequence, which could allow for noncovalent L2 interaction with SUMO. A total number of 
nine potential SIMs was identified by sequence analysis within the HPV16 L2 sequence, which all 
followed the classical (V/I/L)-(V/I/L)-X-(V/I/L) or (V/I/L)-X-(V/I/L)-X-(V/I/L) consensus motif of a SIM 
(Minty 2000; Song 2004; Hannich 2005; Song 2005; Kerscher 2007). From the nine identified 
potential L2 SIMs, only the first six featured significant sequence conservation of the hydrophobic 
core region of the SIM in sequence alignments of high risk HPV16 L2 proteins. Additional conserved 
flanking, positively or negatively charged amino acids and phosphorylation sites, which are important 
for first surface binding of the SIM-containing proteins with SUMO (Gareau 2010), were observed for 
the SIMs at amino-acid positions 105-109, 235-238, and 284-289. Two of these SIMs represented 
double SIM motifs, in which each two SIMs lie directly on top of each other in parallel orientation 
(SIM 105-109, IVSLV) or antiparallel orientation (SIM 284-289, LDIVAL).  
In order to better specify the respective sequence positions of the SIMs, the L2 sequence was 
additionally characterized by bioinformatic tools. L2 structure predictions indicate that there is only a 
small content of helical regions (9%), which are especially located towards the N-terminus. Beta 
strand regions (23%) seem to be distributed all over the primary protein sequence of L2. In general, 
most of the primary sequence seems to feature random coil character (65%) with a tendency 
towards special disorder in several regions, including the foremost parts of the n-terminus and the 
region containing the potential SIM at position 284-289. These results roughly match the data 
obtained from simulation of circular dichroism spectra obtained for purified HPV16 L2 (25% helix, 
20% sheet, 55% random coil). The N-terminus seems to be highly accessible, which can be seen in a 
hydrophobicity/hydrophilicity plot of the L2 protein sequence, and confirms experimental data 
obtained for L2 after binding of HPV to the primary receptor, where the L2 N-terminus is cleaved by 
furin enabling infectious endocytosis (Richards, Lowy et al. 2006). The rest of the protein sequence 
  Discussion 
  147 
shares medium values for hydrophilicity/hydrophobicity, but there are smaller exceptions. Thus, for 
the region of aa 43-57, a significantly increased hydrophobicity was predicted, which overlaps with a 
transmembrane region predicted for the same part of the L2 sequence. The region of the potential 
double-SIM at the L2 sequence position 284-289 and eventually also the double SIM region at 
position 105-109 represent additional spots of locally high hydrophobicity, eventually to better fit 
into the hydrophobic pocket on the SUMO surface. Especially, the double-SIM at position 284-289 is 
additionally flanked by stretches of high hydrophilicity on both sides, perhaps to optimize first 
contact of L2 and SUMO by electrostatic interaction. The double SIM at position 105-109 is located 
directly after the N-terminal cyclophilin B interaction site (aa 97-103) involved in exposition of the L2 
N-terminus after cell binding (Bienkowska-Haba 2009; Bienkowska-Haba, Williams et al. 2012) and 
directly before an L2 interaction site for the annexin A2 heterotetramer (A2t, L2 sequence position 
108-120) proposed as potential secondary receptor facilitating HPV infection (Woodham, Da Silva et 
al. 2012). However, it is unlikely that the L2 SIM is involved in this very early step of infection by 
regulation or competition to the cyclophilin/A2t interaction, as SUMO proteins are mainly localized in 
the nucleus and the cytoplasm and may only be present in endosomes in the context of (poly)-
SUMOylated target proteins involved in their regulation pathways. However, the close neighborhood 
of the SIM to the cyclophilin/A2t interaction site could affect mutation experiments for dissection of 
the functionality of the SIM and interfere with functions based on cyclophilin/A2t binding.  
Taken together, L2 sequence analysis provided direct hints for the existence of more than one SIM in 
the L2 sequence. There are at least two sequence regions containing double SIMs (105-109 and 284-
298) with highest levels of sequence conservation and fulfilling all hallmarks of a classical SIM 
including the hydrophobic core region and flanking negatively charged amino acids important for 
long range electrostatic interaction involved in SIM-based SUMO interaction. In our studies, we 
focused on the L2 SIM at position 284-289. 
 
4.3 L2 directly interacts with SUMO1/2 proteins  
Subsequently, L2 interaction studies with SUMO1/2 were performed. For clarity, all interaction 
results are summarized in Table 4.1. In 3xFLAG-L2 precipitation experiments, a clear coprecipitation 
of GFP-SUMO2 was observed after coexpression of wild-type 3xFLAG-L2 together with GFP-SUMO1 
or GFP-SUMO2. One may only speculate why wild-type L2 only interacts with GFP-SUMO2 in 
immunoprecipitation. One explanation could be the well-known target specificity of SUMO proteins, 
which is not only reported for SUMOylation but also for SIM-based SUMO interaction (Meulmeester 
2008; Gareau 2010) and could be induced by the availability and localization of L2 interaction 
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partners, which are covalently modified by SUMO2, as there is no molecular basis for SUMO isoform 
specifity exclusively based on the SIM sequence, so far (Gareau 2010). The importance of the 
selective interaction of L2 with GFP-SUMO2 could be based on the known situation that SUMO2 and 
the almost identical SUMO3 play key roles in cellular regulation mechanism after cell stress in 
formation of poly-SUMO2/3 chains, which are directly linked with SUMO targeted protein 
degradation by the cellular proteasome (Saitoh 2000; Johnson 2004; Loftus 2009; Vertegaal 2010; 
Wadosky 2011). SUMO1 plays a role as potential chain end of poly-SUMO2/3 chains, but also in 
several more uncommon regulation mechanisms of SUMO1 targets.  
Evidence for a direct L2 interaction with SUMO proteins came from electron paramagnetic resonance 
(EPR) measurements based on affinity purified and spin labeled SUMO1-his6 or SUMO2-his6 together 
with affinity-purified L2-his6. Purified SUMO1 or SUMO2 was efficiently labeled with the EPR spin 
label Proxyl IAA at the helical position C52 (SUMO1) and C48 (SUMO2) by site-directed spin labeling 
(SDSL), incubated with different amounts of purified L2, which was refolded in the presence of SL-
SUMO1/2-his6, and characterized by continuous wave (CW) EPR. In the EPR spectra, a clear L2 dose 
dependent loss of mobility was observed in spectra of SL-SUMO1 and SL-SUMO2, indicating SUMO 
interaction with L2. While the labeling position was characterized as a region of a surface helix for 
SUMO1/2 samples without L2 addition, with increasing L2 amount, the mobility was even more 
limited and the labeling position was classified as a region of a contact helix typical for interaction 
surfaces. Also the L2 mutants C22S and L2 C28S were able to interact with SUMO1/2, indicating that 
the disulfide bridge, which is formed between both cysteines under physiological conditions (Campos 
2009), is not necessary for in vitro interaction of L2 with SUMO1/2. Interestingly, incubation of the L2 
SUMO1/2 samples with an L2 (L2-1) antibody, which recognizes the L2 epitope FTDPSVL (aa 163-
170), led to enhanced mobility of the labeled SUMO1/2 region, indicating a reduction of L2 
interaction with SUMO1/2 because of a higher affinity of the L2 antibody. This is possible due to a 
sterical inhibition of the L2-SUMO interaction based on close vicinity of the L2-1 epitope and the SIM 
in the native L2 protein structure. This could also explain why no coprecipitation of SUMO proteins 
was found after the numerous precipitations of L2 with L2 (L2-1) antibodies.  
For reproduction of the interaction data, additional His- or GST-pulldown experiments were 
performed based on precipitation of GST-SUMO1/2 or SUMO1/2-his6 and coprecipitation of L2, but 
no L2 interaction with SUMO1/2 was observed. The negative interaction results for pulldown 
experiments were most obviously caused by a strong formation of L2 aggregates in the presence of 
PML-containing components in the cell lysates prior to incubation of the separate L2 sample with 
precipitated and purified GST-SUMO1/2 or SUMO1/2-his6, which possibly inhibited L2 interaction 
with SUMO. In contrast, in immunoprecipitation experiments with GFP-SUMO1/2, overexpressed L2 
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was able to interact with coexpressed GFP-SUMO1/2 directly after protein synthesis and before 
potential aggregation of L2 with PML-proteins. Additionally, there was no interaction of L2 with 
SUMO1/2 in mammalian 2-hybrid screening. In these experiments, L2 and SUMO1/2 were 
overexpressed as fusion proteins together with relatively large activation- or DNA binding-domains 
(both about 20 kDa), which could possibly interfere with protein interaction, albeit correct expression 
of fusion proteins. Another possible explanation could be that L2 features an inhibitory effect on 
transactivation due to transcriptional repression, as it is known that L2 also interact with factors like 
DAXX and Tbx, which act as transcription repressors (Wimmer 2012, Schneider 2012).  
Tab. 4.1: Summary of L2/SUMO interaction data. L2 interaction with SUMO1/2 was characterized by different methods 
based on full-length L2 or L2 peptides containing a 22 or 23 amino acid sequence of L2 containing the L2 SIM at position 
296-289. “+++”, “++”, “+” denote a grading for positive interaction of L2 with SUMO, “--“ denotes no interaction, “ND”: not 
determined. Abbreviations for the methods used: IP: immunoprecipitation, IF: immunofluorescence microscopy, EPR: 
Electron Paramagnetic Resonance spectroscopy, PD: pulldown experiments with purified/immobilized SUMO1/2, ITC: 
Isothermal titration calorimetry, FCS: Fluorescence Correlation Spectroscopy, MD: molecular dynamics simulation. 
full-length L2 L2 SIM peptide 
method GFP-SUMO1 GFP-SUMO2 GST-SUMO1/2 SUMO1/2-his6 method SUMO1/2-his6 
IP -- +++ ND ND FCS ++ 
IF +++ +++ ND ND EPR -- 
EPR ND ND ND +++ ITC -- 
PD ND ND -- -- MD ++(+) 
ITC ND ND ND --  
 
4.4 The L2 SIM is crucial for L2 interaction with SUMO proteins 
To check whether the identified L2 SIM at sequence position 284-289 is responsible for L2 interaction 
with SUMO, immunoprecipitation experiments were repeated with mutant L2 lacking the 
hydrophobic core of the SIM (L2 ΔSIM, IVAL286-289AAAA). Remarkably, no interaction of the 
deletion mutant, L2 ΔSIM, with GFP-SUMO2 was observed in immunoprecipitation, indicating that 
the SIM region was directly involved in SUMO interaction. For characterization of the influence of 
SUMOylation on L2 interaction with GFP-SUMO2, also L2 ΔSCM mutants were included in 
immunoprecipitation experiments. The lack of the SUMO conjugation motif did not abrogate L2 
interaction with GFP-SUMO2. Additional hints for L2 interaction with GFP-SUMO proteins came from 
immunofluorescence microscopy after overexpression of L2 together with GFP-SUMO1/2. Here, 
overexpressed wild-type L2, L2 ΔSCM, or L2 ΔPHOS showed the known and characteristic L2 wild-
type phenotype and colocalized at PML-NBs, where also the majority of GFP-SUMO1/2 was located. 
These observations confirmed already published results for wild-type L2 colocalization with PML (Day 
1998; Florin 2002b) and highlight the importance of L2 to locate at the PML-NBs, which represent 
regulation centers for viral defense but also viral transcription and replication and are mainly 
composed of DAXX, Sp100, and PML (Swindle 1999; Day 2004; Wimmer 2012)(Tavalai 2008; Tavalai 
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and Stamminger 2009; Wimmer 2012). All of them are controlled by SUMOylation in multifactorial 
ways, as stabilization, activation, and localization of these SUMO targets is directly affected by 
SUMOylation also explaining the high abundance of SUMO proteins at these sites. Most remarkably, 
L2 lacking the SIM did not localize at PML-NBs. Albeit, after coexpression of GFP-SUMO1/2 and L2, 
SUMO still localized at the PML-NBs, L2 ΔSIM featured a very diffuse localization pattern throughout 
the entire cell nuclei. The missing colocalization of L2 ΔSIM with GFP-SUMO1/2 at PML NBs is an 
additional clear sign that L2 interaction with GFP-SUMO1/2 directly depends on the L2 SIM at 
position 284-289.  
Taken together, interaction studies suggested that the L2 SIM is important for L2 interaction with 
SUMO1/2 featuring a special preference for interaction with SUMO2, which could be induced by 
interaction with L2 targets, which are covalently modified by SUMO2. This also offers an explanation 
why SUMO specificity was readily observed in immunoprecipitations featuring a physiological protein 
context, but was not observed in in vitro interaction studies with purified proteins. 
 
4.5  Flanking sequences around the L2 SIM trigger SUMO interaction of L2 
In a set of biophysical interaction experiments, the interaction of short L2 peptides containing the L2 
SIM at position 284-289 with purified SUMO1 or SUMO2 was characterized. In EPR measurements, 
synthetically L2 SIM peptides containing 22 or 23 amino acids with each one cysteine at a selected 
position, were labeled by site-directed spin labeling and incubated with different amounts of 
nonlabeled SUMO1-his6 or SUMO2-his5. There was no change in mobility for the labeled position 
within the L2 SIM peptide after addition of SUMO proteins indicating no interaction of the L2 SIM 
peptides with SUMO. There was also no interaction in DEER measurements, where both L2 SIM 
peptides and SUMO proteins were spin-labeled, but did not lead to detection of intermolecular DEER 
distances between the labels. It is most likely that the small sequence part around the L2 SIM 
selected for peptide synthesis does not allow for a stable in vitro interaction with SUMO1/2, since 
important flanking positively and negatively charged amino acids are only partially implemented. 
From literature it is known that especially negative charges located on the side chains of these 
residues might modulate SUMO-SIM interaction through long range electrostatic interactions with 
basic residues in the closer vicinity of the hydrophobic pocket of SUMO (Minty 2000; Song 2004; 
Kerscher 2007). The L2 sequence around the SIM at position 284-289 comprises a total number of 
eight negatively and ten positively charged amino acids with partly very high sequence conservation 
in high risk L2 types, from which only each three amino acids were also present in the selected L2 
SIM peptides investigated here. It is plausible that under in vitro conditions, only a significantly 
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enlarged part of the structure region of L2 around the SIM containing a larger amount of charged 
residues is able to bring the SIM together with the hydrophobic interaction pocket of the SUMO 
proteins, as it was seen for full-length L2 and SUMO1/2 in CW EPR.  
Further support for this thesis came from isothermal titration calorimetric (ITC) measurements based 
on the same L2 SIM peptides after titration with nonlabeled SUMO1. The binding constants 
determined by assuming one binding site per SUMO1/2 molecule were only slightly larger than the 
dilution heat indicating no or only very weak interaction of the L2 SIM peptide with SUMO1/2 under 
these conditions. However, it has to be stated that positive interaction of SIM peptides from other 
SUMO targets containing only 9-13 amino acids were able to interact with SUMO under comparable 
experimental conditions yielding dissociation constants of about 3-12 µM (Sekiyama 2008).  
Conversely, positive interaction results for the interaction of the L2 SIM peptide with SUMO1 and 
SUMO2 came from fluorescence correlation spectroscopy (FCS). Here, a large fraction of 
fluorescence labeled L2 SIM peptides (25 - 50%) was able to interact with SUMO1 or SUMO2 to form 
significantly larger L2 SIM-SUMO1 or L2 SIM-SUMO2 complexes with slower diffusion times (about 
100 ns) and a higher hydrodynamic radius (about 1.9 nm) when compared with the fluorescence 
labeled L2 SIM peptide alone (diffusion time: 20 ns, hydrodynamic radius: 0.56 nm). Control 
measurements showed that there was no nonspecific attachment of free fluorescence labels on 
SUMO1 or SUMO2, which could distort interaction parameters. One reason for this situation could be 
that the complex of L2 SIM peptide and SUMO is based on a very weak and unstable interaction, 
which was only detectable by the highly sensitive (to the global aggregates) FCS experimental setup, 
but not with CW EPR, where the local mobility dominates (which might not have changed after 
complex formation) or ITC, which cannot discriminate very short-lived protein interactions. It is 
plausible that only a larger L2 structure context would lead to a more stable association of the L2 SIM 
with SUMO detectable by EPR or ITC. 
 
4.6 The putative L2-SUMO interaction complex based on MD simulation 
In this thesis, an MD approach was used to characterize the possible structure of a potential L2 SIM-
SUMO interaction complex. Thereby, both parallel and antiparallel orientation of the L2 SIM peptide 
with respect to the acceptor beta sheet of SUMO1/2, which is extended by the SIM upon interaction, 
were taken into account and compared with each other. Highest specificity of the L2 SIM attachment 
was found for parallel orientation of the L2 SIM peptide on the interaction surface of SUMO2. Here, a 
total number of four amino acid residues of the L2 SIM peptide was involved in formation of ionic 
interactions with acceptor residues on the SUMO2 surface. The L2 SIM residues ASP3, ASP5, ASP8 
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were in close proximity of the SUMO2 surface residues LYS33, ARG50, and LYS35, which are part of a 
field of positively charged acceptor molecules around the central hydrophobic groove between the 
helix and the beta sheet of SUMO2. Additionally, there was an ionic interaction between ARG14 of 
the L2 SIM peptide and ASP16 on SUMO2. This led to a very stable conformation of the L2 SIM 
peptide with a very low RMSD throughout the entire MD simulation. Especially the hydrophobic core 
region of the SIM including the residues IVAL was deeply buried within a hydrophobic groove on the 
SUMO2 surface. A comparable conservation of the L2 SIM-SUMO interaction complex was observed 
after parallel docking of the L2 SIM peptide onto SUMO1. Here, the L2 SIM residues ASP3 were in 
close proximity of the surface acceptor LYS37, ASP5 in the proximity of LYS39/ARG54, and ASP8 in 
the proximity of LYS46/ARG54. In general, the SUMO surface residues which seemed to be involved 
in attachment of the SIM in these MD simulations also function as acceptors in known SIM-SUMO1 or 
SIM-SUMO2 structures (PDB structures for comparison: 2ASQ, 1Z5S, 2KQS, 2LAS for SUMO1 and 
2RPQ for SUMO2/3).  
Interestingly, two observations indicate that one L2 molecule could potentially interact with more 
than one SUMO molecule at the same time (Fig. 4.1). First, DEER measurements based on spin-
labeled SUMO2 (SL-SUMO2) and L2 in a molar ratio of 3:1 revealed significantly increased 
modulation depths when compared with reference measurements with SL-SUMO2 alone. There is a 
significant contribution of distances around 3.2 nm indicating that at least two SL-SUMO2 molecules 
are orientated next to each other at a fixed orientation with an intermolecular distance of about 3.2 
nm. Since there were no DEER distances in SL-SUMO2 samples, the only plausible reason is that two 
SUMO2 molecules interact with one L2 molecule at the same time via more than one L2 SIM, and 
that the distance between the spin-labels of the L2-bound SL-SUMO2 molecules is about 3.2 nm. This 
theory is in line with the observation that the L2 SIM at L2 position 105-109 was also able to attach to 
SUMO2 in MD simulations. There was a stable conformation of the L2 SIM105-109 peptide after parallel 
attachment (RMSD ≈ 2.8 Å). The conformation was stabilized by dipolar interaction of the L2 SIM105-
109 GLU17 and GLU16 residues with basic LYS35 and LYS45 acceptor residues on the SUMO2 surface. 
As a result, this could indicate that L2 may interact with more than one SUMO protein at the same 
time and could also allow L2 interaction with poly-SUMO2/3 chains via multiple L2 SIMs, which is 
often observed for SUMO or ubiquitin E3 ligase enzymes (Yang and Sharrocks 2010; Boutell 2011). 
However, as the lack of the major L2 SIM at L2 position 286-289 completely inhibits L2 interaction 
with GFP-SUMO2 in immunoprecipitations, it seems that the second SIM does not act independently 
as a SIM, but instead might act as a functional module together with the major SIM at L2 position 
289-289 and could have a potentiating effect on SUMO interaction, as it was also observed for the 
SUMO E3 ligase PC2 (Yang and Sharrocks 2010). In turn, since CW EPR measurements were 
performed with an about 1:1 molar ratio of L2 and SL-SUMO1 or SL-SUMO2, this means that a 
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further increase of SL-SUMO1/2 in CW EPR could lead to even more immobilized CW EPR spectra or 
detection of mix spectra, which contain contributions of a SL-SUMO species bound to the first L2 SIM 
and a SL-SUMO species bound to the second L2 SIM. 
 
Fig. 4.1: The interaction of L2 with SUMO targets. A Schematic view on the putative interaction complex of non-EPR-
labeled L2 with two spin labeled SL-SUMO molecules. A broad distance distribution around 3.2 nm was detected in DEER 
EPR measurements after incubation of nonlabeled L2 with an about threefold molar excess of spin-labeled SUMO2, which 
was not based on random interaction of SL-SUMO molecules, as no DEER distances were measured in reference samples 
containing only SL-SUMO2. This implies that at least two SL-SUMO2 molecules are located next to each other at a fixed 
orientation and with an intermolecular distance of about 3.2 nm between the SUMO2 labeling positions at cysteine 48 
within the SUMO2 helix. One plausible reason explaining the fixed orientation of the SUMO proteins next to each other is 
the interaction of two or more SUMO molecules with one L2 via multiple L2 SIMs. B The L2 ability to interact with more 
than one SUMO molecule in in vitro interaction assays could allow L2 interaction with polySUMO chains of SUMOylated 
target proteins like e.g. Sp100, which could allow for proteasomal degradation of the SUMOylated L2 targets after 
recruitment of E3 ubiquitin ligases. 
 
Thus, our results indicate that L2 accumulates at PML-NBs mediated by the L2 SIM and may interact 
with SUMO or with with (poly-)SUMOylated PML-components under ongoing infection. As a 
speculation, L2 could further target these components for proteasomal degradation, as it was 
already suggested for Sp100 (Florin 2002b). L2 could thereby facilitate degradation of antiviral PML-
components by recruitment of an ubiquitin E3 ligase complex to the polySUMOylated antiviral target 
proteins. 
 
4.7 The challenge of L2 purification and refolding 
With respect to the biophysical characterization of HPV16 L2, it can be summarized that the most 
crucial experimental step is represented by L2 refolding, which had tremendous effects on all follow-
up experiments. Since L2 purification was only possible under denaturing conditions based on his 
affinity purification, so far, L2 refolding had to be performed. This was done by L2 transfer into non-
denaturing buffers after L2 precipitation or by gradual buffer exchange by dialysis or in proteins 
concentrator columns. For all of the protocols, a strong trend of HPV16 L2 for formation of large 
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aggregates was observed. Additional hints for a strong tendency of L2 for aggregation came from 
earlier studies reporting the presence of high molecular weigh L2 aggregates after ultracentrifugation 
of HPV PsV preparations (Becker 2003; Florin 2004) and own observation of L2 aggregation leading to 
extreme stickiness and loss of L2 upon L2 exposition to purification matrixes, like e.g. size exclusion 
columns or centricons. It seems that L2 aggregation can be minimized by L2 refolding in the presence 
of SUMO1 or SUMO2, which was also used as experimental setup for EPR measurements. However, 
in ITC experiments, the L2 and SUMO1/2 solution had to be prepared separately, leading to strong L2 
aggregation levels. Although it was possible to re-dissolve the L2 aggregates by adjustment of the 
buffer salt concentration, no interaction was detected in ITC experiments, indicating that L2 folding is 
not trivial and requires further analysis. Improvement for this situation could be based on promising 
efforts in L2 purification under non-denaturing conditions based on a SUMOstar-L2 fusion protein 
and L2 expression in HEK293 cells, which yielded significantly improved L2 solubility and purification 
levels >65%. Most interestingly, the fusion protein used in this purification was designed based on 
the tertiary structure of SUMO, which could explain the positive stabilizing and chaperoning effects 
observed. Perhaps, L2 purification following this protocol could allow for large levels interaction 
screening based on EPR, CD, FCS, and ITC measurements and replace denaturing L2 purification 
performed here. 
 
4.8 L1/L2 ΔSIM PsVs are non infectious despite correct assembly of the L1/L2 capsid 
In order to characterize a possible effect of SIM-based SUMO interaction on HPV infection, L1/L2 
ΔSIM PsV were prepared and infectivity of the PsVs was characterized. Remarkably, the mutant L1/L2 
ΔSIM PsV were not able to infect HeLa or HaCaT cells. Thus, the lack of the L2 SIM had tremendous 
effects on HPV16 physiology. Now it was checked which SIM-dependent factors could influence loss 
of infectivity of L1/L2 ΔSIM PsVs and at which point of HPV16 infection the phenotype of L1/L2 ΔSIM 
PsVs diverged from that of wild-type PsVs due to the lack of the L2 SIM. First, the assembly of L1/L2 
ΔSIM PsVs from L1 and mutant L2, as well as DNA incorporation into the mutant PsVs, was analyzed. 
It was not clear whether L2 ΔSIM would be correctly assembled into L1/L2 capsomers and final L1/L2 
capsids or whether the L2 ΔSIM mutation would affect reporter DNA packaging into the PsVs. In 
general, after standard preparation of PsVs for infection assays, it is possible that there is still a larger 
amount of non-assembled L1 or L2 in the PsV peak fractions, non-incorporated L2, or possibly also 
high molecular capsomeric aggregates, which would finally ead to a decreased amount of infectious 
PsVs in the preparation. To analyze this, sucrose gradient ultra centrifugation and immunodetection 
of L1/L2 proteins was performed based on the peak fraction of standard purified PsVs (Becker, Florin 
et al. 2004; Florin 2004). Clear L1 and L2 peaks were identified in the same UZ fractions for all PsV 
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and with comparable band intensity. Additionally, there was no L1 or L2 detection in any of the high 
or low density edge fractions, indicating that the majority of the L1 and L2 protein in the standard 
PsVs preparations was in fact assembled into L1/L2 capsids, also for L1/L2 ΔSIM PsVs. For virus-like 
particles (VLPs), which only contain L1, the L1 bands were distributed over a larger number of 
fractions indicating larger polydispersity of the capsids perhaps due to the lack of L2, which features 
a stabilizing effect on HPV capsid structure. After identification of the peak fractions of the PsVs by 
sucrose gradient purification, the peak fractions were pooled and subjected to infection assays to 
reproduce infection data obtained for standard PsV preparations. Again, comparable levels of 
infectivity were found for wild-type and L1/L2 ΔSCM PsVs (50-75% infectivity compared with wild-
type PsVs), while L1/L2 ΔSIM PsVs and L1 VLPs were noninfectious. Also the amount of incorporated 
reporter DNA (luciferase expression plasmid) was quantified, on the one hand to check the general 
ability of the different PsV types for DNA incorporation during PsV preparation, on the other hand to 
exclude artifacts of different reporter DNA levels in infection assays which could bias infection 
results. All PsVs and also the VLPs contained comparable amounts of reporter DNA. Thus, we were 
not able to reproduce a decreased level of DNA incorporation in VLPs, which was reported to be 
based on the lack of L2 in L1 VLPs (Stauffer, Raj et al. 1998; Buck 2004). Furthermore, it can be 
concluded that the L2 ΔSIM mutation did neither affect incorporation of L2 into L1/L2 PsVs nor 
incorporation of reporter DNA.  
The peak fractions were additionally characterized by transmission electron microscopy (TEM) to 
detect possible aberrations of the L1/L2 capsid structure due to the L2 ΔSIM mutation. There were 
no changes of structure and size of L1/L2 ΔSIM PsVs when compared with wild-type PsVs. Also L1 
VLPs and L1/L2 ΔPHOS PsVs showed a wild-type capsid structure with diameters of about 52-55 nm. 
There were no visible structural abnormalities of L1/L2 capsids after assembly from L1 and the 
selected L2 mutants. Also incorporation of 5-ethynyl-2´-deoxyuridine (Edu) as marker molecule, 
allowing staining of viral DNA in PsVs after infection of PsV in fluorescence microscopy, did not result 
in detectable changes of the capsid structure in TEM. 
 
4.9 The L2 SIM is not involved in the early steps of HPV16 infection 
After confirmation of the correct capsid assembly of L1/L2 ΔSIM PsVs, the cell binding properties of 
the mutant PsVs were investigated in flow cytometry. No change of the amount of mutant L1/L2 
ΔSIM PsVs attached to the surfaced of HaCaT or HeLa target cells was observed when compared to 
the amount of wild-type PsVs after cells were incubated with comparable amounts of the different 
PsVs. Thus, the L2 ΔSIM mutation, albeit its location in a L2 sequence region declared as solvent 
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accessible (Kawana 1998), does not seem to significantly influence cell binding of the mutant PsVs. 
These results were also confirmed by passive monitoring of the PsV binding to HaCaT target cells 
with Fremy’s Salt (NDS) in CW EPR measurements (Fig. 4.2).  
 
Fig. 4.2: NDS as a passive sensor for viral cell binding/capsid rearrangement of HPV16 in CW EPR measurements. While 
EPR-active NDS molecules share very long half-life times in standard buffers or after addition of cells or heparin, half-life 
times were significantly reduced after addition of PsVs, most obviously due to a dissociation of NDS molecules at the 
positively charged L1/L2 amino acid patches further referred to as NDS dissociation centers (NDCs). Incubation of the 
NDS/PsV mix with HaCaT cells leads to detection of very short NDS half-life times, most obviously based on even better 
accessibility of the NDCs due to a conformational change of the viral capsid upon binding to the surface of HaCaT cells. 
However, incubation of the NDS/PsV solution with heparin led to extended NDS half-life times, indicating that heparin 
prevents NDS molecules from localization at NDCs and most obviously does not lead to a conformation change of the 
capsid. Even after addition of HaCaT cells, no shortening of NDS half-life times was observed, confirming the ability of 
heparin to inhibit cell binding of PsVs. 
While NDS half-life times and the corresponding EPR activity were maximal for NDS incubation in 
pure buffer solutions or solution containing heparin or HaCaT cells, shortened NDS half-life times 
were observed for incubation of the same amount of NDS with PsVs. This is most obviously due to a 
higher local concentration of NDS molecules at positively charged amino acid patches of L1 and L2 
within the PsVs, which led to a disproportionation reaction of always two NDS molecules and loss of 
the EPR activity of the NDS molecules. Interestingly, incubation of the NDS/PsV solution with HaCaT 
cells resulted in even shorter NDS half-life times. Since incubation of NDS with the same amount of 
HaCaT cells did not result in comparable NDS decay levels, one reasonable explanation would be that 
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the strongly diminished NDS half-life times are caused by an increased accessibility of the centers 
facilitating NDS disproportionation (NDCs) within the PsVs allowed by structural rearrangement of 
the L1/L2 capsid upon cell binding. Thus, this experiment could allow for a systematic 
characterization of the early HPV infection steps, including L1 rearrangement upon L1-driven and L2 
independent PsV binding to heparan sulfate proteoglycans (HSPGs) as the first receptor, followed by 
interaction with cyclophilin B inducing exposure of the L2 N-terminus, which is then cleaved by furin 
(Selinka 2003; Schelhaas 2008; Day 2008a; Day 2008b; Bienkowska-Haba 2009; Bienkowska-Haba, 
Williams et al. 2012). 
At the current state of knowledge, it remains elusive to speculate which L1/L2 rearrangement step 
leads to the well accessible NDCs after cell attachment. However, with the use of cyclophilin or furin 
inhibitors, the effect of the respective PsV processing steps could be dissected systematically. In this 
context, remarkably, incubation of the PsV/NDS solution with the PsV cell binding inhibitor heparin 
(Joyce 1999; Giroglou, Florin et al. 2001; Schelhaas, Shah et al. 2012) results in significantly increased 
NDS half-life times, indicating that the positively charged L1/L2 patches are obviously not accessible 
for NDS molecules in the presence of heparin. One may speculate that the PsV attachment to 
heparin, which mimics the heparan sulfate molecules on the cell surface, was not sufficient to induce 
the L1/L2 conformation change, which leads to the fast decay of NDS molecules upon cell binding. In 
this context, our results are in line with recent reports, arguing that heparin binding of PsVs does not 
lead to obvious changes of the capsid structure of HPV16 in vitro (Dasgupta 2011). Based on this, one 
remaining plausible explanation is that the extremely prolonged NDS half-life times may be caused 
by an attachment of the PsVs to the polyanion heparin, which coats the PsVs within several seconds 
and renders the NDCs, which are positioned within the PsVs, inaccessible for the NDS molecules. As a 
consequence, the NDS molecules reside evenly distributed in the residual buffer volume with NDS 
decay levels comparable with those for NDS in pure buffer. Addition of HaCaT cells to PsVs 
preincubated with heparin did not lead to decreased NDS half-life times, which is a direct 
confirmation of the inhibitory effect of heparin on cell binding proposed before. It seems plausible 
that the heparin coating of the PsVs blocks both, penetration of NDS molecules into the PsVs and 
structural rearrangement of the L1/L2 capsid due to the lack of cell binding. Otherwise, L1/L2 
rearrangement should at least result in a somewhat better accessibility of the NDCs to the NDS 
molecules and in slight reduction of NDS half-life times, which was not observed here. 
In addition, there were no significant differences between NDS half-life times after incubation with 
wild-type L1/L2 PsVs, L1/L2 ΔSIM PsVs, or even L1 VLPs with HaCaT cells, indicating that cell binding 
happened in an equal manner for all virus types in the presence of target cells and did not depend on 
L2, as it was reported before (Selinka 2003; Day, Lowy et al. 2003b; Kämper, Day et al. 2006), or the 
  Discussion 
  158 
L2 SIM. Also the relative changes of half-life times after addition of heparin or HaCaT cells to the 
PsV/NDs solution revealed no significant differences between the different viruses. Thus, the first 
binding steps and subsequent conformational changes of the PsV seem to occur L2-independently. 
The CW EPR approach with NDS as paramagnetic sensor molecule represents a very promising 
biophysical method for characterization of PsV binding and subsequent rearrangement of the HPV 
capsid. This method, for the first time, allows to directly measure effects of HPV inhibitors on L1/L2 
conformation during early steps of infection. 
 
Next, endocytosis of L1/L2 ΔSIM PsVs was characterized by flow cytometry. After 24 h of infection, 
no PsVs were detected on the surface of the target cells, indicating that, analogous to wild-type PsVs, 
also L1/L2 ΔSIM PsVs were taken up by endocytosis in a comparable time scale. Although it seems 
that the L2 ΔSIM mutation does not visibly seem to alter L1/L2 processing on the cell surface or the 
endocytosis step itself and all signs suggest that it develops its influence after disassembly of PsVs in 
the endosomes, it is still possible that the L2 SIM features undiscovered regulatory functions in the 
early steps of infection, which regulate later steps, like e.g. L2 furin cleavage on the cell surface was 
reported to allow endosomal escape of the L2-DNA complex in a much later step (Day 2009). In 
general, such rather small modifications could lead to slight but important conformational changes 
affecting transport from the primary to the secondary receptor and modulate the composition of the 
bio-active high-molecular compounds, which are attached to the incoming PsV after ECM binding as 
it is observed e.g. for cyclophilin B (Bienkowska-Haba 2009). These compounds influence whether 
PsVs are taken up via infectious or non infectious endocytosis pathways and trigger disassembly of 
PsVs in endosomes (Bienkowska-Haba 2009; Bienkowska-Haba, Williams et al. 2012; Surviladze, 
Dziduszko et al. 2012). Unfortunately, experimental setups of the cell binding and endocytosis 
experiments presented here were not able to discriminate between infectious or noninfectious 
binding/endocytosis of PsVs, so we were only able to verify that also L1/L2 ΔSIM PsVs were taken up 
into the cell by any kind of endocytosis. 
 
4.10 No PML-colocalization of L2 or viral DNA after infection with L1/L2 ΔSIM PsVs  
As there were no detectable differences in PsV structure, cell binding, and endocytosis of L1/L2 ΔSIM 
PsVs when compared with wild-type viruses, next, the cellular localization of L2 and viral DNA was 
characterized by immunofluorescence microscopy after PsV infection. Colocalization analysis 
revealed a high level of PML-associated L2 and viral DNA after infection with wild-type PsVs like it 
was also reported before (Schneider 2011). In contrast, almost no L2 or DNA colocalization with PML 
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was observed after infection with L1/L2 ΔSIM PsVs. 24 h post infection with L1/L2 ΔSIM PsVs, almost 
no L2 or viral DNA was located within the cell nuclei. The majority of L2 and viral DNA was located in 
larger aggregates outside of the nucleus. Exact determination of the cellular localization of the L2 
ΔSIM aggregates requires additional experiments and was not further characterized at this point. 
Interestingly, SIM-dependent loss of nuclear translocation of viral proteins was already reported for 
the E3 protein of vaccinia viruses, which also features PML-disruptive functions comparable with the 
HPV L2 protein (Gonzalez-Santamaria, Campagna et al. 2011). Here, additionally, the stability of the 
E3 ΔSIM mutants, as well as E3 SUMOylation, was drastically decreased by lack of the SIM. As for 
HPV16 L2, no significant destabilization of L2 ΔSIM was observed, which could possibly be due to L2 
localization in relatively isolated and large aggregates. However, for overexpressed L2 ΔSIM, which 
was able to locate within the nucleus, but with significantly decreased intensity when compared with 
wild-type L2, no L2 SUMOylation was observed. The reason could be that L2 SUMOylation only takes 
place in the nucleus, which was only reachable for a reduced fraction of L2 ΔSIM after overexpression 
and for almost no L2 ΔSIM after PsV infection with L1/L2 ΔSIM PsVs. However, L2 ΔSIM still 
comprises three potential nuclear localization sites, one at the N-terminus (nNLS), one at the C-
terminus (cNLS), and an additional one in the central L2 region near the L2 SIM (mNLS) (Becker, Florin 
et al. 2004; Darshan, Lucchi et al. 2004; Mamoor, Onder et al. 2012). In fact, the mNLS seems to be 
relevant for nuclear localization of L2 and should allow nuclear transport of L2 ΔSIM. Most 
interestingly, the mNLS was also characterized as nuclear retention signal (Mamoor, Onder et al. 
2012). Thus, it is possible that, although there is indeed nuclear localization of L2 ΔSIM, the lack of L2 
interaction with SUMO based on the SIM near the mNLS nuclear retention signal could lead to the 
loss of nuclear localization of the majority of L2 ΔSIM molecules and result in nuclear export based 
on a leucine-rich export signal (aa 462-473)(Mamoor, Onder et al. 2012). Thus, the L2 SIM might be 
important for L2 interaction with SUMOylated proteins in PML-NBs, which prevents L2 from nuclear 
export.  
 
4.11 The L2 SIM at position 284-289 is not regulated by CK2 phosphorylation 
Interestingly, L1/L2 ΔPHOS PsVs lacking a potential CK2 phosphorylation site near the L2 SIM at 
position 295/6 (TS) showed no aberrations in infectivity when compared with wild-type PsVs, 
including also cell binding and endocytosis. These results confirmed the wild-type phenotype of 
overexpressed L2 ΔPHOS also observed in immunofluorescence or immunoprecipitation, where the 
L2 ΔPHOS mutation did not influence L2 localization or L2 interaction with GFP-SUMO2. Thus, there is 
either no phosphorylation at this highly conserved L2 sequence motif or potential phosphorylation 
does not lead to increased SIM-based SUMO interaction, as it was shown for a number of SUMO 
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interaction partners in different studies. For example, phosphorylation of the SIMs of DAXX or PIAS1 
by casein kinase 2 (CK2) enhanced binding to SUMO targets (Naik ; Shih 2007; Stehmeier 2009). 
However, to the best of our knowledge, there are no examples of phosphorylation regulated SIMs in 
viral proteins reported so far. 
 
4.12 SUMO siRNA knockdown affects HPV16 infectivity 
Infectivity of PsVs was also characterized by siRNA-mediated knockdown of SUMO1/2 proteins. 
Interestingly, knockdown of intrinsic SUMO1 or SUMO2 had diverse effects on infectivity of PsVs. 
While knockdown of SUMO1 resulted in a decreased infectivity for L1/L2 wild-type and L1/L2 ΔSCM 
PsVs, knockdown of SUMO2 drastically increased infection levels for the same PsVs. One plausible 
explanation would be that SUMO2 directly affects antiviral functions by modification and interaction 
with cellular antiviral regulation factors such as DAXX, PML, or Sp100. Under normal conditions, 
(poly)SUMOylation and SUMO interaction of PML-components leads to a complex SUMO network 
interconnecting the PML-component to form functional and antiviral PML-NBs (Boutell 2011). 
Especially SUMO2 and SUMO3 are involved in cellular regulation mechanisms including polySUMO 
chains after cell stress (Wadosky 2011) and might regulate proteasomal degradation of 
(poly)SUMOylated target proteins and also viral proteins in the context of PML-NBs. It is plausible 
that SUMO knockdown and the lack of the SUMO network leads to non-functional PML-NBs, a 
situation which could significantly increase half-life times of viral proteins. However, the contribution 
of SUMO1 to infectivity of HPV PsVs remains elusive. Perhaps SUMO1 siRNA knockdown induces 
DAXX to reside in its state of transcription repression by preventing DAXX SUMOylation by SUMO1, 
which could otherwise enable PML-NB localization of DAXX and attenuation of its repressing function 
(Jang, Ryu et al. 2002; Lin, Huang et al. 2006; Hwang and Kalejta 2009). One might also speculate that 
the effect of SUMO1 knockdown could also be the result of transcription regulation by SUMO1 siRNA 
transfection, as a slight decrease of luciferase expression was detected in control experiments after 
siRNA transfection and overexpression of luciferase.  
Even more remarkably, siRNA-mediated knock down of SUMO1 or SUMO2 led to a partial 
reactivation of infectivity of L1/L2 ΔSIM viruses, but also L1 VLPs. Reasons for this could be that L2 
and finally the viral DNA, which also reaches the cell nucleus in background levels (Selinka 2007), 
regains its infectivity by knockdown of cellular SUMO1/2 and de-functionalization of PML-NBs, which 
would otherwise completely inhibit infectivity by recruitment of antiviral PML-components like DAXX 
and Sp100. Without the complex of L2 with viral DNA, the DNA seems to be entirely blocked for 
transcription explaining noninfectivity of L1/L2 ΔSIM PsVs and L1 VLPs under normal levels of 
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endogenous SUMO1/2. These assumptions were additionally strengthened by the observation that 
DAXX knockdown also allowed medium level infectivity of L1/L2 ΔSIM PsVs and L1 VLPs, and 
underlines the antiviral function of DAXX during HPV infection (data not shown).  
Overexpression of GFP-SUMO1/2 led to a GFP-SUMO1/2 dose-dependent increase of infectivity of 
L1/L2 wild-type and L1/L2 ΔSCM PsVs. As SUMO proteins normally establish functional and antiviral 
PML-NBs by interaction with a manifold of the more than 70 PML-NB associated cell factors by (poly-
) SUMOylation or SUMO interaction, a positive effect of increased levels of cellular and functional 
SUMO proteins on viral infectivity appears to be rather doubtful. Also, stabilization of SUMO targets 
by SUMOylation induced by higher cellular SUMO levels would also affect cellular proteins and would 
not per se favor viral proteins. In contrast, it seems clearly more credible that the overexpressed 
GFP-SUMO proteins are not able to establish the characteristic network of antiviral proteins needed 
for antiviral defense. Most obviously, the GFP-SUMO proteins feature a dominant-negative 
character, allowing interaction of SUMO with some of their interaction partners, but without 
formation of the intact antiviral defense barrier by dose-dependent suppression of the residual and 
fully-functional cellular SUMO proteins. Thus, overexpression of GFP-SUMO seems to support the 
reported effect of L2 to increase SUMOylation of cellular proteins (Marusic 2010), perhaps allowing 
for a better recognition of the polySUMOylated L2 targets by L2, but could additionally lead to 
formation of non-functional PML-NBs. 
Remarkably, overexpression of wild-type L2 was not able to recover infectivity of L1/L2 ΔSIM PsVs. 
One reason could be that the complex of L2 ΔSIM and DNA after L1/L2 ΔSIM PSV infection could not 
even enter the nucleus, where the majority of overexpressed, wild-type L2 is located and therefore 
cannot interfere in infection. There is some experimental evidence that overexpression of a modified 
form of L2 (L2 Δ1-12) lacking the N-terminal part, which is normally removed by furin cleavage upon 
cell binding of PsVs, increases infectivity of wild-type PsVs, but not of L1/L2 ΔSIM PsVs. Interestingly, 
wild-type L2 overexpression did not enhance infectivity of wild-type L1/L2 PsVs. One could speculate 
that only the truncated L2 form represents active L2 and is able to influence/enhance infectivity. 
 
4.13 Tentative model for regulation of the intrinsic antiviral resistance by HPV16 L2 
Based on the reported data, the following mechanistical hypothesis of HPV infection may be drawn 
(Fig. 4.3). All characterized HPV16 PsVs and VLPs are able to bind to the host cells and are 
endocytosed regardless of any L2 mutations influencing L2 SUMOylation or SIM-based SUMO 
interaction. However, after endocytosis and viral disassembly in the endosomes, which was not 
characterized here, the complex of L2 and viral DNA was only able to reach PML-NBs after infection 
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with L1/L2 wild-type and L1/L2 ΔSCM PsVs and not for infection with L1/L2 ΔSIM PsVs and L1 VLPs 
(Fig. 4.3 A). This means that the L2 SIM is absolutely indispensable for the correct nuclear transport 
of the L2/DNA complex from endosomes to PML-NBs. As for infection with L1/L2 wild-type and L1/L2 
ΔSCM PsVs, the next important challenge to gain HPV infectivity is the establishment of the viral 
replication centers in the close vicinity of the PML-NBs or recruitment of the PML-components to the 
L2-DNA complexes (Fig. 4.3, B). On the one hand, the presence of the PML-NBs seems to be crucial 
for HPV replication (Day 2004), on the other hand, for other DNA viruses, PML-NBs and especially 
their constituent DAXX induce repression of viral transcription most obviously by surrounding the 
incoming viral DNA with a network of cellular factors and associated chromatin remodeling factors, 
leading to a quiescence of the viral DNA (Boutell 2011). The direct colocalization of viral DNA with L2 
seems to block transcriptional repression of cellular factors like DAXX, while it activates viral 
transcription based on additional factors (shown in blue in Fig. 4.3). It is already known that 
overexpressed L2 induces Sp100 release from PML-NBs and degradation, while DAXX is recruited to 
the PML-NBs (Florin 2002b), which could lead to a net attenuation of the inhibitory functions of DAXX 
(Li, Leo et al. 2000), which, remarkably, was also observed after overexpression of HPV16 L2 in HCMV 
infection (Schreiner 2012) . The SUMOylation of L2 thereby enhances L2 half-life time and could 
improve L2 linkage with the network of highly (poly-)SUMOylated cellular proteins, facilitating viral 
gene expression (Fig. 4.3 C). L2 ΔSCM is degraded much faster than wild-type L2 after PsV infection 
and results in reduced HPV infectivity due to L2 degradation and quiescence of the residual viral DNA 
based on interaction with the PML NBs (Fig. 4.3, D). Thereby, SUMOylation and SUMO interaction of 
the PML-NB associated proteins seem to play important roles for formation of functional anti-viral 
PML-NBs. Especially loss of SUMO2 by siRNA knockdown results in significantly increased HPV 
infectivity, possibly due to the loss of function of the PML-NBs (Fig. 4.3, E). This is interesting, as 
especially SUMO2/3 is supposed to participate in polySUMOylation of several cellular substrates 
during cell stress as it is also provoked by income of foreign DNA. Also DAXX knockdown leads to 
increased HPV infectivity, indicating a direct antiviral function of DAXX. 
Remarkably, the knockdown of SUMO2 also seems to restore some infectivity to L1/L2 ΔSIM and L1 
VLPs. A reason for that could be that viral DNAs, which enter the nucleus also after noninfectious 
endocytosis at background levels, but are normally targeted and deactivated by intact PML-NBs, 
regain infectivity by loss of function of the antiviral PML-NBs without the presence of SUMO2. 
Overexpression of GFP-SUMO1/2 could possibly have a comparable effect on HPV infection as 
SUMO2 knockdown, since the combination of SUMO1/2 with GFP could interfere with the formation 
of a SUMO network between cellular proteins and render most of the PML-NBs nonfunctional.  
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Fig. 4.3: Model depicting regulation of the intrinsic antiviral defense to HPV16 infection. A Only L2 containing the SIM is 
able to direct the L2-DNA complex into the cell nucleus, most obviously by interaction with a yet unknown factor. B While 
wild-type L2 is able to position most L2-DNA complexes in close vicinity to PML-NBs, a smaller amount of viral DNA reaches 
the PML-NBs in the presence of SUMOylation-deficient L2 ΔSCM. This could be caused by destabilization of L2 ΔSCM due to 
the lack of SUMOylation. The PML-NBs thereby represent the hot spot of the intrinsic antiviral defense by bundling active 
forms of the antiviral, SIM-containing and highly SUMOylated PML, DAXX, and Sp100, but at the same time allow for viral 
replication in the presence of L2. C Wild-type L2 mediates viral replication by deregulation of the antiviral activity of PML, 
DAXX, and Sp100 and enables viral transcription. In a first mechanism, L2 could shield the viral DNA from the PML-NB 
components to prevent quiescence of the DNA (1). It is also plausible that L2 targets some of the (poly)SUMOylated PML-
NB components for degradation (2). D In the presence of L2 ΔSCM, the antiviral factors are shielded from the viral DNA 
enabling transcription (1) but a part of the L2 ΔSCM is rapidly degraded resulting in the quiescene of a large fraction of viral 
DNA upon interaction PML-NB components (2). SUMO2 siRNA knockdown E or GFP-SUMO1/2 overexpression F results in 
the formation of non-functional PML-NBs lacking the SUMO interaction network and lacking antiviral activity, allowing 
transcription of viral DNA which entered the nucleus even after noninfectious endocytosis of L1 VLPs or L1/L2 ΔSIM PsVs. 
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The mechanism by which L2 modulates activity of the PML-NBs and/or induces even their disruption, 
as it is sometimes observed for HPV, still remains elusive. As our results show only a subordinate role 
of L2 SUMOylation on HPV16 infection, the focus clearly is on SIM-based interaction of L2. It is 
plausible that L2 could fulfill important functions in proteasomal degradation of cellular target 
proteins as suggested by the observed loss of Sp100 after L2 overexpression (Florin 2002b). As there 
were direct hints that L2 could be able to interact with more than one SUMO2 molecules at the same 
time in in vitro assays, in a speculation, also interaction with polySUMO2/3 chains would be possible. 
This could be a link to a possible SUMOylation targeted ubiquitin ligase function of L2 targeting 
polySUMOylated proteins for degradation. Especially interaction with poly-SUMO2/3 chains is one of 
the hallmarks of RING-finger containing SUMO-targeted ubiquitin ligases (StUbLs), which target poly-
SUMOylated cellular proteins for proteasomal degradation by polyubiquitination, as it was also 
suggested for the L2 analogue structure protein ICP0 of HSV-1 (Boutell 2011). Since HPV16 L2 does 
not seem to represent an StUbL itself, as it does not contain a RING or HECT domain itself, but in 
general is to be able to interact with multiple SUMOylated PML-components, L2 could possibly target 
known E3 ubiquitin ligases with known SUMOylated L2 interaction partners, inducing transfer of 
(poly-)ubiquitin from E2 ubiquitin ligases to the SUMOylated target molecules to enable proteasomal 
degradation. There are two major E3 ubiquitin ligase families: HECT (homology to E6-assiciated 
protein carboxyl terminus) and RING (Really Interesting New Gene) E3 ubiquitin ligases. Cullin-RING 
ubiquitin ligases (CRLs) represent the largest class containing cullin, a RING finger protein, and a 
substrate recognition unit. It was already shown that HPV viruses utilize the system of ubiquitin 
ligases for proteasomal degradation of cellular target proteins and thus, also L2 interaction with 
ubiquitin E3 ligases may be possible. For example, the HPV16 E6 protein interacts with a group of 
cellular E6-AP E3 ubiquitin ligase, inducing binding and ubiquitin-mediated proteolysis of the tumor 
suppressor protein p53 (Huibregtse, Scheffner et al. 1995; Tomaic, Pim et al. 2011). In another 
example, the HPV E7 protein binds to pRb and recruits the cullin 2 ubiquitin ligase for ubiquitination 
and subsequent proteosomal degradation of pRb (Barrow-Laing, Chen et al. 2010).  
Based on the E3 ubiquitin ligase function of ICP0 and the interaction of a large group of viral proteins 
with components involved in proteasomal degradation (Tavalai and Stamminger 2009; Wimmer 
2012), we checked whether L2 would be able to interact with ubiquitin. Interestingly, we were able 
to observe a SIM-dependent L2 interaction with ubiquitin in ubiquitin pulldown experiments. 
However, since L2 does not contain characteristic RING or HECT domains important for interaction 
with ubiquitin E2 ligases for transfer of (poly)ubiquitin, it is most likely that L2 only represents a 
recognition element for identification of potential targets and is probably part of a larger E3 ligase 
complex including L2 interaction with further elements featuring E3 ligase function. Interestingly, in 
yeast 2-hybrid screening, obscurin-like 1 (OBSL1) was identified as an L2 interaction partner 
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(Schneider 2011). OBSL1 functions as cytoskeletal linker, contains at least seven bona fide SIMs, and 
regulates the activity of the cullin7 E3 ubiquitin ligase (Geisler, Robinson et al. 2007; Hanson, Murray 
et al. 2009). One may speculate that the L2 interaction with OBSL1 could represent one possibility of 
L2 to mediate activity of cellular E3 ubiquitin ligases. As also the E3 SUMO ligase RanBP9 (Ran binding 
protein 9) is a ligand of the Rho-GEF domain of obscurin (Bowman, Catino et al. 2008). Therefore, the 
characterization of the interplay of L2, OBSL1, and potential ubiquitin or SUMO ligases could reveal 
important hints for functionality of HPV infection, since obscurins and cullins seem to play important 
roles in several cancer tissues also triggering apoptosis (Haagenson, Tait et al. 2012; Perry, Shriver et 
al. 2012). Finally, HPV16 L2 may join the group of viral proteins, in which SUMO interaction and 
SUMOylation may influence viral infectivity by disruption/modification of PML-NBs, as it was already 
observed for many viral proteins including ICP0 of the Herpes Simplex Virus 1, ORF61p of the 
Vaccinia Zoster Virus, IE1/2 and pp71 of the Human Cytomegalovirus, BZLF-1, EBNA-LP, and EBNA1 
from Epstein-Barr Virus, LAN2 of the Kaposi's Sarcoma-associated Herpesvirus, E3L of the Vaccinia 
Virus, and ORF75c of the Mouse Hepatitis Virus 68 (Tavalai and Stamminger 2009; Wimmer 2012), 
from which direct effects of viral SIMs on infection were identified for ICP0 (Boutell 2011), ORF61 
(Wang, Oliver et al. 2011), IE2 (Kim 2010), and E3L (Gonzalez-Santamaria, Campagna et al. 2011) 
partially also containing SIM-based interaction with components involved in ubiquitination. 
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  5. Conclusions 
 
Here, we report for the first time that the minor capsid protein L2 of the human papillomavirus (HPV) 
type 16, is able to interact with SUMO, not only by SUMOylation, as it was reported before, but also 
by noncovalent SIM-based SUMO interaction. The direct L2 interaction with SUMO proteins, which 
represent one of the most important key players in modulating activity of anti-viral proteins bundled 
in PML-NBs, is closely correlated with the presence of at least one bona fide and highly conserved 
SIM at L2 sequence position 286-289. HPV16 pseudoviruses (PsVs) lacking the SIM are noninfectious. 
Cell binding and endocytosis were not visibly interfered by the lack of the SIM. These results were 
also confirmed by a novel CW EPR attempt, which passively measures the cell binding ability of PsVs 
and, in addition, features selectivity for structural rearrangement of the L1/L2 capsid after successful 
attachment to the target cells. Additionally, the inhibitory effect of heparin on cell binding and 
structural L1/L2 rearrangement was confirmed, which also elucidated the potential of this method to 
study early steps of HPV infection occurring on the cell surface, such as e.g. inhibition of interaction 
with cyclophilin, furin, the annexin A2 heteroteteramer, or MMP/ADAM proteases with the 
respective inhibitors. The L2 SIM seems to be closely entangled with the fate of the L2-DNA complex, 
which is transported to the PML-NBs in the nucleus for wild-type viruses but cannot be detected in 
the nucleus or at PML-NBs after infection with L1/L2 ΔSIM PsVs. However, it is possible that the L2 
SIM mediates L2 interaction with SUMO-modified proteins and could thereby participate in 
regulatory functions modulating the activity of transcription factors and the antiviral defense at the 
PML-NBs. The L2 SIM could also posses some influence on HPV morphogenesis, since overexpressed 
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L2 ΔSIM, which was localized within the nucleus, was not able to colocalize with PML-NBs indicating 
multiple functions of the L2 SIM. However, preparation of correctly assembled PsVs was also possible 
based on mutant L2 lacking the SIM, which could indicate that PML-localization of L2 is not needed 
for HPV morphogenesis. Speculations about the viral mechanism which counteracts antiviral defense 
are beyond the scope of this work. Nevertheless, we were able to collect several hints providing the 
following tentative picture which is in line with the general trends observed during infection of other 
viruses: i) The L2 SIM could be be crucial for nuclear transport of the L2-DNA complex and also for its 
association with PML-NBs facilitating viral transcription and replication. ii) L2 possibly facilitates 
interaction with SUMO and most obviously (poly-)SUMOylated cellular proteins, including the 
transcription co-repressor DAXX and Sp100, which could lead to modulation of their antiviral activity: 
e.g. attenuation of the repressive function of DAXX upon L2-induced PML-localization of DAXX, which 
otherwise induces quiescence of incoming viral DNA in remote nuclear regions or degradation of 
Sp100. iii) an possible E3 ubiquitin ligase function of L2 could lead to modulation and/or degradation 
of antiviral cellular proteins, which could be based on the L2 ability to identify (poly)SUMOylated 
cellular factors with its multiple SIMs and concomitant interaction with E3 ubiquitin-ligase 
complexes, like e.g. cullin inducing proteasomal degradation, as it was already observed for p53 and 
pRb degradation by HPV16 E6 and E7. It is possible that L2 plays a major role in escape from or in 
enduring intrinsic antiviral defense for HPVs, facilitating productive infection. 
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FCS  fetal calf serum 
Fig.  figure  
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g  gravitational acceleration (9.80665 m x s-1)  
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HIV  Humanes Immunodefiency Virus 
HPV  Human Papillomavirus  
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HSV  Herpes Simplex Virus  
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IP  immunpräzipitation  
IPTG  isopropyl-ß-D-1-thiogalactopyranosid  
Kan  Kanamycin  
kb  kilobase pairs 
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L  late expressed protein  
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M  molarity (mol / l)  
min  minute 
mRNA  messanger-RNA  
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Ori  Origin of Replication 
  Abbreviations 
  190 
p670  late HPV16 promotor  
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Tab.  table 
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VLP  virus-like particle ( virus particles composed of a L1 capsid and reporter DNA) 
w/v  weight per volume 
WB  Western Blot  
wt  wild-type  
X-band  microwave frequency range of ~9.1 GHz to ~9.8 GHz 
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Tab. I: Symbols for nucleic acids. 
symbol significance nucleic acid symbol significance 
A A adenine W A or T 
C C cytosine S C or G 
G G guanine Y C or T 
T T thymine K G or T 
U U uracile V A, C, or G 
N G, A, T, C  H A, C, or T 
M A or C  D A, G, or T 
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Tab. II: Single letter and three letter code for amino acids. 
signe letter code three letter code amino acid 
A Ala alanine 
B Asx aspartatic acid or asparagine 
C Cys cysteine 
D Asp aspartate 
E Glu glutamic acid 
F Phe phenylalanine 
G Gly glycine 
H His histidine 
I Ile isoleucine 
K Lys lysine 
L Leu leucine 
M Met methionine 
N Asn asparagine 
P Pro proline 
Q Gln glutamine 
R Arg arginine 
S Ser serine 
T Thr threonine 
V Val valine 
W Trp Trypthophan 
X Xaa unknown or any amino acid 
Y Tyr tyrosine 
Z Glx glutamic acid or glutamine 
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